

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Bidirectional Association between Migraine and Fibromyalgia: Two Population-Based Retrospective Cohort Analyses

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026581
Article Type:	Research
Date Submitted by the Author:	10-Sep-2018
Complete List of Authors:	Penn, I-Wen Chuang, Eric Chuang, Tien-Yow Lin, Cheng-Li Kao, Chia-Hung; China Medical University,
Keywords:	fibromyalgia, Migraine < NEUROLOGY, bidirectional analysis, retrospective cohort

SCHOLARONE™
Manuscripts

View Only

1
2
3
4 **Bidirectional Association between Migraine and Fibromyalgia: Two**
5
6 **Population-Based Retrospective Cohort Analyses**
7

8
9 **Running title:** Bidirectional Association between Fibromyalgia and Migraine
10
11

12
13
14
15 I-Wen Penn¹, Eric Chuang², Tien-Yow Chuang³, Cheng-Li Lin^{4,5}, Chia-Hung Kao^{6,7,8}
16
17
18
19

20
21 ¹Department of Physical Medicine and Rehabilitation, School of Medicine, Fu Jen
22
23 Catholic University and Affiliated Hospital, New Taipei City, Taiwan
24

25
26 ²UC Berkeley Mishler Lab Undergraduate Researcher, Intended B.S. Molecular and
27
28 Cell Biology, University of CA, Berkeley, USA
29
30

31
32 ³Department of Physical Medicine and Rehabilitation, Taipei Veterans General
33
34 Hospital and National Yang-Ming University, Taipei, Taiwan
35
36

37
38 ⁴Management Office for Health Data, China Medical University Hospital, Taichung,
39
40 Taiwan
41
42

43
44 ⁵College of Medicine, China Medical University, Taichung, Taiwan
45

46
47 ⁶Graduate Institute of Biomedical Sciences and School of Medicine, College of
48
49 Medicine, China Medical University, Taichung, Taiwan
50

51
52 ⁷Department of Nuclear Medicine and PET Center, China Medical University
53
54 Hospital, Taichung, Taiwan
55
56

1
2
3
4⁸Department of Bioinformatics and Medical Engineering, Asia University, Taichung,
5
6
7 Taiwan.

8
9
10
11
12 *** Tien-Yow Chuang and Chun-Hung Tseng contribute equally to this work**

13
14
15 ***Corresponding author:** Chia-Hung Kao, MD, Graduate Institute of Biomedical
16
17 Sciences and School of Medicine, College of Medicine, China Medical University,
18
19 No. 2, Yuh-Der Road, Taichung 404, Taiwan. E-mail: d10040@mail.cmuh.org.tw;
20
21 dr.kaochiahung@gmail.com
22
23
24
25
26
27
28
29

30 **Author contributions:**

31
32 Conceptualization: IWP, CHK.

33
34 Methodology: CLL, CHK.

35
36 Software: CLL, CHK.

37
38 Validation: IWP, EC, TYC, CLL, CHK

39
40 Formal analysis: IWP, EC, TYC, CLL, CHK

41
42 Investigation: CLL, CHK.

43
44 Resources: CLL, CHK.

45
46 Data curation: IWP, EC, TYC, CLL, CHK

47
48 Writing (original draft preparation): IWP, EC, TYC, CLL, CHK
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Writing (review and editing): IWP, EC, TYC, CLL, CHK
5

6 Visualization: IWP, EC, TYC, CLL, CHK
7

8
9 Supervision: CHK.
10

11
12 Project administration: CHK.
13

14
15 Funding acquisition: CHK.
16
17
18
19

20
21 **Acknowledgments:**
22

23 This work was supported by grants from the Ministry of Health and Welfare, Taiwan
24
25 (MOHW107-TDU-B-212-123004), China Medical University Hospital
26
27 (DMR-107-192), Academia Sinica Stroke Biosignature Project (BM10701010021),
28
29 MOST Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005),
30
31 Tseng-Lien Lin Foundation, Taichung, Taiwan, and Katsuzo and Kiyo Aoshima
32
33 Memorial Funds, Japan. The funders had no role in the study design, data collection
34
35 and analysis, decision to publish, or preparation of the manuscript. No additional
36
37 external funding was received for this study.
38
39
40
41
42
43
44
45
46
47
48
49

50 **Conflict of Interest:**
51

52 All authors report no conflicts of interest.
53
54
55
56
57
58
59
60

List of abbreviations

FM: Fibromyalgia; HR: hazard ratio; CI: confidence interval; ICD-9-CM:

International Classification of Diseases, Ninth Revision, Clinical Modification; NHI:

National Health Insurance; LHID: Longitudinal Health Insurance Database

For peer review only

Abstract

Objective: Fibromyalgia (FM) and migraine are common pain disorders and tend to coexist. This study determined whether these two conditions exhibited any mutual influences.

Setting: Cohort Study.

Participants: A retrospective, longitudinal cohort study was conducted by using the data from a nationwide healthcare database. This study has two separate arms. Arm 1 included 33,216 FM patients, and Arm 2 contained 7420 migraine patients; all of these patients were diagnosed between 2000 and 2010. Using the same database, control subjects who had neither FM nor migraine and who were matched with the FM and migraine patients by sex, age, and index date of diagnosis were recruited. Each control cohort was four times the size of the relevant study cohort. Both the control and study cohorts were followed until the end of 2011.

Results: The incidence rates of migraine and FM were calculated in Arm 1 and Arm 2, respectively. The overall incidence of migraine was greater in the FM cohort than in the control cohort [4.39 vs. 2.07 per 1000 person-years; crude hazard ratio (HR) = 2.12, 95% confidence interval (CI) = 1.96–2.30; adjusted hazard ratio (aHR) = 1.89, 95% CI = 1.75–2.05], after adjustment for sex, age, and comorbidities. The overall

1
2
3 incidence of FM in the migraine cohort was 1.57 times greater than in the control
4
5
6 cohort (7.01 vs. 4.49 per 1000 person-years; aHR = 1.52, 95% CI = 1.39–1.65).
7
8

9 **Conclusions:** The present study demonstrates the presence of a bidirectional link
10
11 between FM and migraine.
12
13

14
15
16
17
18 *Key words:* fibromyalgia, migraine, bidirectional analysis, retrospective cohort
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

peer review only

Strengths and limitations of this study

1. Our study contained a large sample size because of our population-based design approach.
2. We based our study solely on the information from diagnoses in patient files, so we did not include any patients whose cases were unidentified.
3. This study is naturally more prone to observational bias since patients with migraines and FM are generally more likely to seek medical attention for another condition.

Introduction

One of the major symptoms of fibromyalgia (FM) is a headache. Among those different types of headaches, there are migraines—some bad enough to debilitate a person. Interestingly, similarities exist between migraines and fibromyalgia, and as we consider the two conditions in the same context, many instances of overlapping symptoms, causes, and treatments are noted [1]. Several studies have reported that a high proportion (20%–36%) of patients with migraine have FM [2-5]. By contrast, the frequency of migraine in patients with FM is approximately 45%–80%, suggesting that migraine is common in patients with FM [6, 7]. Despite that episodic migraine, chronic headaches and FM could be sourced to the same cause [8-10], explanations for this high degree of co-occurrence between migraine and FM are unknown.

Migraine is a complex, recurrent disorder that manifests as a throbbing headache, which is frequently associated with nausea, allodynia, and sound or light sensitivity, and may develop into a chronic condition and disability [11,12]. The pain is considered to occur due to the nociceptive activation of the trigeminovascular system, including the sensory neurons from the trigeminal ganglion and upper cervical nerve roots, which modulate central signals to numerous subcortical sites [13]. The combination of tonic nociceptive input and central disinhibition may also play a role in the development of FM. Many migraineurs experience a condition termed

1
2
3
4 “allodynia” during migraine attacks. Usually, allodynia is confined to the head and
5
6 neck but may involve other areas of the body [14]. Increasing evidence indicates that
7
8 the peripheral tissues are relevant contributors to painful impulse input, which might
9
10 either initiate or maintain central sensitization, thus contributing to the progression of
11
12 FM [15]. Migraine is also supposed to be a trigger factor for FM. The repeated
13
14 headaches in migraine patients might increase the neuronal response to both
15
16 nociceptive and non-nociceptive stimulation and induce spontaneous neuronal activity,
17
18 which might concurrently heighten the sensitivity of the patient to FM [16]. Several
19
20 studies have highlighted the role of the hypothalamus in migraines [14]. Evidence
21
22 indicates its direct and indirect anatomical connections to the thalamus and autonomic
23
24 brainstem nuclei, supporting its role in nociceptive and autonomic modulation among
25
26 migraine patients [17]. However, the brain mechanisms also common to FM suffers
27
28 result in central sensitization of pain neurons leading to the evolution of a complex
29
30 syndrome [18].
31
32
33
34
35
36
37
38
39
40
41
42

43 Early in the course of disease, the widespread musculoskeletal pain of FM
44
45 patients often appears in the neck or shoulder region [19]. Neck pain may activate
46
47 local nociceptors and transmit painful impulses through the upper cervical spinal
48
49 nerves, such as the greater occipital nerve, to the trigeminal nucleus caudalis, thus
50
51 inducing a migraine attack [20]. Some experts believe that FM and migraine
52
53
54
55
56
57
58
59
60

1
2
3
4 headaches both involve defects in the systems that regulate certain chemical
5
6 messengers in the brain, including serotonin and epinephrine (adrenaline) [1]. which
7
8 might reflect in their similar psychological comorbidities: depression, anxiety,
9
10 interpersonal sensitivity, somatization, etc [9]. Psychosocial distress and
11
12 psychological abnormality are common to occur in patients suffering from migraine
13
14 as well as patients suffering from FM.
15
16
17
18
19

20
21 Although previous research has demonstrated a high comorbidity rate for
22
23 migraines and FM, several vital issues must be highlighted. (1) Most of these studies
24
25 were performed at tertiary care centers. Patients are often referred to tertiary clinics
26
27 due to high pain complaints, disability, or medication overuse. Hence, the sample
28
29 populations may differ from patients treated in general practice. (2) Most of these
30
31 studies used a cross-sectional design for investigating the prevalence instead of the
32
33 incidence of migraine or FM. (3) If there is a significant association, whether people
34
35 with migraine are more likely than the general population to develop FM or vice versa
36
37 remains unknown. Therefore, our population-based longitudinal cohort study is trying
38
39 to investigate the links between migraine and FM.
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **Methods**

Data source

The data for this research were sourced from the Longitudinal Health Insurance Database (LHID). The LHID comprises the data of 1 million insurants' health claims from the Taiwan National Health Insurance (NHI) program, which covers 99% of 23 million Taiwan citizens with single-payer health insurance. According to the government's report, no differences were noted in the demographic features between the LHID and Taiwan NHI program. The health claims information in the LHID includes general information regarding the insurants (such as birthdate, sex, and occupation), disease documents (recorded according to the International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-9-CM), and other medical service-related data.

Data Availability Statement

The dataset used in this study is held by the Taiwan Ministry of Health and Welfare (MOHW). The Ministry of Health and Welfare must approve our application to access this data. Any researcher interested in accessing this dataset can submit an application form to the Ministry of Health and Welfare requesting access. Please contact the staff of MOHW (Email: stcarolwu@mohw.gov.tw) for further assistance.

Taiwan Ministry of Health and Welfare Address: No.488, Sec. 6, Zhongxiao E. Rd.,

1
2
3
4 Nangang Dist., Taipei City 115, Taiwan (R.O.C.). Phone: +886-2-8590-6848. All
5

6 relevant data are within the paper.
7
8
9

10 11 12 **Ethics Statement** 13

14
15 The National Health Insurance Research Databank (NHIRD) encrypts patient
16
17 personal information to protect privacy and provides researchers with anonymous
18
19 identification numbers associated with relevant claims information, including sex,
20
21 date of birth, medical services received, and prescriptions. Therefore, patient consent
22
23 is not required to access the NHIRD. This study was approved to fulfill the condition
24
25 for exemption by the Institutional Review Board (IRB) of China Medical University
26
27 (CMUH104-REC2-115-CR2). The IRB also specifically waived the consent
28
29 requirement.
30
31
32
33
34
35
36
37
38
39
40

41 **Study Cohorts** 42

43 A bidirectional cohort study design was used to interpret the longitudinal
44
45 association between FM and migraine.
46
47

48
49 Figure 1 shows the procedure for establishing the two study Arms. For study
50
51 Arm 1, we identified patients with FM (ICD-9-CM code 729.1) who were aged ≥ 20
52
53 years and were newly diagnosed consecutively ≥ 3 times within 3 months in
54
55
56
57

1
2
3
4 2000–2010. The first diagnosis date was designated as the index date for entry into
5
6 the FM cohort. Patients with a history of migraine (ICD-9-CM codes 346) were
7
8 excluded from the cohort. For each FM patient, we randomly selected four persons
9
10 free of FM and migraine from the population of the LHID2000, who were
11
12 frequency-matched by sex, age (in 5-year increments), and entry date of the FM
13
14 patient; these subjects were recruited to the non-FM (control) cohort.
15
16
17
18
19

20
21 For study Arm 2, a similar procedure to that for study Arm 1 was used to
22
23 establish a migraine cohort of patients who did not have a history of FM, were aged
24
25 ≥ 20 years, and were newly diagnosed consecutively ≥ 3 times within 3 months in
26
27 2000–2010.
28
29
30

31
32 Subjects in the study Arms 1 and 2 were followed until the diagnosis of
33
34 migraine or FM, withdrawal from the NHI program, death, or December 31, 2011.
35
36 The patients in two cohorts contained some baseline comorbidities: diabetes
37
38 (ICD-9-CM code 250), hypertension (ICD-9-CM codes 401–405), hyperlipidemia
39
40 (ICD-9-CM code 272), depression (ICD-9-CM codes 296.2, 296.3, 296.5, 300.4, 309,
41
42 and 311), anxiety (ICD-9-CM code 300.0, 300.2, 300.3, 308.3, and 309.81), sleep
43
44 disorder (ICD-9-CM codes 307.4 and 780.5), coronary artery disease (CAD;
45
46 ICD-9-CM codes 410–414), chronic fatigue syndrome (CFS; ICD-9-CM code 780.71),
47
48 and irritable bowel syndrome (IBS; ICD-9-CM code 564.1).
49
50
51
52
53
54
55
56
57
58
59
60

Statistical analyses

The characteristics of the study cohorts are expressed as the mean and corresponding standard deviation for age and as number and percentage for sex and comorbidities. Age difference was assessed using the t-test, and sex and comorbidity distributions were tested using the chi-square test. The incidence density for each cohort was calculated as the total event number divided by the sum of follow-ups [per 1000 person-years (PY)]. The cumulative incidence curve for each cohort was measured using the Kaplan–Meier method, with the curve difference being calculated using the log-rank test. To determine the migraine and fibromyalgia risks in Arms 1 and 2, respectively, the hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were estimated using single-variable and multivariable Cox proportional hazard models. Data management and all statistical analyses were performed using SAS software for Windows (Version 9.4, SAS Institute, Cary, NC, USA), and incidence curves was plotted using R software. All significance levels were set at two-sided $p < 0.05$.

Results

1
2
3
4 Table 1 shows the demographic characteristics of the FM and non-FM cohorts.
5
6 The age- and sex-matched cohorts demonstrated differences in the comorbidity
7
8 distribution. The prevalence of comorbidities was significantly higher in the FM
9
10 cohort than in non-FM cohort ($p < 0.001$).
11
12
13

14
15 Table 2 shows the migraine incidence was 4.39 and 2.07 per 1000 PY in the FM
16
17 and non-FM cohorts, respectively. Figure 2 shows a higher incidence curve for the
18
19 FM cohort and a lower curve for the non-FM cohort (log rank test=371.4, $p < 0.001$).
20
21 After adjustment for age, sex, and comorbidities, the FM patients exhibited a
22
23 1.89-fold higher risk of migraine than did the non-FM subjects (HR = 1.89, 95% CI =
24
25 1.75–2.05). Among females, the relative risk of migraine was 1.76-fold higher in the
26
27 FM patients than in the non-FM subjects (HR = 1.76, 95% CI 1.60–1.93), whereas the
28
29 risk among males was 2.29-fold higher in the FM patients than in the non-FM
30
31 subjects (HR = 2.29, 95% CI = 1.97–2.67). Regarding the age effect, the HRs for
32
33 migraine in the FM cohort were 2.06 (95% CI = 1.85–2.29), 1.66 (95% CI =
34
35 1.43–1.92), and 1.69 (95% CI = 1.39–2.05) for age ≤ 50 , 51–65, and ≥ 65 years,
36
37 respectively.
38
39
40
41
42
43
44
45
46
47
48

49 Table 3 shows the influence of factors associated with the occurrence of migraine
50
51 in the FM cohort. Male sex, hyperlipidemia, depression, anxiety, sleep disorder, CAD,
52
53 CFS, and IBS were associated with a higher risk of migraine (all p-value < 0.05).
54
55
56
57
58
59
60

1
2
3
4 Table 4 lists the comorbidities as well as the age- and sex-matched comparisons
5
6 in the migraine cohort. The migraine cohort showed higher prevalent comorbidities
7
8 than non-migraine cohort.
9
10

11
12 Table 5 and Figure 3 show the significantly higher incidence of FM in migraine
13
14 patients than that in non-migraine subjects (7.01 vs. 4.49 per 1000 PY; log-rank
15
16 test=116.7, $p < 0.001$). After adjustment for age, sex, and comorbidities, the migraine
17
18 patients exhibited a 1.52-fold higher risk of FM than did non-migraine subjects (HR =
19
20 1.52, 95% CI = 1.39–1.65). The female migraine patients displayed a 1.43-fold higher
21
22 risk of FM than did the non-migraine subjects (HR = 1.43, 95% CI = 1.29–1.59),
23
24 whereas the male migraine patients exhibited a 1.78-fold higher risk of FM (95% CI =
25
26 1.50–2.11). Regarding the age effect, the HRs for FM were 1.64 (95% CI =
27
28 1.46–1.84), 1.30 (95% CI = 1.09–1.53), and 1.28 (95% CI = 1.03–1.58) in migraine
29
30 patients aged <50, 50–64, and ≥ 65 years, respectively.
31
32
33
34
35
36
37
38
39

40 Table 6 shows the associations of sex, age, and comorbidities with the risk of FM.
41
42 The variables, including age, migraine, hypertension, hyperlipidemia, depression,
43
44 sleep disorder, and CAD, were all associated with a lower risk of FM.
45
46
47
48
49
50
51
52
53

54 Discussion

55
56
57
58
59
60

1
2
3
4 The results of the two cohort arms suggested a bidirectional risk of migraine
5
6 and FM in patients with FM and migraine, respectively. In the Arm 1 analysis, the
7
8 incidence rates for migraine were 4.39 and 2.07 per 1000 PY in FM patients and
9
10 non-FM subjects, respectively [adjusted hazard ratio (aHR) = 1.89 and 95% CI =
11
12 1.75–2.05 in FM patients]. In the Arm 2 analysis, the incidence rates for FM were
13
14 7.01 and 4.49 per 1000 PY in migraine patients and non-migraine subjects,
15
16 respectively (aHR = 1.52 and 95% CI = 1.39–1.65 in migraine patients). This
17
18 indicated that FM has a stronger predictive power for the onset of migraine than does
19
20 migraine for the onset of FM.
21
22
23
24
25
26
27
28

29 The Kaplan–Meier plots demonstrated that the incidence of migraine in the FM
30
31 cohort and the incidence of FM in the migraine cohort increased steadily during the
32
33 12-year follow-up period. Moreover, similar patterns were observed in the two
34
35 corresponding comparison cohorts. The cumulative incidence measured by the
36
37 Kaplan–Meier plots revealed a greater risk of migraine among FM patients than that
38
39 of FM among migraine patients.
40
41
42
43
44
45

46 Our predictive analytics could potentially dictate diagnosis and treatment. For
47
48 example, a subsequent diagnosis of FM could come from the failure of anti-migraine
49
50 treatment to alleviate fatigue [21]. Since migraine is often better managed, the authors
51
52 would hypothesize that FM patients are more likely to be treated for migraine than
53
54
55
56
57
58
59
60

1
2
3
4 vice versa. Therefore, clinical trials of migraine patients in the future have the
5
6 potential to evaluate the effects of FM on health outcomes and its treatment efficacy
7
8
9 [10].
10

11 12 13 14 15 **Cohort analysis for the association between FM and the risk of new-onset** 16 17 18 **migraine** 19

20
21 This study revealed a positive association between the diagnosis of FM and the
22
23 risk of migraine. Adjustment for factors, including hypertension, CAD, and CFS, had
24
25 no strong influence on this association. However, sex, age (particularly in patients
26
27 under 49 years of age), diabetes, hyperlipidemia, depression, anxiety, sleep disorder,
28
29 and IBS remained statistically significant.
30
31
32
33

34
35 Several hypotheses have been proposed to explain the development of chronic
36
37 widespread pain and/or episodic throbbing or pulsing pain over the head and neck
38
39 regions as the possible effects of comorbidities, including depression and anxiety.
40
41 Depression and anxiety disorders have been identified as important secondary
42
43 symptoms of FM [22, 23]. The pain of FM may initiate the development of mood
44
45 disorders as a result of the stress created on the body. In addition, depression and
46
47 anxiety might also induce the onset or present as a prodrome of migraine, according
48
49 to several evidence-based studies [24, 25]. Research has indicated that serotonin
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 levels might be related to the interconnections between anxiety and migraine [26]. A
5
6
7 lower level of serotonin may be central to the dysregulation of descending
8
9
10 antinociceptive systems, leading to the occurrence of FM and migraine [26, 27].

11
12 Nonrefreshing sleep or sleep deprivation in healthy persons can induce
13
14 symptoms of fibromyalgia [28], implying that sleep abnormalities might be a
15
16
17 pathology and not only a result of pain [29]. To date, the literature has documented the
18
19
20 advantage of targeting sleep conditions to possibly relieve the symptoms of migraine
21
22
23 [30]. As the prevalence of sleep disorders soars in both FM and migraine patients,
24
25
26 appreciation of the close links between FM and migraine increases.

27
28
29 IBS frequently coexists with both FM and migraine [31, 32]. The underlying
30
31
32 mechanisms for the association of FM with an increasing risk of IBS and migraine are
33
34
35 unclear. FM, migraine, and IBS may be three distinct manifestations of a common
36
37
38 pathophysiologic process affecting the gastrointestinal tract. These disorders are
39
40
41 known as “central sensitivity syndrome” and are mutually associated [33]. A growing
42
43
44 body of evidence indicates that central sensitization phenomena play a role in the
45
46
47 pathogenesis of both FM and migraine. Central sensitization at the levels of the spinal
48
49
50 dorsal horn and trigeminal nucleus may also be involved in the progression of
51
52
53 migraine attacks, and the prolonged nociceptive inputs may result in the maintenance
54
55
56 of supraspinal sensitization and central neuroplastic changes, leading to the

1
2
3
4 conversion of episodic headaches into chronic [34]. Interestingly, increased intestinal
5
6 permeability (IP) may be observed in IBS [35]. Altered IP with intestinal bacteria
7
8 overgrowth may trigger the development of FM [36] and migraine [37]. The
9
10 microbiome–gut–brain axis, a bidirectional communication between the central and
11
12 enteric nervous systems with microbiome via the neural, humoral, endocrine, and
13
14 immune pathways [31, 32, 38] was proposed as one of the multidisciplinary
15
16 pathophysiologic mechanisms underlying IBS [38], FM [39, 40] and migraine [37,
17
18 41]. The gut microbiota interacts with the central, autonomic, and enteric nervous
19
20 systems and hypothalamic–pituitary–adrenal axis and vice versa [38].
21
22
23
24
25
26
27
28
29
30
31

32 **Cohort analysis for the association between migraine and the risk of new-onset**

33 **FM**

34
35
36
37 This study also revealed a higher risk of FM in migraine patients than in
38
39 non-migraine subjects in every factor-based subset of the cohorts. One interesting
40
41 feature was that patients with hyperlipidemia had a higher risk of FM. Adverse lipid
42
43 profiles occurred more frequently in migraine patients with a higher body mass index
44
45 [42, 43]. Lack of exercise may precipitate the development of an adverse lipid profile;
46
47 however, exercise may trigger acute migraine attacks [44], and some patients might
48
49 avoid exercise in the hope of preventing migraines. This hypothesis could be
50
51
52
53
54
55
56
57
58
59
60

1
2
3 supported by a study which revealed that headache patients have less aerobic
4 endurance and flexibility than do healthy controls [45]. Aerobic exercise could relieve
5 depression and anxiety and avoid the harmful consequences of stress [46]. Avoiding
6 exercise may worsen mood distress and is thus possibly related to the development of
7 FM.
8
9
10
11
12
13
14
15
16
17

18 Increased migraine frequency—with the transformation of migraine to chronic
19 migraine—intensifies the sensitivity to pain in somatic areas outside the cephalic
20 region and may predispose to FM [6]. Hypothalamic neuroendocrine dysfunction has
21 been proposed as a brain mechanism common to both FM and migraine [47]. Both
22 conditions also share the mechanism of central sensitization of pain neurons.
23 Magnesium, which is often used as an agent for relieving migraine headaches, is also
24 beneficial for treating FM. Low magnesium levels can exacerbate FM symptoms, and
25 they are implicated in migraines [48]. Researchers have discovered that people who
26 do not respond to standard migraine treatments are often affected with FM [14].
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 and hormonal influence, which may predispose to the development of FM [1, 6, 31,
5
6 32, 38, 47].
7

8
9 Our study contained a large sample size because of our population-based design
10
11 approach. Additionally, we were careful in our analyses to reduce selection bias, and
12
13 our vast documents of medical profiles allowed for minimal effect from our
14
15 confounding factors in the subjects. However, there are still certain limitations in our
16
17 study. We based our study solely on the information from diagnoses in patient files, so
18
19 we did not include any patients whose cases were unidentified. In the event of poor
20
21 categorization of a patient's symptoms, it is possible that it may affect the
22
23 discernibility between migraine and fibromyalgia. Since many crucial variables are
24
25 not retrievable and there are multitudes of ways to diagnose fibromyalgia as well as
26
27 the numerous subtypes of migraines, our data provides merely a glimpse of these two
28
29 conditions. It is also impossible to assess treatment response from our large database
30
31 analysis, so it's hard to sort out "diagnosis by exclusion" in this study. Future studies
32
33 are needed to better delineate "diagnosis by exclusion". Furthermore, this study did
34
35 not take into account the severity of FM and migraines in patients, therefore, no
36
37 definitive statement can be made in regards to the intensity of FM and subsequent risk
38
39 of developing migraine conditions, and vice versa. Moreover, this study is naturally
40
41 more prone to observational bias since patients with migraines and FM are generally
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 more likely to seek medical attention for another condition.
5
6
7

8 9 **Conclusion**

10
11 This study is the first to reveal a population-based bidirectional association
12
13 between the onsets of FM and migraine in patients with migraine and FM,
14
15 respectively. The risk of developing migraine is greater than the risk of developing
16
17 FM. The incidence rates of FM in the migraine cohort and of migraine in the FM
18
19 cohort increased with age in both directions. However, the HRs relative to the
20
21 corresponding comparison cohorts were attenuated with the increase in age.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Migraine headache and fibromyalgia.
<http://www.fibromyalgia-symptoms.org/migraine-headaches-and-fibromyalgia.html>
2. Evans RW, de Tommaso M. Migraine and Fibromyalgia. *Headache*. 2011;51:295-299.
3. de Tommaso M, Federici A, Serpino C, Vecchio E, Franco G, Sardaro M, et al. Clinical features of headache patients with fibromyalgia comorbidity. *J Headache Pain*. 2011;12:629–638.
4. Küçükşen S, Genç E, Yılmaz H, Sallı A, Gezer İA, Karahan AY, et al. The prevalence of fibromyalgia and its relation with headache characteristics in episodic migraine. *Clin Rheumatol*. 2013;32:983-990.
5. Marcus DA, Bhowmick A. Fibromyalgia comorbidity in a community sample of adults with migraine. *Clin Rheumatol*. 2013;32:1553–1556.
6. Giamberardino MA, Affaitati G, Martelletti P, Tana C, Negro A, Lapenna D, et al. Impact of migraine on fibromyalgia symptoms. *J Headache Pain*. 2015;17:28.
7. Vij B, Whipple MO, Tepper SJ, Mohabbat AB, Stillman M, Vincent A. Frequency of Migraine Headaches in Patients With Fibromyalgia. *Headache*. 2015;55:860–865.

- 1
2
3
4 8. Centonze V, Bassi A, Cassiano A, Munno I, Dalfino L, Causarano V. Migraine,
5
6 daily chronic headache and fibromyalgia in the same patient: an evolutive
7
8
9 'continuum' of non organic chronic pain? About 100 clinical cases. *Neurol Sci*
10
11
12 2004; 25:S291–S292.
13
- 14
15 9. Ifergane G, Buskila D, Simiseshvely N, Zeev K, Cohen H. Prevalence of
16
17 fibromyalgia syndrome in migraine patients. *Cephalalgia* 2006;26:451–456.
18
- 19
20 10. Peres MF, Zukerman E, Young WB, Silberstein SD. Fatigue in chronic migraine
21
22 patients. *Cephalalgia* 2002;22:720–724.
23
- 24
25 11. Headache Classification Committee of the International Headache Society (IHS).
26
27 The International Classification of Headache Disorders, 3rd edition (beta version).
28
29
30
31
32 *Cephalalgia*. 2013; 33:629–808.
33
- 34
35 12. Dodick DW. Clinical practice: chronic daily headache. *N Engl J Med*. 2006;354:
36
37 158-165.
38
- 39
40 13. Nosedá R, Burstein R. Migraine pathophysiology: anatomy of the
41
42 trigeminovascular pathway and associated neurological symptoms, CSD,
43
44 sensitization and modulation of pain. *Pain*. 2013; 154:1.
45
- 46
47
48 14. Fibromyalgia, migraine, and more. www.migrainesurvival.com/fibromyalgia
49
- 50
51 15. Staud R. Peripheral pain mechanisms in chronic widespread pain. *Best Pract Res*
52
53
54
55 *Clin Rheumatol*. 2011;25:155-164.
56

- 1
2
3
4 16. Burstein R. Deconstructing migraine headache into peripheral and central
5
6 sensitization. *Pain*. 2001; 89:107–110.
7
8
9 17. Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding
10
11 and future directions. *J Neurol*. 2017; 3:1-9.
12
13
14 18. Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic
15
16 widespread pain in patients with fibromyalgia and chronic fatigue syndrome. *Clin*
17
18 *Rheumatol*. 2007; 26: 465–473.
19
20
21 19. Clauw DJ. Fibromyalgia A Clinical Review. *JAMA*. 2014;311:1547-1555.
22
23
24 20. Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive
25
26 neurons to cervical input after stimulation of the dura mater.
27
28 *Brain*. 2003;126:1801-1813.
29
30
31 21. Marcus DA, Bernstein C, Rudy TE. Fibromyalgia and headache: an
32
33 epidemiological study supporting migraine as part of the fibromyalgia syndrome.
34
35 *Clin Rheumatol* 2005; 24:595–601
36
37
38 22. González-Roldán AM, Bomba IC, Diesch E, Montoya P, Flor H, Kamping S.
39
40 Controllability and hippocampal activation during pain expectation in
41
42 fibromyalgia syndrome. *Biol Psychol*. 2016;121:39-48.
43
44
45 23. Santos DM, Lage LV, Jabur EK, Kaziyama HHS, Iosifescu DV, De Lucia MCS,
46
47 et al. The influence of depression on personality traits in patients with
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 fibromyalgia: a case-control study. *Clin Exp Rheumatol*. 2017;35 Suppl
5
6 105:13-19.
7
8
9 24. Amouroux R, Rousseau-Salvador C. Anxiety and depression in children and
10
11 adolescents with migraine: a review of the literature. *Encephale*.
12
13 2008;34:504-510.
14
15
16
17 25. Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger
18
19 factors. *Med Clin North Am*. 2001;85:911-941.
20
21
22
23 26. Panconesi A. Serotonin and migraine: a reconsideration of the central theory. *J*
24
25 *Headache Pain*. 2008; 9: 267–276.
26
27
28
29 27. Becker S, Schweinhardt P. Dysfunctional Neurotransmitter Systems in
30
31 Fibromyalgia, Their Role in Central Stress Circuitry and Pharmacological Actions
32
33 on These Systems. *Pain Res Treat*. 2012;2012:741746.
34
35
36
37 28. McBeth J, Lacey RJ, Wilkie R. Predictors of New-Onset Widespread Pain in
38
39 Older Adults. *Arthritis & Rheumatology*. 2014; 66: 757–767.
40
41
42
43 29. Choy EH. The role of sleep in pain and fibromyalgia. *Nat Rev*
44
45 *Rheumatol*. 2015;11:513-520.
46
47
48
49 30. Moldofsky H. Sleep and pain. *Sleep Medicine Reviews*. 2001; 5: 387–398.
50
51
52 31. Chen X, Souza RD, Hong ST. The role of gut microbiota in the gut-brain axis:
53
54 current challenges and perspectives. *Protein Cell* 2013; 4: 403–414.
55
56
57
58
59
60

- 1
2
3
4 32. Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior.
5
6 *Neurogastroenterol Motil.* 2011; 23:187-192.
7
8
9 33. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology
10
11 for fibromyalgia and overlapping conditions, and related issue of disease versus
12
13 illness. *Semin Arthritis Rheum.* 2008; 37:339-352.
14
15
16 34. Bernstein C, Burstein R. Sensitization of the Trigeminovascular Pathway:
17
18 Perspective and Implications to Migraine Pathophysiology. *J Clin Neurol*
19
20 2012;8:89-99.
21
22
23 35. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and
24
25 hypersensitivity in the irritable bowel syndrome. *Pain.* 2009;146:41-46.
26
27
28 36. Goebel A, Buhner S, Schedel R, Lochs H, Sprutte G. Altered intestinal
29
30 permeability in patients with primary fibromyalgia and in patients with complex
31
32 regional pain syndrome. *Rheumatology* 2008;47:1223-1227.
33
34
35 37. van Hemert S, Breedveld AC, Rovers JM, Vermeiden JP, Witteman BJ, Smits
36
37 MG, et al. Migraine associated with gastrointestinal disorders: review of the
38
39 literature and clinical implications. *Front Neurol.* 2014; 21:241.
40
41
42 38. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions
43
44 between enteric microbiota, central and enteric nervous systems. *Ann*
45
46 *Gastroenterol.* 2015; 28: 203-209.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 39. Berstad A, Valeur J. Gut gateway to generalized pain. *Scand J Pain.* 2016;
5
6 13:164–165.
7
8
9 40. Mu C, Yang Y, Zhu W. Gut microbiota: the brain peacekeeper. *Front Microbiol*
10
11 2016;7:345.
12
13
14 41. Dai YJ, Wang HY, Wang XJ, Kaye AD, Sun YH. Potential Beneficial Effects of
15
16 Probiotics on Human Migraine Headache: A Literature Review. *Pain Physician.*
17
18 2017; 20: 251-255.
19
20
21 42. Saberi A, Hatamian HR, Kazemnejad E, Ghorbannejad N. Hyperlipidemia in
22
23 migraine: Is it more frequent in migraineurs? *Iran J Neurol.* 2011; 10:46-50.
24
25
26 43. Salmasi M, Amini L, Javanmard SH, Saadatnia M. Metabolic syndrome in
27
28 migraine headache: A case-control study. *J Res Med Sci.* 2014; 19: 13–17.
29
30
31 44. Koppen H, van Veldhoven PL. Migraineurs with exercise-triggered attacks have a
32
33 distinct migraine. *J Headache Pain.* 2013;14:99.
34
35
36 45. Neuss K, Neumann B, Steinhoff BJ, Thegeder H, Bauer A, Reimers D. Physical
37
38 activity and fitness in patients with headache disorders. *Int J Sports Med.*
39
40 1997;18:607-611.
41
42
43 46. Salmon P. Effects of Physical exercise on anxiety, depression, and sensitivity to
44
45 stress: a unifying theory. *Clin Psychol Rev.* 2001; 21: 33-61.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 47. Valença MM, Medeiros FL, Martins HA, Massaud RM, Peres MF.
5
6 Neuroendocrine dysfunction in fibromyalgia and migraine. *Curr Pain Headache*
7
8
9 *Rep.* 2009;13:358-364.
10
11
12 48. Assarzadegan F, Asgarzadeh S, Hatamabadi HR, Shahrami A, Tabatabaey A,
13
14 Asgarzadeh M. Serum concentration of magnesium as an independent risk factor
15
16 in migraine attacks: a matched case-control study and review of the literature. *Int*
17
18 *Clin Psychopharmacol.* 2016;31:287-292.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legend:

Figure 1. Flow chart showing selection of study subjects.

Figure 2. Cummulative incidence of migraine compared between patients with and without fibromyalgia using the Kaplan-Meier method.

Figure 3. Cummulative incidence of fibromyalgia compared between patients with and without migraine using the Kaplan-Meier method.

Table 1. Demographic characteristics and comorbidity in patient with and without fibromyalgia.

Variable	Fibromyalgia		p-value
	No N =132863	Yes N =33216	
Sex	n(%)	n(%)	0.99
Female	71880(54.1)	17970(54.1)	
Male	60983(45.9)	15246(45.9)	
Age, mean(SD)	50.9(16.9)	51.4(16.7)	<0.001 [#]
Stratify age			0.99
≤49	64292(48.4)	10673(48.4)	
50-65	36820(27.7)	9205(27.7)	
65+	31751(23.9)	7938(23.9)	
Comorbidity			
Diabetes	10485(7.89)	3193(9.61)	<0.001
Hypertension	37284(28.1)	11287(34.0)	<0.001
Hyperlipidemia	22446(16.9)	7301(22.0)	<0.001
Depression	4690(3.53)	1804(5.43)	<0.001
Anxiety	10494(7.90)	4214(12.7)	<0.001
Sleep disorder	21095(15.9)	8121(24.5)	<0.001
CAD	17918(13.5)	5821(17.5)	<0.001
Chronic fatigue syndrome	199(0.15)	93(0.28)	<0.001
Irritable bowel syndrome	5125(3.86)	1870(5.63)	<0.001

Chi-Square Test; [#]: Two sample T-test

Table 2. Comparison of incidence and hazard ratio of migraine stratified by sex, and age between patients with and without fibromyalgia.

Variable	Without fibromyalgia					With fibromyalgia				
	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)
All	1810	876077	2.07	1(Reference)	1(Reference)	954	217386	4.39	2.12(1.96, 2.30)***	1.89(1.75, 2.05)***
Sex										
Female	1373	487506	2.82	1(Reference)	1(Reference)	669	120773	5.54	1.97(1.79, 2.16)***	1.76(1.60, 1.93)***
Male	437	388571	1.12	1(Reference)	1(Reference)	285	96613	2.95	2.62(2.26, 3.05)***	2.29(1.97, 2.67)***
Stratify age										
≤50	922	444710	2.07	1(Reference)	1(Reference)	548	110557	4.96	2.39(2.15, 2.66)***	2.06(1.85, 2.29)***
50-65	564	245579	2.30	1(Reference)	1(Reference)	258	60603	4.26	1.85(1.60, 2.15)***	1.66(1.43, 1.92)***
65+	324	185788	1.74	1(Reference)	1(Reference)	148	46226	3.20	1.83(1.51, 2.23)***	1.69(1.39, 2.05)***
Comorbidity[‡]										
No	774	508879	1.52	1(Reference)	1(Reference)	311	95605	3.25	2.14(1.88, 2.44)***	2.13(1.87, 2.43)***
Yes	1036	367197	2.82	1(Reference)	1(Reference)	643	121780	5.28	1.88(1.71, 2.08)***	1.80(1.63, 1.98)***

Rate[#], incidence rate, per 1,000 person-years; Crude HR, crude hazard ratio

Adjusted HR[†]: multivariable analysis including sex, age, and comorbidities of diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, CAD, chronic fatigue syndrome, and irritable bowel syndrome

***p<0.001

Comorbidity[‡]: Patients with any one of the comorbidities diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, CAD, chronic fatigue syndrome, and irritable bowel syndrome were classified as the comorbidity group

Table 3. Cox model with hazard ratios and 95% confidence intervals of migraine associated with fibromyalgia and covariates.

Variable	Crude		Adjusted [†]	
	HR	(95% CI)	HR	(95% CI)
Fibromyalgia	2.12	(1.96, 2.30)***	1.89	(1.74, 2.04)***
Sex(Women vs. Men)	2.28	(2.09, 2.48)***	2.08	(1.91, 2.27)***
Age, years	1.00	(0.99, 1.00)**	0.99	(0.99, 1.00)***
Baseline comorbidities (yes vs. no)				
Diabetes	0.82	(0.70, 0.96)*	0.73	(0.61, 0.860)***
Hypertension	1.06	(0.97, 1.15)	-	-
Hyperlipidemia	1.30	(1.19, 1.43)***	1.14	(1.03, 1.27)*
Depression	2.37	(2.06, 2.72)***	1.20	(1.03, 1.39)*
Anxiety	2.68	(2.44, 2.95)***	1.64	(1.47, 1.84)***
Sleep disorder	2.63	(2.43, 2.85)***	1.97	(1.80, 2.15)***
CAD	1.30	(1.18, 1.44)***	1.10	(0.98, 1.23)
Chronic fatigue syndrome	2.24	(1.01, 4.99)*	1.45	(0.65, 3.22)
Irritable bowel syndrome	1.98	(1.71, 2.29)***	1.36	(1.17, 1.58)***

Crude HR, relative hazard ratio; Adjusted[†] : multivariable analysis including sex, age, and comorbidities of diabetes, hyperlipidemia, depression, anxiety, sleep disorder, CAD, chronic fatigue syndrome, and irritable bowel syndrome;

*p<0.05, **p<0.01, ***p<0.001

Table 4. Demographic characteristics and comorbidity in patient with and without migraine.

Variable	migraine		p-value
	No N =69680	Yes N =17420	
Sex	n(%)	n(%)	0.99
Female	51176(73.4)	12794(73.4)	
Male	18504(26.6)	4626(26.6)	
Age, mean(SD)	44.2(15.6)	44.5(15.3)	0.04 [#]
Stratify age			0.99
≤49	46768(67.1)	11692(67.1)	
50-65	14940(21.4)	3735(21.4)	
65+	7972(11.4)	1993(11.4)	
Comorbidity			
Diabetes	3567(5.12)	975(5.60)	0.01
Hypertension	12563(18.0)	4551(26.1)	<0.001
Hyperlipidemia	8278(11.9)	3187(18.3)	<0.001
Depression	2019(2.90)	1851(10.6)	<0.001
Anxiety	4366(6.27)	3724(21.4)	<0.001
Sleep disorder	9469(13.6)	6976(40.1)	<0.001
CAD	5560(7.98)	2449(14.1)	<0.001
Chronic fatigue syndrome	71(0.10)	41(0.24)	<0.001
Irritable bowel syndrome	2106(3.02)	1224(7.03)	<0.001

Chi-Square Test; [#]: Two sample T-test

Table 5. Comparison of incidence and hazard ratio of fibromyalgia stratified by sex, and age between patients with and without migraine

Variable	Without migraine					With migraine				
	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)
All	2034	453130	4.49	1(Reference)	1(Reference)	800	114070	7.01	1.57(1.44, 1.70)***	1.52(1.39, 1.65)***
Sex										
Female	1556	335328	4.64	1(Reference)	1(Reference)	568	84606	6.71	1.45(1.32, 1.60)***	1.43(1.29, 1.59)***
Male	478	117802	4.06	1(Reference)	1(Reference)	232	29464	7.87	1.94(1.66, 2.27)***	1.78(1.50, 2.11)***
Stratify age										
≤50	1060	310621	3.41	1(Reference)	1(Reference)	470	78131	6.02	1.77(1.58, 1.97)***	1.64(1.46, 1.84)***
50-65	608	96607	6.29	1(Reference)	1(Reference)	207	24189	8.56	1.36(1.16, 1.59)***	1.30(1.09, 1.53)**
65+	366	45902	7.97	1(Reference)	1(Reference)	123	11751	10.5	1.329(1.07, 1.61)**	1.28(1.03, 1.58)*
Comorbidity[‡]										
No	1082	309229	3.50	1(Reference)	1(Reference)	255	43664	5.84	1.67(1.46, 1.92)***	1.79(1.56, 2.06)***
Yes	952	143901	6.62	1(Reference)	1(Reference)	545	70406	7.74	1.18(1.06, 1.31)**	1.299(1.16, 1.44)***

Rate[#], incidence rate, per 1,000 person-years; Crude HR, crude hazard ratio

Adjusted HR[†]: multivariable analysis including sex, age, and comorbidities of diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, CAD, and irritable bowel syndrome

*p<0.05, **p<0.01, ***p<0.001


Comorbidity[‡]: Patients with any one of the comorbidities diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, CAD, chronic fatigue syndrome, and irritable bowel syndrome were classified as the comorbidity group

Table 6. Cox model with hazard ratios and 95% confidence intervals of fibromyalgia associated with migraine and covariates

Variable	Crude		Adjusted [†]	
	HR	(95% CI)	HR	(95% CI)
Migraine	1.57	(1.44, 1.70)***	1.51	(1.38, 1.65)***
Sex(Women vs. Men)	1.05	(0.97, 1.15)	-	-
Age, years	1.02	(1.02, 1.03)***	1.02	(1.01, 1.02)***
Baseline comorbidities (yes vs. no)				
Diabetes	1.58	(1.36, 1.82)***	0.99	(0.85, 1.16)
Hypertension	1.81	(1.67, 1.96)***	1.10	(0.99, 1.22)
Hyperlipidemia	1.69	(1.54, 1.85)***	1.15	(1.03, 1.28)*
Depression	1.38	(1.17, 1.63)***	1.06	(0.89, 1.26)
Anxiety	1.34	(1.19, 1.51)***	0.92	(0.80, 1.05)
Sleep disorder	1.45	(1.33, 1.58)***	1.09	(0.98, 1.20)
CAD	1.74	(1.57, 1.94)***	1.01	(0.89, 1.14)
Chronic fatigue syndrome	2.11	(0.79, 5.62)	-	-
Irritable bowel syndrome	1.28	(1.06, 1.53)**	0.94	(0.78, 1.13)


Crude HR, relative hazard ratio; Adjusted[†]: multivariable analysis including age, and comorbidities of diabetes, hypertension, hyperlipidemia, anxiety, sleep disorder, stroke, and peptic ulcer disease, and medication of NSAID;

*p<0.05, **p<0.01, ***p<0.001




126x86mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



112x104mm (300 x 300 DPI)



108x105mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Included on page:
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,5,6
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	5,6
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8-10
Objectives	3	State specific objectives, including any pre-specified hypotheses	10
Methods			
Study design	4	Present key elements of study design early in the paper	11-14
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	11-14
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	11-14
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	11-14
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	11-14
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	11-14
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	11-14
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-14
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11-14
Bias	9	Describe any efforts to address potential sources of bias	11-14
Study size	10	Explain how the study size was arrived at	11-14
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11-14
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	11-14
		(b) Describe any methods used to examine subgroups and interactions	11-14

		(c) Explain how missing data were addressed	11-14
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	11-14
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	11-14
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	11-14
		(e) Describe any sensitivity analyses	11-14
Continued on next page			
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	15,16
		(b) Give reasons for non-participation at each stage	15,16
		(c) Consider use of a flow diagram	15,16
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	15,16
		(b) Indicate number of participants with missing data for each variable of interest	15,16
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	15,16
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	15,16
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	15,16
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	15,16
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	15,16
		(b) Report category boundaries when continuous variables were categorized	15,16
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	15,16
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	15,16
Discussion			
Key results	18	Summarise key results with reference to study objectives	17-23
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	22

1 2 3 4	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-23
5 6 7	Generalisability	21	Discuss the generalisability (external validity) of the study results	17-23
8	Other information			
9 10 11 12	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	2, 3

13
14
15 Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

16
17
18 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Bidirectional Association between Migraine and Fibromyalgia: Two Population-Based Retrospective Cohort Analyses

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026581.R1
Article Type:	Research
Date Submitted by the Author:	09-Jan-2019
Complete List of Authors:	Penn, I-Wen ; Fu Jen Catholic University, School of Medicine Chuang, Eric ; University of California Berkeley, Intended B.S. Molecular and Cell Biology Chuang, Tien-Yow ; Taipei Veterans General Hospital, Department of Physical Medicine and Rehabilitation Lin, Cheng-Li; China Medical University Hospital, Management Office for Health Data Kao, Chia-Hung; China Medical University, School of Medicine
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	General practice / Family practice, Neurology, Rehabilitation medicine, Rheumatology
Keywords:	fibromyalgia, Migraine < NEUROLOGY, bidirectional analysis, retrospective cohort

SCHOLARONE™
Manuscripts

1
2
3
4 **Bidirectional Association between Migraine and Fibromyalgia: Two Population-**
5
6
7 **Based Retrospective Cohort Analyses**
8
9

10 **Running title:** Bidirectional Association between Fibromyalgia and Migraine
11
12
13
14
15

16 I-Wen Penn^{1,2}, Eric Chuang³, Tien-Yow Chuang⁴, Cheng-Li Lin^{5,6}, Chia-Hung Kao^{7,8,9}
17
18
19
20
21

22 ¹School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
23
24

25 ²Department of Physical Medicine and Rehabilitation, Fu Jen Catholic University
26
27
28 Hospital, Fu Jen Catholic University, New Taipei City, Taiwan
29
30

31 ³UC Berkeley Mishler Lab Undergraduate Researcher, Intended B.S. Molecular and
32
33
34 Cell Biology, University of CA, Berkeley, USA
35
36

37 ⁴Department of Physical Medicine and Rehabilitation, Taipei Veterans General
38
39
40 Hospital and National Yang-Ming University, Taipei, Taiwan
41
42

43 ⁵Management Office for Health Data, China Medical University Hospital, Taichung,
44
45
46 Taiwan
47
48

49 ⁶College of Medicine, China Medical University, Taichung, Taiwan
50
51

52 ⁷Graduate Institute of Biomedical Sciences and School of Medicine, College of
53
54
55 Medicine, China Medical University, Taichung, Taiwan
56
57
58
59
60

1
2
3
4 ⁸Department of Nuclear Medicine and PET Center, China Medical University Hospital,
5
6
7 Taichung, Taiwan
8
9

10 ⁹Department of Bioinformatics and Medical Engineering, Asia University, Taichung,
11
12
13 Taiwan.
14
15
16
17

18
19 ***Corresponding author:** Chia-Hung Kao, MD, Graduate Institute of Biomedical
20
21
22 Sciences and School of Medicine, College of Medicine, China Medical University, No.
23
24
25 2, Yuh-Der Road, Taichung 404, Taiwan. E-mail: d10040@mail.cmuh.org.tw;
26
27
28 dr.kaochiahung@gmail.com
29
30
31
32
33
34

35 **List of abbreviations**

36
37

38 FM: Fibromyalgia; HR: hazard ratio; CI: confidence interval; ICD-9-CM: International
39
40 Classification of Diseases, Ninth Revision, Clinical Modification; NHI: National
41
42
43 Health Insurance; LHID: Longitudinal Health Insurance Database
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: Fibromyalgia (FM) and migraine are common pain disorders and tend to coexist. This study determined whether these two conditions exhibited any mutual influences.

Setting: Cohort Study.

Participants: A retrospective, longitudinal cohort study was conducted by using the data from a nationwide healthcare database. This study has two separate arms. Arm 1 included 33,216 FM patients, and Arm 2 contained 7420 migraine patients; all of these patients were diagnosed between 2000 and 2010. Using the same database, control subjects who had neither FM nor migraine and who were matched with the FM and migraine patients by sex, age, and index date of diagnosis were recruited. Each control cohort was four times the size of the relevant study cohort. Both the control and study cohorts were followed until the end of 2011.

Results: The incidence rates of migraine and FM were calculated in Arm 1 and Arm 2, respectively. The overall incidence of migraine was greater in the FM cohort than in the control cohort [4.39 vs. 2.07 per 1000 person-years; crude hazard ratio (HR) = 2.12, 95% confidence interval (CI) = 1.96–2.30; adjusted hazard ratio (aHR) = 1.89, 95% CI = 1.75–2.05], after adjustment for sex, age, and comorbidities. The overall incidence of

1
2
3
4 FM in the migraine cohort was 1.57 times greater than in the control cohort (7.01 vs.
5
6
7 4.49 per 1000 person-years; aHR = 1.52, 95% CI = 1.39–1.65).
8
9

10 **Conclusions:** The present study demonstrates the presence of a bidirectional link
11
12
13 between FM and migraine.
14
15
16
17
18

19 *Key words:* fibromyalgia, migraine, bidirectional analysis, retrospective cohort
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study:

1. Our study contained a large sample size because of our population-based design approach.
2. We based our study solely on the information from diagnoses in patient files, so we did not include any patients whose cases were unidentified.
3. This study is naturally more prone to observational bias since patients with migraines and FM are generally more likely to seek medical attention for another condition.
4. The health claims information in the LHID includes mainly disease documents recorded according to ICD-9-CM, but lack descriptions on clinical subsets of disease manifestation or progression, such as episodic or chronic migraine, with or without aura, etc.
5. The selections of two study and control cohorts were based on the inclusion and exclusion criteria only. There is no subjective patient omission in the process.

Introduction

One of the major symptoms of fibromyalgia (FM) is a headache. Among those different types of headaches, there are migraines—some bad enough to debilitate a person. Interestingly, similarities exist between migraines and fibromyalgia, and as we consider the two conditions in the same context, many instances of overlapping symptoms, causes, and treatments are noted [1]. Several studies have reported that a high proportion (20%–36%) of patients with migraine have FM [2-5]. By contrast, the frequency of migraine in patients with FM is approximately 45%–80%, suggesting that migraine is common in patients with FM [6, 7]. Despite previous reports demonstrated that the prevalence of fibromyalgia was higher among migraine patients, and vice versa [8-13], explanations for this high degree of co-occurrence are unknown.

Migraine is a complex, recurrent disorder that manifests as a throbbing headache, which is frequently associated with nausea, allodynia, and sound or light sensitivity, and may develop into a chronic condition and disability [14,15]. The pain is considered to occur due to the nociceptive activation of the trigeminovascular system, including the sensory neurons from the trigeminal ganglion and upper cervical nerve roots, which modulate central signals to numerous subcortical sites [16]. The combination of tonic nociceptive input and central disinhibition may also play a role in the development of FM. Many migraineurs experience a condition termed “allodynia” during migraine

1
2
3
4 attacks. Usually, allodynia is confined to the head and neck but may involve other areas
5
6
7 of the body [17]. Increasing evidence indicates that the peripheral tissues are relevant
8
9
10 contributors to painful impulse input, which might either initiate or maintain central
11
12
13 sensitization, thus contributing to the progression of FM [18]. Migraine is also supposed
14
15
16 to be a trigger factor for FM. The repeated headaches in migraine patients might
17
18
19 increase the neuronal response to both nociceptive and non-nociceptive stimulation and
20
21
22 induce spontaneous neuronal activity, which might concurrently heighten the
23
24
25 sensitivity of the patient to FM [19]. Several studies have highlighted the role of the
26
27
28 hypothalamus in migraines [17]. Evidence indicates its direct and indirect anatomical
29
30
31 connections to the thalamus and autonomic brainstem nuclei, supporting its role in
32
33
34 nociceptive and autonomic modulation among migraine patients [20]. However, the
35
36
37 brain mechanisms also common to FM suffers result in central sensitization of pain
38
39
40 neurons leading to the evolution of a complex syndrome [21].

41
42
43 Early in the course of disease, the widespread musculoskeletal pain of FM patients
44
45
46 often appears in the neck or shoulder region [22]. Neck pain may activate local
47
48
49 nociceptors and transmit painful impulses through the upper cervical spinal nerves,
50
51
52 such as the greater occipital nerve, to the trigeminal nucleus caudalis, thus inducing a
53
54
55 migraine attack [23]. Some experts believe that FM and migraine headaches both
56
57
58 involve defects in the systems that regulate certain chemical messengers in the brain,
59
60

1
2
3
4 including serotonin and epinephrine (adrenaline) [1]. which might reflect in their
5
6
7 similar psychological comorbidities: depression, anxiety, interpersonal sensitivity,
8
9
10 somatization, etc [9]. Psychosocial distress and psychological abnormality are common
11
12
13 to occur in patients suffering from migraine as well as patients suffering from FM.
14
15

16 Although previous research has demonstrated a high comorbidity rate for
17
18
19 migraines and FM, several vital issues must be highlighted. (1) Most of these studies
20
21
22 were performed at tertiary care centers. Patients are often referred to tertiary clinics due
23
24
25 to high pain complaints, disability, or medication overuse. Hence, the sample
26
27
28 populations may differ from patients treated in general practice. (2) Most of these
29
30
31 studies used a cross-sectional design for investigating the prevalence instead of the
32
33
34 incidence of migraine or FM. (3) If there is a significant association, whether people
35
36
37 with migraine are more likely than the general population to develop FM or vice versa
38
39
40 remains unknown. Therefore, our population-based longitudinal cohort study is trying
41
42
43 to investigate the links between migraine and FM.
44
45
46
47
48
49
50
51

52 **Methods**

53 **Patient and Public Involvement**

54
55 The data for this research were sourced from the Longitudinal Health Insurance
56
57
58
59
60

1
2
3
4 Database (LHID). The LHID comprises the data of 1 million insurants' health claims
5
6
7 from the Taiwan National Health Insurance (NHI) program, which covers 99% of 23
8
9
10 million Taiwan citizens with single-payer health insurance. According to the
11
12
13 government's report, no differences were noted in the demographic features between
14
15
16 the LHID and Taiwan NHI program. The health claims information in the LHID
17
18
19 includes general information regarding the insurants (such as birthdate, sex, and
20
21
22 occupation), disease documents (recorded according to the International Classification
23
24
25 of Diseases, Ninth Revision, Clinical Modification; ICD-9-CM), and other medical
26
27
28 service-related data.
29
30
31
32
33

34 **Data Availability Statement**

35
36
37 The dataset used in this study is held by the Taiwan Ministry of Health and Welfare
38
39 (MOHW). The Ministry of Health and Welfare must approve our application to access
40
41
42 this data. Any researcher interested in accessing this dataset can submit an application
43
44
45 form to the Ministry of Health and Welfare requesting access. Please contact the staff
46
47
48 of MOHW (Email: stcarolwu@mohw.gov.tw) for further assistance. Taiwan Ministry
49
50
51 of Health and Welfare Address: No.488, Sec. 6, Zhongxiao E. Rd., Nangang Dist.,
52
53
54 Taipei City 115, Taiwan (R.O.C.). Phone: +886-2-8590-6848. All relevant data are
55
56
57
58 within the paper.
59
60

Ethics Statement

The National Health Insurance Research Databank (NHIRD) encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH104-REC2-115-CR3). The IRB also specifically waived the consent requirement.

Study Cohorts

A bidirectional cohort study design was used to interpret the longitudinal association between FM and migraine.

Figure 1 shows the procedure for establishing the two study Arms. For study Arm 1, we identified patients with FM (ICD-9-CM code 729.1) who were aged ≥ 20 years and were newly diagnosed consecutively ≥ 3 times within 3 months in 2000–2010. The first diagnosis date was designated as the index date for entry into the FM cohort. Patients with a history of migraine (ICD-9-CM codes 346) were excluded from the

1
2
3
4 cohort. For each FM patient, we randomly selected four persons free of FM and
5
6
7 migraine from the population of the LHID2000, who were frequency-matched by sex,
8
9
10 age (in 5-year increments), and entry date of the FM patient; these subjects were
11
12
13 recruited to the non-FM (control) cohort.
14
15

16 For study Arm 2, a similar procedure to that for study Arm 1 was used to establish
17
18 a migraine cohort of patients who did not have a history of FM, were aged ≥ 20 years,
19
20 and were newly diagnosed consecutively ≥ 3 times within 3 months in 2000–2010.
21
22
23
24

25 Subjects in the study Arms 1 and 2 were followed until the diagnosis of migraine
26
27 or FM, withdrawal from the NHI program, death, or December 31, 2011. The patients
28
29
30 in two cohorts contained some baseline comorbidities: diabetes (ICD-9-CM code 250),
31
32
33 hypertension (ICD-9-CM codes 401–405), hyperlipidemia (ICD-9-CM code 272),
34
35
36 depression (ICD-9-CM codes 296.2, 296.3, 296.5, 300.4, 309, and 311), anxiety (ICD-
37
38
39 9-CM code 300.0, 300.2, 300.3, 308.3, and 309.81), sleep disorder (ICD-9-CM codes
40
41
42 307.4 and 780.5), coronary artery disease (CAD; ICD-9-CM codes 410–414), chronic
43
44
45 fatigue syndrome (CFS; ICD-9-CM code 780.71), and irritable bowel syndrome (IBS;
46
47
48 ICD-9-CM code 564.1).
49
50
51
52
53
54

55 **Statistical analyses**

56
57

58 The characteristics of the study cohorts are expressed as the mean and
59
60

1
2
3
4 corresponding standard deviation for age and as number and percentage for sex and
5
6
7 comorbidities. Age difference was assessed using the t-test, and sex and comorbidity
8
9
10 distributions were tested using the chi-square test. The incidence density for each cohort
11
12
13 was calculated as the total event number divided by the sum of follow-ups [per 1000
14
15
16 person-years (PY)]. The cumulative incidence curve for each cohort was measured
17
18
19 using the Kaplan–Meier method, with the curve difference being calculated using the
20
21
22 log-rank test. To determine the migraine and fibromyalgia risks in Arms 1 and 2,
23
24
25 respectively, the hazard ratios (HRs) and corresponding 95% confidence intervals (CIs)
26
27
28 were estimated using single-variable and multivariable Cox proportional hazard models.
29
30
31 Data management and all statistical analyses were performed using SAS software for
32
33
34 Windows (Version 9.4, SAS Institute, Cary, NC, USA), and incidence curves was
35
36
37 plotted using R software. All significance levels were set at two-sided $p < 0.05$.
38
39
40
41
42
43
44
45

46 **Results**

47
48
49 Table 1 shows the demographic characteristics of the FM and non-FM cohorts.
50
51
52 The age- and sex-matched cohorts demonstrated differences in the comorbidity
53
54
55 distribution. The prevalence of comorbidities was significantly higher in the FM cohort
56
57
58 than in non-FM cohort ($p < 0.001$).
59
60

1
2
3
4 Table 2 shows the migraine incidence was 4.39 and 2.07 per 1000 PY in the FM
5
6
7 and non-FM cohorts, respectively. Figure 2 shows a higher incidence curve for the FM
8
9
10 cohort and a lower curve for the non-FM cohort (log rank test=371.4, $p < 0.001$). After
11
12
13 adjustment for age, sex, and comorbidities, the FM patients exhibited a 1.89-fold higher
14
15
16 risk of migraine than did the non-FM subjects (HR = 1.89, 95% CI = 1.75–2.05).
17
18
19 Among females, the relative risk of migraine was 1.76-fold higher in the FM patients
20
21
22 than in the non-FM subjects (HR = 1.76, 95% CI 1.60–1.93), whereas the risk among
23
24
25 males was 2.29-fold higher in the FM patients than in the non-FM subjects (HR = 2.29,
26
27
28 95% CI = 1.97–2.67). Regarding the age effect, the HRs for migraine in the FM cohort
29
30
31 were 2.06 (95% CI = 1.85–2.29), 1.66 (95% CI = 1.43–1.92), and 1.69 (95% CI = 1.39–
32
33
34 2.05) for age ≤ 50 , 51–65, and ≥ 65 years, respectively.
35
36

37 Table 3 shows the influence of factors associated with the occurrence of migraine
38
39
40 in the FM cohort. Male sex, hyperlipidemia, depression, anxiety, sleep disorder, CAD,
41
42
43 CFS, and IBS were associated with a higher risk of migraine (all p -value < 0.05).
44
45

46 Table 4 lists the comorbidities as well as the age- and sex-matched comparisons
47
48
49 in the migraine cohort. The migraine cohort showed higher prevalent comorbidities
50
51
52 than non-migraine cohort.
53
54

55 Table 5 and Figure 3 show the significantly higher incidence of FM in migraine
56
57
58 patients than that in non-migraine subjects (7.01 vs. 4.49 per 1000 PY; log-rank
59
60

1
2
3
4 test=116.7, $p < 0.001$). After adjustment for age, sex, and comorbidities, the migraine
5
6
7 patients exhibited a 1.52-fold higher risk of FM than did non-migraine subjects (HR =
8
9
10 1.52, 95% CI = 1.39–1.65). The female migraine patients displayed a 1.43-fold higher
11
12
13 risk of FM than did the non-migraine subjects (HR = 1.43, 95% CI = 1.29–1.59),
14
15
16 whereas the male migraine patients exhibited a 1.78-fold higher risk of FM (95% CI =
17
18
19 1.50–2.11). Regarding the age effect, the HRs for FM were 1.64 (95% CI = 1.46–1.84),
20
21
22 1.30 (95% CI = 1.09–1.53), and 1.28 (95% CI = 1.03–1.58) in migraine patients aged
23
24
25 <50, 50–64, and ≥ 65 years, respectively.
26
27

28 Table 6 shows the associations of sex, age, and comorbidities with the risk of FM.
29
30
31 The variables, including age, migraine, hypertension, hyperlipidemia, depression, sleep
32
33
34 disorder, and CAD, were all associated with a lower risk of FM.
35
36
37
38
39
40
41
42

43 Discussion

44
45
46 The results of the two cohort arms suggested a bidirectional risk of migraine and
47
48
49 FM in patients with FM and migraine, respectively. In the Arm 1 analysis, the incidence
50
51
52 rates for migraine were 4.39 and 2.07 per 1000 PY in FM patients and non-FM subjects,
53
54
55 respectively [adjusted hazard ratio (aHR) = 1.89 and 95% CI = 1.75–2.05 in FM
56
57
58 patients]. In the Arm 2 analysis, the incidence rates for FM were 7.01 and 4.49 per 1000
59
60

1
2
3
4 PY in migraine patients and non-migraine subjects, respectively (aHR = 1.52 and 95%
5
6
7 CI = 1.39–1.65 in migraine patients). This indicated that FM has a stronger predictive
8
9
10 power for the onset of migraine than does migraine for the onset of FM.
11
12

13 The Kaplan–Meier plots demonstrated that the incidence of migraine in the FM
14
15 cohort and the incidence of FM in the migraine cohort increased steadily during the 12-
16
17 year follow-up period. Moreover, similar patterns were observed in the two
18
19 corresponding comparison cohorts. The cumulative incidence measured by the Kaplan–
20
21 Meier plots revealed a greater risk of migraine among FM patients than that of FM
22
23 among migraine patients.
24
25
26
27
28
29
30

31 Our predictive analytics could potentially dictate diagnosis and treatment. For
32
33 example, a subsequent diagnosis of FM could come from the failure of anti-migraine
34
35 treatment to alleviate fatigue [24]. Since migraine is often better managed, the authors
36
37 would hypothesize that FM patients are more likely to be treated for migraine than vice
38
39 versa. Therefore, clinical trials of migraine patients in the future have the potential to
40
41 evaluate the effects of FM on health outcomes and its treatment efficacy [10].
42
43
44
45
46
47
48
49
50
51

52 **Cohort analysis for the association between FM and the risk of new-onset migraine**

53

54
55 This study revealed a positive association between the diagnosis of FM and the
56
57 risk of migraine. Adjustment for factors, including hypertension, CAD, and CFS, had
58
59
60

1
2
3
4 no strong influence on this association. However, sex, age (particularly in patients under
5
6
7 49 years of age), diabetes, hyperlipidemia, depression, anxiety, sleep disorder, and IBS
8
9
10 remained statistically significant.
11
12

13 “High frequency and chronic migraine increase the sensitivity to pain in
14
15 fibromyalgia (FM) patients [25], such heightened pain sensitivity may be attenuated by
16
17 comorbid diabetes. There is also a documented report showing a significant positive
18
19 association between migraine frequency and intensity with total and LDL cholesterol,
20
21 independent of diet and lifestyle [26].” Several hypotheses have been proposed to
22
23 explain the development of chronic widespread pain and/or episodic throbbing or
24
25 pulsing pain over the head and neck regions as the possible effects of comorbidities,
26
27 including depression and anxiety. Depression and anxiety disorders have been
28
29 identified as important secondary symptoms of FM [11, 27, 28]. The pain of FM may
30
31 initiate the development of mood disorders as a result of the stress created on the body.
32
33 In addition, depression and anxiety might also induce the onset or present as a prodrome
34
35 of migraine, according to several evidence-based studies [29, 30]. Research has
36
37 indicated that serotonin levels might be related to the interconnections between anxiety
38
39 and migraine [31]. A lower level of serotonin may be central to the dysregulation of
40
41 descending antinociceptive systems, leading to the occurrence of FM and migraine [31,
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58 32].
59
60

1
2
3
4 Nonrefreshing sleep or sleep deprivation in healthy persons can induce symptoms
5
6
7 of fibromyalgia [33], implying that sleep abnormalities might be a pathology and not
8
9
10 only a result of pain [34]. To date, the literature has documented the advantage of
11
12
13 targeting sleep conditions to possibly relieve the symptoms of migraine [35]. As the
14
15
16 prevalence of sleep disorders soars in both FM and migraine patients, appreciation of
17
18
19 the close links between FM and migraine increases.
20
21

22 IBS frequently coexists with both FM and migraine [36, 37]. The underlying
23
24
25 mechanisms for the association of FM with an increasing risk of IBS and migraine are
26
27
28 unclear. FM, migraine, and IBS may be three distinct manifestations of a common
29
30
31 pathophysiologic process affecting the gastrointestinal tract. These disorders are known
32
33
34 as “central sensitivity syndrome” and are mutually associated [38]. A growing body of
35
36
37 evidence indicates that central sensitization phenomena play a role in the pathogenesis
38
39
40 of both FM and migraine. Central sensitization at the levels of the spinal dorsal horn
41
42
43 and trigeminal nucleus may also be involved in the progression of migraine attacks, and
44
45
46 the prolonged nociceptive inputs may result in the maintenance of supraspinal
47
48
49 sensitization and central neuroplastic changes, leading to the conversion of episodic
50
51
52 headaches into chronic [39]. Interestingly, increased intestinal permeability (IP) may
53
54
55 be observed in IBS [40]. Altered IP with intestinal bacteria overgrowth may trigger the
56
57
58 development of FM [41] and migraine [42]. The microbiome–gut–brain axis, a
59
60

1
2
3
4 bidirectional communication between the central and enteric nervous systems with
5
6
7 microbiome via the neural, humoral, endocrine, and immune pathways [36, 37, 43] was
8
9
10 proposed as one of the multidisciplinary pathophysiologic mechanisms underlying IBS
11
12
13 [43], FM [44, 45] and migraine [42, 46]. The gut microbiota interacts with the central,
14
15
16 autonomic, and enteric nervous systems and hypothalamic–pituitary–adrenal axis and
17
18
19 vice versa [43].
20
21
22
23
24

25 **Cohort analysis for the association between migraine and the risk of new-onset** 26 27 28 **FM**

29
30
31 This study also revealed a higher risk of FM in migraine patients than in non-
32
33
34 migraine subjects in every factor-based subset of the cohorts. One interesting feature
35
36
37 was that patients with hyperlipidemia had a higher risk of FM. Adverse lipid profiles
38
39
40 occurred more frequently in migraine patients with a higher body mass index [47, 48].
41
42
43 Lack of exercise may precipitate the development of an adverse lipid profile; however,
44
45
46 exercise may trigger acute migraine attacks [49], and some patients might avoid
47
48
49 exercise in the hope of preventing migraines. This hypothesis could be supported by a
50
51
52 study which revealed that headache patients have less aerobic endurance and flexibility
53
54
55 than do healthy controls [50]. Aerobic exercise could relieve depression and anxiety
56
57
58 and avoid the harmful consequences of stress [51]. Avoiding exercise may worsen
59
60

1
2
3
4 mood distress and is thus possibly related to the development of FM.
5
6

7 Increased migraine frequency—with the transformation of migraine to chronic
8
9
10 migraine—intensifies the sensitivity to pain in somatic areas outside the cephalic region
11
12
13 and may predispose to FM [6]. Hypothalamic neuroendocrine dysfunction has been
14
15
16 proposed as a brain mechanism common to both FM and migraine [52]. Both conditions
17
18
19 also share the mechanism of central sensitization of pain neurons. Magnesium, which
20
21
22 is often used as an agent for relieving migraine headaches, is also beneficial for treating
23
24
25 FM. Low magnesium levels can exacerbate FM symptoms, and they are implicated in
26
27
28 migraines [53]. Researchers have discovered that people who do not respond to
29
30
31 standard migraine treatments are often affected with FM [17]. Given the high
32
33
34 comorbidity rate of migraine and FM, many professionals still assume the role of
35
36
37 central nervous system pain-processing abnormalities, including central sensitization
38
39
40 and inadequate pain inhibition with repeated headache episodes, and beyond that, tonic
41
42
43 peripheral nociceptive input to be associated with the augmented windup in the
44
45
46 responses to neurotransmitters, immunomodulation, vascular changes, and hormonal
47
48
49 influence, which may predispose to the development of FM [1, 6, 36, 37, 43, 52].
50

51
52 Our study contained a large sample size because of our population-based design
53
54
55 approach. Additionally, we were careful in our analyses to reduce selection bias, and
56
57
58 our vast documents of medical profiles allowed for minimal effect from our
59
60

1
2
3
4 confounding factors in the subjects. However, there are still certain limitations in our
5
6
7 study. We based our study solely on the information from diagnoses in patient files, so
8
9
10 we did not include any patients whose cases were unidentified. In the event of poor
11
12
13 categorization of a patient's symptoms, it is possible that it may affect the discernibility
14
15
16 between migraine and fibromyalgia. Since many crucial variables are not retrievable
17
18
19 and there are multitudes of ways to diagnose fibromyalgia as well as the numerous
20
21
22 subtypes of migraines, our data provides merely a glimpse of these two conditions. It
23
24
25 is also impossible to assess treatment response from our large database analysis, so it's
26
27
28 hard to sort out "diagnosis by exclusion" in this study. Future studies are needed to
29
30
31 better delineate "diagnosis by exclusion". Furthermore, this study did not take into
32
33
34 account the severity of FM and migraines in patients, therefore, no definitive statement
35
36
37 can be made in regards to the intensity of FM and subsequent risk of developing
38
39
40 migraine conditions, and vice versa. Moreover, this study is naturally more prone to
41
42
43 observational bias since patients with migraines and FM are generally more likely to
44
45
46 seek medical attention for another condition.
47
48
49
50

51 **Conclusion**

52
53
54
55 This study is the first to reveal a population-based bidirectional association
56
57
58 between the onsets of FM and migraine in patients with migraine and FM, respectively.
59
60

1
2
3
4 The risk of developing migraine is greater than the risk of developing FM. The
5
6
7 incidence rates of FM in the migraine cohort and of migraine in the FM cohort increased
8
9
10 with age in both directions. However, the HRs relative to the corresponding comparison
11
12
13 cohorts were attenuated with the increase in age.
14
15
16
17
18

19 **Author contributions:**

20
21
22 **Conceptualization:** I-Wen Penn, Chia-Hung Kao.
23

24
25 **Methodology:** Cheng-Li Lin, Chia-Hung Kao.
26

27
28 **Software:** Cheng-Li Lin, Chia-Hung Kao.
29

30
31 **Validation:** I-Wen Penn, Eric Chuang, Tien-Yow Chuang, Cheng-Li Lin, Chia-Hung
32
33
34 Kao.
35

36
37 **Formal analysis:** I-Wen Penn, Eric Chuang, Tien-Yow Chuang, Cheng-Li Lin, Chia-
38
39
40 Hung Kao.
41

42
43 **Investigation:** Cheng-Li Lin, Chia-Hung Kao.
44

45
46 **Resources:** Cheng-Li Lin, Chia-Hung Kao.
47

48
49 **Data curation:** IWP, EC, TYC, CLL, CHK.
50

51
52 **Writing (original draft preparation):** I-Wen Penn, Eric Chuang, Tien-Yow Chuang,
53
54
55 Cheng-Li Lin, Chia-Hung Kao.
56

57
58 **Writing (review and editing):** I-Wen Penn, Eric Chuang, Tien-Yow Chuang, Cheng-
59
60

1
2
3
4 Li Lin, Chia-Hung Kao.
5
6

7 **Visualization:** I-Wen Penn, Eric Chuang, Tien-Yow Chuang, Cheng-Li Lin, Chia-
8
9 Hung Kao.
10
11
12

13 **Supervision:** Chia-Hung Kao.
14
15

16 **Project administration:** Chia-Hung Kao.
17
18

19 **Funding acquisition:** Chia-Hung Kao.
20
21
22

23
24
25 **Funding:**
26
27

28 This work was supported by grants from the Ministry of Health and Welfare, Taiwan
29
30 (MOHW108-TDU-B-212-133004), China Medical University Hospital (DMR-107-
31
32 192), Academia Sinica Stroke Biosignature Project (BM10701010021), MOST Clinical
33
34 Trial Consortium for Stroke (MOST 107-2321-B-039 -004-), Tseng-Lien Lin
35
36 Foundation, Taichung, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds,
37
38 Japan. The funders had no role in the study design, data collection and analysis, decision
39
40 to publish, or preparation of the manuscript. No additional external funding was
41
42 received for this study.
43
44
45
46
47
48
49
50
51
52
53
54
55

56 **Conflict of Interest:**
57
58

59 All authors report no conflicts of interest.
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Reference

1. de Tommaso M. Prevalence, clinical features and potential therapies for fibromyalgia in primary headaches. *Expert Rev Neurother*. 2012;12:287–95.
2. Evans RW, de Tommaso M. Migraine and Fibromyalgia. *Headache*. 2011;51:295-299.
3. de Tommaso M, Federici A, Serpino C, Vecchio E, Franco G, Sardaro M, et al. Clinical features of headache patients with fibromyalgia comorbidity. *J Headache Pain*. 2011;12:629–638.
4. Küçükşen S, Genç E, Yılmaz H, Sallı A, Gezer İA, Karahan AY, et al. The prevalence of fibromyalgia and its relation with headache characteristics in episodic migraine. *Clin Rheumatol*. 2013;32:983-990.
5. Marcus DA, Bhowmick A. Fibromyalgia comorbidity in a community sample of adults with migraine. *Clin Rheumatol*. 2013;32:1553–1556.
6. Giamberardino MA, Affaitati G, Martelletti P, Tana C, Negro A, Lapenna D, et al. Impact of migraine on fibromyalgia symptoms. *J Headache Pain*. 2015;17:28.
7. Vij B, Whipple MO, Tepper SJ, Mohabbat AB, Stillman M, Vincent A. Frequency of Migraine Headaches in Patients With Fibromyalgia. *Headache*. 2015;55:860–865.

- 1
2
3
4 8. Centonze V, Bassi A, Cassiano A, Munno I, Dalfino L, Causarano V. Migraine,
5
6
7 daily chronic headache and fibromyalgia in the same patient: an evolutive
8
9
10 'continuum' of non organic chronic pain? About 100 clinical cases. *Neurol Sci* 2004;
11
12
13 25:S291–S292.
14
15
- 16 9. Ifergane G, Buskila D, Simisheshely N, Zeev K, Cohen H. Prevalence of
17
18
19 fibromyalgia syndrome in migraine patients. *Cephalalgia* 2006;26:451–456.
20
21
- 22 10. Peres MF, Zukerman E, Young WB, Silberstein SD. Fatigue in chronic migraine
23
24
25 patients. *Cephalalgia* 2002;22:720–724.
26
27
- 28 11. Whealy M, Nanda S, Vincent A, Mandrekar J, Cutrer FM. Fibromyalgia in migraine:
29
30
31 a retrospective cohort study. *J Headache Pain*. 2018;19(1):61.
32
33
- 34 12. de Tommaso M, Sciruicchio V, Delussi M, Vecchio E, Goffredo M, Simeone M,
35
36
37 Barbaro MGF. Symptoms of central sensitization and comorbidity for juvenile
38
39
40 fibromyalgia in childhood migraine: an observational study in a tertiary headache
41
42
43 center. *J Headache Pain*. 2017;18(1):59.
44
45
- 46 13. de Tommaso M. Migraine and fibromyalgia. *J Headache Pain*. 2015;16(Suppl
47
48
49 1):A45.
50
51
- 52 14. Headache Classification Committee of the International Headache Society (IHS).
53
54
55 The International Classification of Headache Disorders, 3rd edition (beta version).
56
57
58 *Cephalalgia*. 2013; 33:629–808.
59
60

- 1
2
3
4 15. Dodick DW. Clinical practice: chronic daily headache. *N Engl J Med*. 2006;354:
5
6 158-165.
7
8
9
10 16. Nosedá R, Burstein R. Migraine pathophysiology: anatomy of the
11
12 trigeminovascular pathway and associated neurological symptoms, CSD,
13
14 sensitization and modulation of pain. *Pain*. 2013; 154:1.
15
16
17
18 17. Lolognier S, Eijkelkamp N, Wood JN. Mechanical allodynia. *Pflugers Arch*.
19
20 2015;467(1):133-9.
21
22
23
24 18. Staud R. Peripheral pain mechanisms in chronic widespread pain. *Best Pract Res*
25
26 *Clin Rheumatol*. 2011;25:155-164.
27
28
29
30 19. Burstein R. Deconstructing migraine headache into peripheral and central
31
32 sensitization. *Pain*. 2001; 89:107–110.
33
34
35
36 20. Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding
37
38 and future directions. *J Neurol*. 2017; 3:1-9.
39
40
41
42 21. Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic
43
44 widespread pain in patients with fibromyalgia and chronic fatigue syndrome. *Clin*
45
46 *Rheumatol*. 2007; 26: 465–473.
47
48
49
50 22. Clauw DJ. Fibromyalgia A Clinical Review. *JAMA*. 2014;311:1547-1555.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 23. Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive
5
6
7 neurons to cervical input after stimulation of the dura mater. *Brain*. 2003;126:1801-
8
9
10 1813.
11
12
13 24. Marcus DA, Bernstein C, Rudy TE. Fibromyalgia and headache: an
14
15
16 epidemiological study supporting migraine as part of the fibromyalgia syndrome.
17
18
19 *Clin Rheumatol* 2005; 24:595–601
20
21
22 25. Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states- maybe it is
23
24
25 all in their head. *Best Pract Res Clin Rheumatol*. 2011;25(2):141-54
26
27
28 26. Tana C, Santilli F, Martelletti P, di Vincenzo A, Cipollone F, Davi G,
29
30
31 Giamberardino MA. Correlation between migraine severity and cholesterol levels.
32
33
34 *Pain Pract*. 2015;15(7):662-70.
35
36
37 27. González-Roldán AM, Bomba IC, Diesch E, Montoya P, Flor H, Kamping S.
38
39
40 Controllability and hippocampal activation during pain expectation in fibromyalgia
41
42
43 syndrome. *Biol Psychol*. 2016;121:39-48.
44
45
46 28. Santos DM, Lage LV, Jabur EK, Kaziyama HHS, Iosifescu DV, De Lucia MCS, et
47
48
49 al. The influence of depression on personality traits in patients with fibromyalgia: a
50
51
52 case-control study. *Clin Exp Rheumatol*. 2017;35 Suppl 105:13-19.
53
54
55 29. Amouroux R, Rousseau-Salvador C. Anxiety and depression in children and
56
57
58 adolescents with migraine: a review of the literature. *Encephale*. 2008;34:504-510.
59
60

- 1
2
3
4 30. Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger
5
6
7 factors. *Med Clin North Am.* 2001;85:911-941.
8
9
- 10 31. Panconesi A. Serotonin and migraine: a reconsideration of the central theory. *J*
11
12
13 *Headache Pain.* 2008; 9: 267–276.
14
15
- 16 32. Becker S, Schweinhardt P. Dysfunctional Neurotransmitter Systems in
17
18
19 Fibromyalgia, Their Role in Central Stress Circuitry and Pharmacological Actions
20
21
22 on These Systems. *Pain Res Treat.* 2012;2012:741746.
23
24
- 25 33. McBeth J, Lacey RJ, Wilkie R. Predictors of New-Onset Widespread Pain in Older
26
27
28 Adults. *Arthritis & Rheumatology.* 2014; 66: 757–767.
29
30
- 31 34. Choy EH. The role of sleep in pain and fibromyalgia. *Nat Rev*
32
33
34 *Rheumatol.* 2015;11:513-520.
35
36
- 37 35. Moldofsky H. Sleep and pain. *Sleep Medicine Reviews.* 2001; 5: 387–398.
38
39
- 40 36. Chen X, Souza RD, Hong ST. The role of gut microbiota in the gut-brain axis:
41
42
43 current challenges and perspectives. *Protein Cell* 2013; 4: 403–414.
44
45
- 46 37. Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior.
47
48
49 *Neurogastroenterol Motil.* 2011; 23:187-192.
50
51
- 52 38. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for
53
54
55 fibromyalgia and overlapping conditions, and related issue of disease versus illness.
56
57
58 *Semin Arthritis Rheum.* 2008; 37:339-352.
59
60

- 1
2
3
4 39. Bernstein C, Burstein R. Sensitization of the Trigeminovascular Pathway:
5
6
7 Perspective and Implications to Migraine Pathophysiology. *J Clin Neurol*
8
9
10 2012;8:89-99.
11
12
13 40. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and
14
15
16 hypersensitivity in the irritable bowel syndrome. *Pain*. 2009;146:41–46.
17
18
19 41. Goebel A, Buhner S, Schedel R, Lochs H, Sprotte G. Altered intestinal permeability
20
21
22 in patients with primary fibromyalgia and in patients with complex regional pain
23
24
25 syndrome. *Rheumatology* 2008;47:1223-1227.
26
27
28 42. van Hemert S, Breedveld AC, Rovers JM, Vermeiden JP, Witteman BJ, Smits MG,
29
30
31 et al. Migraine associated with gastrointestinal disorders: review of the literature
32
33
34 and clinical implications. *Front Neurol*. 2014; 21:241.
35
36
37 43. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions
38
39
40 between enteric microbiota, central and enteric nervous systems. *Ann Gastroenterol*.
41
42
43 2015; 28: 203–209.
44
45
46 44. Berstad A, Valeur J. Gut gateway to generalized pain. *Scand J Pain*.. 2016; 13:164–
47
48
49 165.
50
51
52 45. Mu C, Yang Y, Zhu W. Gut microbiota: the brain peacekeeper. *Front Microbiol*
53
54
55 2016;7:345.
56
57
58
59
60

- 1
2
3
4 46. Dai YJ, Wang HY, Wang XJ, Kaye AD, Sun YH. Potential Beneficial Effects of
5
6
7 Probiotics on Human Migraine Headache: A Literature Review. *Pain Physician*.
8
9
10 2017; 20: 251-255.
11
12
13 47. Saberi A, Hatamian HR, Kazemnejad E, Ghorbannejad N. Hyperlipidemia in
14
15
16 migraine: Is it more frequent in migraineurs? *Iran J Neurol*. 2011; 10:46-50.
17
18
19 48. Salmasi M, Amini L, Javanmard SH, Saadatnia M. Metabolic syndrome in
20
21
22 migraine headache: A case-control study. *J Res Med Sci*. 2014; 19: 13–17.
23
24
25 49. Koppen H, van Veldhoven PL. Migraineurs with exercise-triggered attacks have a
26
27
28 distinct migraine. *J Headache Pain*. 2013;14:99.
29
30
31 50. Neususs K, Neumann B, Steinhoff BJ, Thegeder H, Bauer A, Reimers D. Physical
32
33
34 activity and fitness in patients with headache disorders. *Int J Sports Med*.
35
36
37 1997;18:607-611.
38
39
40 51. Salmon P. Effects of Physical exercise on anxiety, depression, and sensitivity to
41
42
43 stress: a unifying theory. *Clin Psychol Rev*. 2001; 21: 33-61.
44
45
46 52. Valença MM, Medeiros FL, Martins HA, Massaud RM, Peres MF. Neuroendocrine
47
48
49 dysfunction in fibromyalgia and migraine. *Curr Pain Headache Rep*. 2009;13:358-
50
51
52 364.
53
54
55 53. Assarzaghan F, Asgarzadeh S, Hatamabadi HR, Shahrami A, Tabatabaey A,
56
57
58 Asgarzadeh M. Serum concentration of magnesium as an independent risk factor in
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

migraine attacks: a matched case-control study and review of the literature. *Int Clin Psychopharmacol.* 2016;31:287-292.

For peer review only

1
2
3
4 **Figure Legend:**
5
6

7 Figure 1. Flow chart showing selection of study subjects.
8
9

10
11
12
13 Figure 2. Cummulative incidence of migraine compared between patients with and
14
15
16 without fibromyalgia using the Kaplan-Meier method.
17
18

19
20
21
22 Figure 3. Cummulative incidence of fibromyalgia compared between patients with
23
24
25 and without migraine using the Kaplan-Meier method.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic characteristics and comorbidity in patient with and without fibromyalgia.

Variable	Fibromyalgia		p-value
	No N =132863	Yes N =33216	
Sex	n(%)	n(%)	0.99
Female	71880(54.1)	17970(54.1)	
Male	60983(45.9)	15246(45.9)	
Age, mean(SD)	50.9(16.9)	51.4(16.7)	<0.001#
Stratify age			0.99
≤49	64292(48.4)	10673(48.4)	
50-65	36820(27.7)	9205(27.7)	
65+	31751(23.9)	7938(23.9)	
Comorbidity			
Diabetes	10485(7.89)	3193(9.61)	<0.001
Hypertension	37284(28.1)	11287(34.0)	<0.001
Hyperlipidemia	22446(16.9)	7301(22.0)	<0.001
Depression	4690(3.53)	1804(5.43)	<0.001
Anxiety	10494(7.90)	4214(12.7)	<0.001
Sleep disorder	21095(15.9)	8121(24.5)	<0.001
CAD	17918(13.5)	5821(17.5)	<0.001
Chronic fatigue syndrome	199(0.15)	93(0.28)	<0.001
Irritable bowel syndrome	5125(3.86)	1870(5.63)	<0.001

Chi-Square Test; #: Two sample T-test

Table 2. Comparison of incidence and hazard ratio of migraine stratified by sex, and age between patients with and without fibromyalgia.

Variable	Without fibromyalgia					With fibromyalgia				
	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)
All	1810	876077	2.07	1(Reference)	1(Reference)	954	217386	4.39	2.12(1.96, 2.30)***	1.89(1.75, 2.05)***
Sex										
Female	1373	487506	2.82	1(Reference)	1(Reference)	669	120773	5.54	1.97(1.79, 2.16)***	1.76(1.60, 1.93)***
Male	437	388571	1.12	1(Reference)	1(Reference)	285	96613	2.95	2.62(2.26, 3.05)***	2.29(1.97, 2.67)***
Stratify age										
≤50	922	444710	2.07	1(Reference)	1(Reference)	548	110557	4.96	2.39(2.15, 2.66)***	2.06(1.85, 2.29)***
50-65	564	245579	2.30	1(Reference)	1(Reference)	258	60603	4.26	1.85(1.60, 2.15)***	1.66(1.43, 1.92)***
65+	324	185788	1.74	1(Reference)	1(Reference)	148	46226	3.20	1.83(1.51, 2.23)***	1.69(1.39, 2.05)***
Comorbidity[‡]										
No	774	508879	1.52	1(Reference)	1(Reference)	311	95605	3.25	2.14(1.88, 2.44)***	2.13(1.87, 2.43)***
Yes	1036	367197	2.82	1(Reference)	1(Reference)	643	121780	5.28	1.88(1.71, 2.08)***	1.80(1.63, 1.98)***

Rate[#], incidence rate, per 1,000 person-years; Crude HR, crude hazard ratio

Adjusted HR[†]: multivariable analysis including sex, age, and comorbidities of diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, CAD, chronic fatigue syndrome, and irritable bowel syndrome

***p<0.001

Comorbidity[‡]: Patients with any one of the comorbidities diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, CAD, chronic fatigue syndrome, and irritable bowel syndrome were classified as the comorbidity group

Table 3. Cox model with hazard ratios and 95% confidence intervals of migraine associated with fibromyalgia and covariates.

Variable	Crude		Adjusted [†]	
	HR	(95% CI)	HR	(95% CI)
Fibromyalgia	2.12	(1.96, 2.30)***	1.89	(1.74, 2.04)***
Sex(Women vs. Men)	2.28	(2.09, 2.48)***	2.08	(1.91, 2.27)***
Age, years	1.00	(0.99, 1.00)**	0.99	(0.99, 1.00)***
Baseline comorbidities (yes vs. no)				
Diabetes	0.82	(0.70, 0.96)*	0.73	(0.61, 0.860)***
Hypertension	1.06	(0.97, 1.15)	-	-
Hyperlipidemia	1.30	(1.19, 1.43)***	1.14	(1.03, 1.27)*
Depression	2.37	(2.06, 2.72)***	1.20	(1.03, 1.39)*
Anxiety	2.68	(2.44, 2.95)***	1.64	(1.47, 1.84)***
Sleep disorder	2.63	(2.43, 2.85)***	1.97	(1.80, 2.15)***
CAD	1.30	(1.18, 1.44)***	1.10	(0.98, 1.23)
Chronic fatigue syndrome	2.24	(1.01, 4.99)*	1.45	(0.65, 3.22)
Irritable bowel syndrome	1.98	(1.71, 2.29)***	1.36	(1.17, 1.58)***

Crude HR, relative hazard ratio; Adjusted[†] : multivariable analysis including sex, age, and comorbidities of diabetes, hyperlipidemia, depression, anxiety, sleep disorder, CAD, chronic fatigue syndrome, and irritable bowel syndrome;

*p<0.05, **p<0.01, ***p<0.001

Table 4. Demographic characteristics and comorbidity in patient with and without migraine.

Variable	migraine		p-value
	No N =69680	Yes N =17420	
Sex	n(%)	n(%)	0.99
Female	51176(73.4)	12794(73.4)	
Male	18504(26.6)	4626(26.6)	
Age, mean(SD)	44.2(15.6)	44.5(15.3)	0.04 [#]
Stratify age			0.99
≤49	46768(67.1)	11692(67.1)	
50-65	14940(21.4)	3735(21.4)	
65+	7972(11.4)	1993(11.4)	
Comorbidity			
Diabetes	3567(5.12)	975(5.60)	0.01
Hypertension	12563(18.0)	4551(26.1)	<0.001
Hyperlipidemia	8278(11.9)	3187(18.3)	<0.001
Depression	2019(2.90)	1851(10.6)	<0.001
Anxiety	4366(6.27)	3724(21.4)	<0.001
Sleep disorder	9469(13.6)	6976(40.1)	<0.001
CAD	5560(7.98)	2449(14.1)	<0.001
Chronic fatigue syndrome	71(0.10)	41(0.24)	<0.001
Irritable bowel syndrome	2106(3.02)	1224(7.03)	<0.001

Chi-Square Test; #: Two sample T-test

Table 5. Comparison of incidence and hazard ratio of fibromyalgia stratified by sex, and age between patients with and without migraine

Variable	Without migraine					With migraine				
	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)
All	2034	453130	4.49	1(Reference)	1(Reference)	800	114070	7.01	1.57(1.44, 1.70)***	1.52(1.39, 1.65)***
Sex										
Female	1556	335328	4.64	1(Reference)	1(Reference)	568	84606	6.71	1.45(1.32, 1.60)***	1.43(1.29, 1.59)***
Male	478	117802	4.06	1(Reference)	1(Reference)	232	29464	7.87	1.94(1.66, 2.27)***	1.78(1.50, 2.11)***
Stratify age										
≤50	1060	310621	3.41	1(Reference)	1(Reference)	470	78131	6.02	1.77(1.58, 1.97)***	1.64(1.46, 1.84)***
50-65	608	96607	6.29	1(Reference)	1(Reference)	207	24189	8.56	1.36(1.16, 1.59)***	1.30(1.09, 1.53)**
65+	366	45902	7.97	1(Reference)	1(Reference)	123	11751	10.5	1.32(1.07, 1.61)**	1.28(1.03, 1.58)*
Comorbidity[‡]										
No	1082	309229	3.50	1(Reference)	1(Reference)	255	43664	5.84	1.67(1.46, 1.92)***	1.79(1.56, 2.06)***
Yes	952	143901	6.62	1(Reference)	1(Reference)	545	70406	7.74	1.18(1.06, 1.31)**	1.29(1.16, 1.44)***

Rate[#], incidence rate, per 1,000 person-years; Crude HR, crude hazard ratio

Adjusted HR[†]: multivariable analysis including sex, age, and comorbidities of diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, CAD, and irritable bowel syndrome

*p<0.05, **p<0.01, ***p<0.001


Comorbidity[‡]: Patients with any one of the comorbidities diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, CAD, chronic fatigue syndrome, and irritable bowel syndrome were classified as the comorbidity group

Table 6. Cox model with hazard ratios and 95% confidence intervals of fibromyalgia associated with migraine and covariates


Variable	Crude		Adjusted [†]	
	HR	(95% CI)	HR	(95% CI)
Migraine	1.57	(1.44, 1.70)***	1.51	(1.38, 1.65)***
Sex(Women vs. Men)	1.05	(0.97, 1.15)	-	-
Age, years	1.02	(1.02, 1.03)***	1.02	(1.01, 1.02)***
Baseline comorbidities (yes vs. no)				
Diabetes	1.58	(1.36, 1.82)***	0.99	(0.85, 1.16)
Hypertension	1.81	(1.67, 1.96)***	1.10	(0.99, 1.22)
Hyperlipidemia	1.69	(1.54, 1.85)***	1.15	(1.03, 1.28)*
Depression	1.38	(1.17, 1.63)***	1.06	(0.89, 1.26)
Anxiety	1.34	(1.19, 1.51)***	0.92	(0.80, 1.05)
Sleep disorder	1.45	(1.33, 1.58)***	1.09	(0.98, 1.20)
CAD	1.74	(1.57, 1.94)***	1.01	(0.89, 1.14)
Chronic fatigue syndrome	2.11	(0.79, 5.62)	-	-
Irritable bowel syndrome	1.28	(1.06, 1.53)**	0.94	(0.78, 1.13)

Crude HR, relative hazard ratio; Adjusted[†] : multivariable analysis including age, and comorbidities of diabetes, hypertension, hyperlipidemia, anxiety, sleep disorder, stroke, and peptic ulcer disease, and medication of NSAID;

*p<0.05, **p<0.01, ***p<0.001




126x86mm (300 x 300 DPI)



112x104mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



108x105mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Included on page:
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,5,6
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	5,6
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8-10
Objectives	3	State specific objectives, including any pre-specified hypotheses	10
Methods			
Study design	4	Present key elements of study design early in the paper	11-14
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	11-14
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	11-14
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	11-14
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	11-14
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	11-14
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	11-14
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-14
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11-14
Bias	9	Describe any efforts to address potential sources of bias	11-14
Study size	10	Explain how the study size was arrived at	11-14
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11-14
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	11-14
		(b) Describe any methods used to examine subgroups and interactions	11-14

		(c) Explain how missing data were addressed	11-14
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	11-14
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	11-14
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	11-14
		(e) Describe any sensitivity analyses	11-14
Continued on next page			
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	15,16
		(b) Give reasons for non-participation at each stage	15,16
		(c) Consider use of a flow diagram	15,16
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	15,16
		(b) Indicate number of participants with missing data for each variable of interest	15,16
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	15,16
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	15,16
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	15,16
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	15,16
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	15,16
		(b) Report category boundaries when continuous variables were categorized	15,16
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	15,16
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	15,16
Discussion			
Key results	18	Summarise key results with reference to study objectives	17-23
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	22

1 2 3 4	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-23
5 6 7	Generalisability	21	Discuss the generalisability (external validity) of the study results	17-23
8	Other information			
9 10 11 12	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	2, 3

13
14
15 Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

16
17
18 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Bidirectional Association between Migraine and Fibromyalgia: Retrospective Cohort Analyses of Two Populations

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026581.R2
Article Type:	Research
Date Submitted by the Author:	22-Feb-2019
Complete List of Authors:	Penn, I-Wen ; Fu Jen Catholic University, School of Medicine Chuang, Eric ; University of California Berkeley, Intended B.S. Molecular and Cell Biology Chuang, Tien-Yow ; Taipei Veterans General Hospital, Department of Physical Medicine and Rehabilitation Lin, Cheng-Li; China Medical University Hospital, Management Office for Health Data Kao, Chia-Hung; China Medical University, School of Medicine
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	General practice / Family practice, Neurology, Rehabilitation medicine, Rheumatology
Keywords:	fibromyalgia, Migraine < NEUROLOGY, bidirectional analysis, retrospective cohort

SCHOLARONE™
Manuscripts

1
2
3
4 **Bidirectional Association between Migraine and Fibromyalgia: Retrospective**
5
6
7 **Cohort Analyses of Two Populations**
8
9

10 **Running title:** Bidirectional Association between Fibromyalgia and Migraine
11
12
13
14
15

16 I-Wen Penn^{1,2}, Eric Chuang³, Tien-Yow Chuang⁴, Cheng-Li Lin^{5,6}, Chia-Hung
17
18 Kao^{7,8,9}
19
20
21
22
23
24

25 ¹School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
26
27

28 ²Department of Physical Medicine and Rehabilitation, Fu Jen Catholic University
29
30 Hospital, Fu Jen Catholic University, New Taipei City, Taiwan
31
32
33

34 ³UC Berkeley Mishler Lab Undergraduate Researcher, Intended B.S. Molecular and
35
36 Cell Biology, University of CA, Berkeley, USA
37
38
39

40 ⁴Department of Physical Medicine and Rehabilitation, Taipei Veterans General
41
42 Hospital and National Yang-Ming University, Taipei, Taiwan
43
44
45

46 ⁵Management Office for Health Data, China Medical University Hospital, Taichung,
47
48 Taiwan
49
50
51

52 ⁶College of Medicine, China Medical University, Taichung, Taiwan
53
54

55 ⁷Graduate Institute of Biomedical Sciences and School of Medicine, College of
56
57 Medicine, China Medical University, Taichung, Taiwan
58
59
60

1
2
3
4 ⁸Department of Nuclear Medicine and PET Center, China Medical University
5
6
7 Hospital, Taichung, Taiwan
8

9
10 ⁹Department of Bioinformatics and Medical Engineering, Asia University, Taichung,
11
12
13 Taiwan.
14

15
16
17
18
19 ***Corresponding author:** Chia-Hung Kao, MD, Graduate Institute of Biomedical
20
21
22 Sciences and School of Medicine, College of Medicine, China Medical University,
23
24
25 No. 2, Yuh-Der Road, Taichung 404, Taiwan. E-mail: d10040@mail.cmuh.org.tw;
26
27
28 dr.kaochiahung@gmail.com
29

30
31
32
33
34
35 **List of abbreviations**
36

37
38 FM: Fibromyalgia; HR: hazard ratio; CI: confidence interval; ICD-9-CM:
39
40 International Classification of Diseases, Ninth Revision, Clinical Modification; NHI:
41
42
43
44 National Health Insurance; LHID: Longitudinal Health Insurance Database
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: Fibromyalgia (FM) and migraine are common pain disorders that tend to coexist. This study determined whether these two conditions exhibited any mutual influences.

Setting: Cohort study

Participants: A retrospective, longitudinal cohort study was conducted using data obtained from a nationwide health care database. This study had two arms. Arm 1 comprised 33,216 patients with FM, and Arm 2 consisted of 7420 patients with migraine; all of these patients were diagnosed between 2000 and 2010. Using the aforementioned database, control subjects who had neither FM nor migraine and were matched with the FM and migraine patients by sex, age, and index date of diagnosis were recruited. Each control cohort was four times the size of the corresponding study cohort. Follow-up for the control and study cohorts was conducted until the end of 2011.

Results: The incidence rates of FM and migraine were calculated in Arms 1 and 2, respectively. The overall incidence of migraine was greater in the FM cohort than in the corresponding control cohort [4.39 vs. 2.07 per 1000 person-years; crude hazard ratio (HR) = 2.12, 95% confidence interval (CI) = 1.96–2.30; adjusted HR (aHR) = 1.89, 95% CI = 1.75–2.05]. After adjustment for sex, age, and comorbidities, the

1
2
3
4 overall incidence of FM in the migraine cohort was 1.57 times greater than that in the
5
6
7 corresponding control cohort (7.01 vs. 4.49 per 1000 person-years; aHR = 1.52, 95%
8
9
10 CI = 1.39–1.65).

11
12
13 **Conclusions:** The present study revealed a bidirectional link between FM and
14
15
16 migraine.

17
18
19
20
21
22 *Keywords:* fibromyalgia, migraine, bidirectional analysis, retrospective cohort
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Peer review only

Strengths and limitations of this study

1. Our study contained a large sample size because of its population-based design.
2. We based our study solely on information from diagnoses in patient files and included no information on patients whose cases were unidentified.
3. This study was naturally highly prone to observational bias because patients with migraine and those with FM are generally more likely to seek medical attention for other conditions than are those with neither.
4. Health claims information in the Longitudinal Health Insurance Database mainly comprises documentation on diseases recorded according to the International Classification of Diseases, Ninth Revision, Clinical Modification but lacks descriptions of clinical subsets for disease manifestation or progression such as episodic or chronic migraine and migraine with or without aura.
5. The selection process of two study cohorts and two control cohorts was based solely on inclusion and exclusion criteria and did not involve subjective patient omission.

Introduction

A major symptom of fibromyalgia (FM) is headache. Migraine is a type of headaches, and some migraines are severe enough to be debilitating. Notably, similarities have been observed between migraines and FM, and many instances of overlapping symptoms, causes, and treatments were noted in the present study, where the two conditions were considered in the same context [1]. Several studies have reported that high proportions (20%–36%) of patients with migraine also have FM [2-5]. Similarly, the frequency of migraine occurrence in patients with FM is 45%–80%, suggesting that migraine is common in patients with FM [6, 7]. Despite reports that the prevalence of FM is higher among migraine patients and vice versa [8-13], no explanations have been provided for this high rate of co-occurrence.

Migraine is a complex, recurrent disorder that manifests as a throbbing headache and is frequently associated with nausea, allodynia, and sensitivity to sound or light. Migraines may develop into a chronic condition or disability [14, 15]. Migraine pain is believed to be caused by the nociceptive activation of the trigeminovascular system, including sensory neurons from the trigeminal ganglion and upper cervical nerve roots, which modulate central signals to numerous subcortical sites [16]. The combination of tonic nociceptive input and central disinhibition may also play a role in the development of FM. Many migraineurs experience a condition referred to as

1
2
3
4 “allodynia” during migraine attacks. Typically, allodynia is confined to the head and
5
6
7 neck but may involve other areas of the body [17]. Increasing evidence indicates that
8
9
10 peripheral tissues are relevant contributors to painful impulse input and can initiate or
11
12
13 maintain central sensitization, thereby contributing to the progression of FM [18].
14
15
16 Migraine is believed to trigger FM. Repeated headaches in patients with migraine
17
18
19 may increase the neuronal response to both nociceptive and nonnociceptive
20
21
22 stimulation and induce spontaneous neuronal activity, which may concurrently
23
24
25 increase patient sensitivity to FM [19]. Several studies have highlighted the role of the
26
27
28 hypothalamus in migraines [17]. Evidence indicates the direct and indirect anatomical
29
30
31 connections of the hypothalamus to the thalamus and autonomic brainstem nuclei,
32
33
34 thereby supporting the role of the hypothalamus in nociceptive and autonomic
35
36
37 modulation in patients with migraine [20]. However, brain mechanisms common in
38
39
40 patients with FM result in the central sensitization of pain neurons, leading to the
41
42
43 evolution of a complex syndrome [21].
44
45

46 Early in the course of FM, widespread musculoskeletal pain often appears in the
47
48
49 neck or shoulder region [22]. Neck pain may activate local nociceptors and transmit
50
51
52 pain impulses through upper cervical spinal nerves such as the greater occipital nerve
53
54
55 to the trigeminal nucleus caudalis, thereby inducing a migraine attack [23]. Some
56
57
58 experts believe that FM and migraine headaches both involve defects in the systems
59
60

1
2
3
4 that regulate certain chemical messengers in the brain, including serotonin and
5
6
7 epinephrine (adrenaline) [1]. These defects may be reflected in the similar
8
9
10 psychological comorbidities of the two conditions, including depression, anxiety,
11
12
13 interpersonal sensitivity, and somatization [9]. Psychosocial distress or abnormalities
14
15
16 commonly occur in patients with migraine and those with FM.

17
18
19 Although studies have reported high comorbidity rates for migraine and FM, the
20
21
22 following crucial concerns must be addressed. (1) Most such studies were conducted
23
24
25 at tertiary care centers. Patients are often referred to tertiary clinics when they present
26
27
28 with extreme pain, disability, or medication overuse. Therefore, such sample
29
30
31 populations may differ from patients treated in general practice. (2) Most such studies
32
33
34 used a cross-sectional design to investigate prevalence rather than incidence of
35
36
37 migraine or FM. (3) Whether a significant association exists, suggesting that people
38
39
40 with migraine are more likely to develop FM than the general population or vice versa,
41
42
43 remains unknown. Therefore, our population-based longitudinal cohort was employed
44
45
46 to investigate the link between migraine and FM.

54 55 **Methods**

56 57 58 **Patient and public involvement**

1
2
3
4 Data for this research were obtained from the Longitudinal Health Insurance
5
6
7 Database (LHID). The LHID comprises data of insurance claims filed by 1 million
8
9
10 patients under Taiwan's National Health Insurance (NHI) program, which covers 99%
11
12
13 of Taiwan's 23 million citizens with single-payer health insurance. According to a
14
15
16 government report, no differences between the LHID and Taiwan's NHI program
17
18
19 exist with respect to demographic characteristics. The health claims information in the
20
21
22 LHID includes general patient information (e.g., birthdate, sex, occupation),
23
24
25 documentation of diseases [recorded according to the International Classification of
26
27
28 Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)], and other data related
29
30
31 to medical services.
32
33
34
35
36

37 **Data availability statement**

38
39
40 The dataset used in this study was obtained from Taiwan's Ministry of Health
41
42
43 and Welfare (MOHW), from which we were required to obtain approval to access the
44
45
46 data. Any researcher interested in accessing this dataset can submit an application
47
48
49 form to the MOHW requesting access. Please contact the staff of the MOHW (email:
50
51
52 stcarolwu@mohw.gov.tw) for further assistance. Taiwan MOHW Address: No. 488,
53
54
55 Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 115, Taiwan (ROC). Phone:
56
57
58 +886-2-8590-6848. All relevant data are provided in this manuscript.
59
60

Ethics statement

The NHI Research Databank encrypts patients' personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, birthdate, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHI Research Databank. This study was approved for exemption by the Institutional Review Board of China Medical University (CMUH104-REC2-115-CR3). In addition, the Institutional Review Board waived the requirement for patient consent.

Study cohorts

A bidirectional cohort study design was used to interpret the longitudinal association between FM and migraine.

Figure 1 displays the procedure for establishing the two arms of this study. For Arm 1, we identified patients with FM (ICD-9-CM code 729.1) aged ≥ 20 years and newly diagnosed ≥ 3 times consecutively within 3 months from 2000–2010. The first diagnosis date was designated as the index date for entry into the FM cohort. Patients with a history of migraine (ICD-9-CM code 346) were excluded from this arm. For each patient with FM, we randomly selected four individuals without FM or migraine

1
2
3
4 from the population of the LHID2000 who were frequency-matched by sex, age (in
5
6
7 5-year increments), and entry date of the patient with FM; these subjects were
8
9
10 recruited into the non-FM (control) cohort.
11
12

13 A similar procedure was used for Arm 2 to establish a cohort of patients with
14
15
16 migraine who had no history of FM, were aged ≥ 20 years, and were newly diagnosed
17
18
19 ≥ 3 times consecutively within 3 months from 2000–2010.
20
21

22 Subjects in both arms were followed until diagnosis of migraine or FM,
23
24
25 withdrawal from the NHI program, death, or December 31, 2011. The patients in the
26
27
28 two cohorts presented with some baseline comorbidities: diabetes (ICD-9-CM code
29
30
31 250), hypertension (ICD-9-CM codes 401–405), hyperlipidemia (ICD-9-CM code
32
33
34 272), depression (ICD-9-CM codes 296.2, 296.3, 296.5, 300.4, 309, and 311), anxiety
35
36
37 (ICD-9-CM codes 300.0, 300.2, 300.3, 308.3, and 309.81), sleep disorder (ICD-9-CM
38
39
40 codes 307.4 and 780.5), coronary artery disease (CAD; ICD-9-CM codes 410–414),
41
42
43 chronic fatigue syndrome (CFS; ICD-9-CM code 780.71), and irritable bowel
44
45
46 syndrome (IBS; ICD-9-CM code 564.1).
47
48
49
50
51

52 **Statistical analyses**

53
54

55 The characteristics of the study cohorts are expressed as means and
56
57
58 corresponding standard deviations for age and as numbers and percentages for sex and
59
60

1
2
3
4 comorbidities. Age difference was assessed using a t test, and sex and comorbidity
5
6
7 distributions were tested using a chi-square test. The incidence density for each cohort
8
9
10 was calculated as the total event number divided by the sum of follow-ups [per 1000
11
12
13 person-years (PY)]. The cumulative incidence curve for each cohort was measured
14
15
16 using the Kaplan–Meier method, and the curve difference was calculated using the
17
18
19 log-rank test. To determine the risks of migraine and FM in Arms 1 and 2,
20
21
22 respectively, hazard ratios (HRs) and corresponding 95% confidence intervals (CIs)
23
24
25 were estimated using single-variable and multivariable Cox proportional hazard
26
27
28 models. Data management and all statistical analyses were performed using SAS for
29
30
31 Windows (Version 9.4, SAS Institute, Cary, NC, USA), and incidence curves was
32
33
34 plotted using R software. All significance levels were set as two-sided $p < 0.05$.

43 **Results**

44
45
46 Table 1 presents the demographic characteristics of the FM and non-FM cohorts.
47
48
49 The age- and sex-matched cohorts exhibited differences in comorbidity distribution.
50
51
52 The prevalence of comorbidities was significantly higher in the FM cohort than in the
53
54
55 non-FM cohort ($p < 0.001$).

56
57
58 Table 2 indicates that the migraine incidences were 4.39 and 2.07 per 1000 PY in
59
60

1
2
3
4 the FM and non-FM cohorts, respectively. Figure 2 reveals a higher incidence curve
5
6
7 for the FM cohort than for the non-FM cohort (log-rank test = 371.4, $p < 0.001$). After
8
9
10 adjustment for age, sex, and comorbidities, the patients with FM exhibited a
11
12
13 1.89-times higher risk of migraine compared with the non-FM subjects (HR = 1.89,
14
15
16 95% CI = 1.75–2.05). Among women, the relative risk of migraine was 1.76-times
17
18
19 higher in patients with FM compared with non-FM subjects (HR = 1.76, 95% CI
20
21
22 1.60–1.93), whereas among men, the risk was 2.29-times higher in patients with FM
23
24
25 than in non-FM subjects (HR = 2.29, 95% CI = 1.97–2.67). Regarding age, the HRs
26
27
28 for migraine in the FM cohort were 2.06 (95% CI = 1.85–2.29), 1.66 (95% CI =
29
30
31 1.43–1.92), and 1.69 (95% CI = 1.39–2.05) for ≤ 50 , 51–65, and ≥ 65 years,
32
33
34 respectively.

35
36
37 Table 3 presents the influence of factors associated with migraine occurrence in
38
39
40 the FM cohort. Male sex, hyperlipidemia, depression, anxiety, sleep disorder, CAD,
41
42
43 CFS, and IBS were all associated with higher risk of migraine (all $p < 0.05$).

44
45
46 Table 4 lists the comorbidities as well as the age- and sex-matched comparisons
47
48
49 in the migraine cohort, which exhibited a higher prevalence of comorbidities than did
50
51
52 the nonmigraine cohort.

53
54
55 Table 5 and Figure 3 reveal that the incidence of FM was significantly higher in
56
57
58 patients with migraine than in those without (7.01 vs. 4.49 per 1000 PY; log-rank test
59
60

1
2
3
4 = 116.7, $p < 0.001$). After adjustment for age, sex, and comorbidities, patients with
5
6
7 migraine exhibited a 1.52-times higher risk of FM compared with those without
8
9
10 migraine (HR = 1.52, 95% CI = 1.39–1.65). Among female patients, those with
11
12
13 migraine exhibited a 1.43-times higher risk of FM compared with nonmigraine
14
15
16 subjects (HR = 1.43, 95% CI = 1.29–1.59), whereas among male patients, those with
17
18
19 migraine exhibited a 1.78-times higher risk of FM compared with nonmigraine
20
21
22 subjects (95% CI = 1.50–2.11). Regarding age, the HRs for FM were 1.64 (95% CI =
23
24
25 1.46–1.84), 1.30 (95% CI = 1.09–1.53), and 1.28 (95% CI = 1.03–1.58) in patients
26
27
28 with migraine aged <50 , 50–64, and ≥ 65 years, respectively.
29

30
31 Table 6 presents the associations of sex, age, and comorbidities with risk of FM.
32
33
34 The variables, including age, migraine, hypertension, hyperlipidemia, depression,
35
36
37 sleep disorder, and CAD, were all associated with lower risk of FM.
38
39
40
41
42
43
44
45

46 Discussion

47
48
49 The results of comparing the two cohort arms suggested a bidirectional risk of
50
51
52 migraine and FM in patients with FM and those with migraine, respectively. The
53
54
55 analysis of Arm 1 revealed incidence rates for migraine of 4.39 and 2.07 per 1000 PY
56
57
58 in patients with and without FM, respectively [adjusted HR (aHR) = 1.89, 95% CI =
59
60

1
2
3
4 1.75–2.05 in patients with FM]. The analysis of Arm 2 revealed incidence rates for
5
6
7 FM of 7.01 and 4.49 per 1000 PY in patients with and without migraine, respectively
8
9
10 (aHR = 1.52, 95% CI = 1.39–1.65 in patients with migraine). These results indicated
11
12
13 that FM had stronger predictive power for the onset of migraine than did migraine for
14
15
16 the onset of FM.

17
18
19 The Kaplan–Meier plots demonstrated that incidence of migraine in the FM
20
21
22 cohort and that of FM in the migraine cohort increased steadily during the 12-year
23
24
25 follow-up period. Moreover, similar patterns were observed in the two corresponding
26
27
28 comparison cohorts. The cumulative incidence measured by the Kaplan–Meier plots
29
30
31 revealed greater risk of migraine among patients with FM than risk of FM among
32
33
34 patients with migraine.

35
36
37 Our predictive analytics have the potential to guide diagnosis and treatment. For
38
39
40 example, a subsequent diagnosis of FM may result from failure of antimigraine
41
42
43 treatment to alleviate fatigue [24]. Because migraine is often more effectively
44
45
46 managed than FM, the authors hypothesized that patients with FM are more likely to
47
48
49 be treated for migraine than are patients with migraine to be treated for FM. Therefore,
50
51
52 clinical trials of patients with migraine in the future have the potential to evaluate the
53
54
55 effects of FM on health outcomes and the efficacy of FM treatment [10].
56
57
58
59
60

Cohort analysis for the association between FM and risk of new-onset migraine

This study revealed a positive association between FM diagnosis and the risk of migraine. Adjusting for hypertension, CAD, and CFS had no strong influence on this association. However, sex, age (particularly in patients aged less than 49 years), diabetes, hyperlipidemia, depression, anxiety, sleep disorder, and IBS continued to demonstrate statistically significant effects.

Because “high frequency and chronic migraine increase sensitivity to pain in fibromyalgia (FM) patients [25], such heightened pain sensitivity may be attenuated by comorbid diabetes. There is also a documented report showing a significant positive association between migraine frequency and intensity with total and [low-density lipoprotein] cholesterol, independent of diet and lifestyle [26].” Several hypotheses have been proposed to explain the development of chronic widespread pain and episodic throbbing or pulsating pain across the head and neck regions as possible effects of comorbidities such as depression and anxiety. Depression and anxiety disorders have been identified as crucial secondary symptoms of FM [11, 27, 28]. The pain associated with FM may initiate the development of mood disorders as a result of stress imposed on the body. Furthermore, according to multiple evidence-based studies, depression and anxiety may induce the onset or present as a prodrome of migraine [29, 30].

1
2
3
4 Research has indicated that serotonin levels might be related to interconnections
5
6
7 between anxiety and migraine [31]. A lower level of serotonin may be central to
8
9
10 the dysregulation of descending antinociceptive systems, leading to FM and
11
12
13 migraine [31, 32].
14

15
16 Poor sleep quality or sleep deprivation in healthy individuals can induce
17
18
19 symptoms of FM [33], suggesting that sleep abnormalities may be a pathological
20
21
22 characteristic of FM rather than merely a result of pain [34]. Relevant literature has
23
24
25 reported the advantages of targeting sleep conditions to relieve the symptoms of
26
27
28 migraine [35]. As the prevalence of sleep disorders increases in both patients with FM
29
30
31 and those with migraine, appreciation of the strong links between FM and migraine
32
33
34 also increases.
35

36
37 IBS frequently coexists with both FM and migraine [36, 37]; however, the
38
39
40 underlying mechanisms for the association of FM with increased risks of IBS and
41
42
43 migraine are unclear. FM, migraine, and IBS may be distinct manifestations of a
44
45
46 common pathophysiological process affecting the gastrointestinal tract. These
47
48
49 disorders are referred to as “central sensitivity syndrome” and are mutually associated
50
51
52 [38]. A growing amount of evidence indicates that central sensitization phenomena
53
54
55 play a role in the pathogenesis of FM and that of migraine. Central sensitization at the
56
57
58 levels of the spinal dorsal horn and trigeminal nucleus may also be involved in the
59
60

1
2
3
4 progression of migraine attacks, and prolonged nociceptive inputs may result in the
5
6
7 maintenance of supraspinal sensitization and central neuroplastic changes, causing
8
9
10 episodic headaches to become chronic [39]. Notably, increased intestinal permeability
11
12
13 may be observed in IBS [40]. Altered intestinal permeability with overgrowth of
14
15
16 intestinal bacteria may trigger the development of FM [41] and that of migraine [42].
17
18
19 The microbiome–gut–brain axis—a bidirectional communication route of the central
20
21
22 and enteric nervous systems with microbiome through the neural, humoral, endocrine,
23
24
25 and immune pathways [36, 37, 43]—has been proposed as a multifaceted
26
27
28 pathophysiological mechanism underlying IBS [43], FM [44, 45], and migraine [42,
29
30
31 46]. In addition, mutual interaction has been established between gut microbiota and
32
33
34 the central, autonomic, and enteric nervous systems through the
35
36
37 hypothalamic–pituitary–adrenal axis [43].
38
39
40
41
42

43 **Cohort analysis for the association between migraine and risk of new-onset FM**

44
45
46 This study revealed higher risk of FM in patients with migraine than in those
47
48
49 without in every factor-based subset of the cohorts. Notably, patients with
50
51
52 hyperlipidemia had higher risk of FM. Moreover, adverse lipid profiles occurred more
53
54
55 frequently in patients with migraine who had a higher body mass index [47, 48].
56
57
58 Although lack of exercise may precipitate the development of an adverse lipid profile,
59
60

1
2
3
4 exercise may trigger acute migraine attacks [49], and some patients may avoid
5
6
7 exercise to prevent migraines. This hypothesis could be supported by the results of
8
9
10 one study that revealed that patients with headache had lower aerobic endurance and
11
12
13 flexibility than did healthy controls [50]. Aerobic exercise could relieve depression
14
15
16 and anxiety and prevent the negative effects of stress [51]. Furthermore, avoiding
17
18
19 exercise may exacerbate mood distress, and thus could be related to the development
20
21
22 of FM.
23

24
25 Increased migraine frequency as a result of migraines becoming chronic
26
27
28 intensifies the sensitivity to pain in somatic areas outside of the cephalic region and
29
30
31 may predispose patients to FM [6]. Hypothalamic neuroendocrine dysfunction has
32
33
34 been proposed as a brain mechanism common to both FM and migraine [52]. Both
35
36
37 conditions also share the mechanism of central sensitization of pain neurons.
38
39
40 Magnesium, which is often used as an agent for relieving migraine headaches, is also
41
42
43 beneficial for treating FM. Low magnesium levels can exacerbate symptoms of FM
44
45
46 and are also implicated in migraines [53]. Researchers have discovered that people
47
48
49 who do not respond to standard migraine treatments often also have FM [17].
50
51
52 Considering the high comorbidity rates of migraine and FM, many professionals
53
54
55 assume that the central nervous system is responsible for pain-processing
56
57
58 abnormalities, including central sensitization and inadequate pain inhibition alongside
59
60

1
2
3
4 repeated headache episodes. Moreover, tonic peripheral nociceptive input is
5
6
7 associated with augmented windup in response to neurotransmitters,
8
9
10 immunomodulation, vascular changes, and hormone influence, which may increase
11
12
13 the risk of FM [1, 6, 36, 37, 43, 52].
14
15

16 Our study contained a large sample because of our population-based design.
17
18 Moreover, we were careful to minimize selection bias during analysis, and our ample
19
20
21 documentation of medical profiles allowed for minimal effects from confounding
22
23
24 factors among the subjects. However, this study had limitations. We based our study
25
26
27 solely on information from diagnoses in patient files and included no information
28
29
30 from patients whose cases were unidentified. Poor categorization of a patient's
31
32
33 symptoms may have affected the discernibility between migraine and FM. Because
34
35
36 many crucial variables are not retrievable and various methods are used to diagnose
37
38
39 FM and the numerous subtypes of migraines, our data provides merely a glimpse of
40
41
42 these two conditions. Furthermore, assessing treatment responses in our large
43
44
45 database analysis was impossible, rendering the identification of “diagnosis by
46
47
48 exclusion” difficult in this study. Future studies are recommended to further delineate
49
50
51 “diagnosis by exclusion.” Furthermore, this study did not consider the severity of FM
52
53
54 and migraines in patients; therefore, no definitive statement can be made regarding
55
56
57 the intensity of FM and subsequent risk of developing migraine conditions, or vice
58
59
60

1
2
3
4 versa. Moreover, this study was naturally highly prone to observational bias because
5
6
7 patients with migraine and those with FM are generally more likely to seek medical
8
9
10 attention for other conditions than are those with neither.
11
12
13
14
15

16 **Conclusion**

17
18
19 This study was the first to reveal a population-based bidirectional association
20
21
22 between onset of FM and that of migraine in patients with migraine and those with
23
24
25 FM, respectively. The risk of migraine was reportedly greater than that of FM. The
26
27
28 incidence rates of FM in the migraine cohort and migraine in the FM cohort increased
29
30
31 with age in both directions. However, the HRs relative to the corresponding
32
33
34 comparison cohorts were attenuated with increases in age.
35
36
37
38
39

40 **Author contributions:**

41
42
43 **Conceptualization:** I-Wen Penn, Chia-Hung Kao.
44
45

46 **Methodology:** Cheng-Li Lin, Chia-Hung Kao.
47
48

49 **Software:** Cheng-Li Lin, Chia-Hung Kao.
50
51

52 **Validation:** I-Wen Penn, Eric Chuang, Tien-Yow Chuang, Cheng-Li Lin, Chia-Hung
53
54
55 Kao.
56
57

58 **Formal analysis:** I-Wen Penn, Eric Chuang, Tien-Yow Chuang, Cheng-Li Lin,
59
60

1
2
3
4 Chia-Hung Kao.
5
6

7 **Investigation:** Cheng-Li Lin, Chia-Hung Kao.
8
9

10 **Resources:** Cheng-Li Lin, Chia-Hung Kao.
11
12

13 **Data curation:** IWP, EC, TYC, CLL, CHK.
14
15

16 **Writing (original draft preparation):** I-Wen Penn, Eric Chuang, Tien-Yow Chuang,
17
18

19 Cheng-Li Lin, Chia-Hung Kao.
20
21

22 **Writing (review and editing):** I-Wen Penn, Eric Chuang, Tien-Yow Chuang,
23
24

25 Cheng-Li Lin, Chia-Hung Kao.
26
27

28 **Visualization:** I-Wen Penn, Eric Chuang, Tien-Yow Chuang, Cheng-Li Lin,
29
30

31 Chia-Hung Kao.
32
33

34 **Supervision:** Chia-Hung Kao.
35
36

37 **Project administration:** Chia-Hung Kao.
38
39

40 **Funding acquisition:** Chia-Hung Kao.
41
42
43
44
45

46 **Funding**

47
48

49 This work was supported by grants from the MOHW, Taiwan
50
51 (MOHW108-TDU-B-212-133004), China Medical University Hospital
52
53 (DMR-107-192), Academia Sinica Stroke Biosignature Project (BM10701010021),
54
55 the Ministry of Science and Technology (MOST) Clinical Trial Consortium for
56
57
58
59
60

1
2
3
4 Stroke (MOST 107-2321-B-039 -004-), the Tseng-Lien Lin Foundation, Taichung,
5
6
7 Taiwan, and the Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had
8
9
10 no role in the study design, data collection and analysis, the decision to publish, or the
11
12
13 preparation of the manuscript. No additional external funding was received for this
14
15
16 study.
17
18
19
20
21
22

23 **Conflicts of Interest**

24
25
26 All authors report no conflicts of interest.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. de Tommaso M. Prevalence, clinical features and potential therapies for fibromyalgia in primary headaches. *Expert Rev Neurother*. 2012;12:287–95.
2. Evans RW, de Tommaso M. Migraine and Fibromyalgia. *Headache*. 2011;51:295-299.
3. de Tommaso M, Federici A, Serpino C, Vecchio E, Franco G, Sardaro M, et al. Clinical features of headache patients with fibromyalgia comorbidity. *J Headache Pain*. 2011;12:629–638.
4. Küçükşen S, Genç E, Yılmaz H, Sallı A, Gezer İA, Karahan AY, et al. The prevalence of fibromyalgia and its relation with headache characteristics in episodic migraine. *Clin Rheumatol*. 2013;32:983-990.
5. Marcus DA, Bhowmick A. Fibromyalgia comorbidity in a community sample of adults with migraine. *Clin Rheumatol*. 2013;32:1553–1556.
6. Giamberardino MA, Affaitati G, Martelletti P, Tana C, Negro A, Lapenna D, et al. Impact of migraine on fibromyalgia symptoms. *J Headache Pain*. 2015;17:28.
7. Vij B, Whipple MO, Tepper SJ, Mohabbat AB, Stillman M, Vincent A. Frequency of Migraine Headaches in Patients With Fibromyalgia. *Headache*. 2015;55:860–865.

- 1
2
3
4 8. Centonze V, Bassi A, Cassiano A, Munno I, Dalfino L, Causarano V. Migraine,
5
6
7 daily chronic headache and fibromyalgia in the same patient: an evolutive
8
9
10 'continuum' of non organic chronic pain? About 100 clinical cases. *Neurol Sci*
11
12
13 2004; 25:S291–S292.
14
15
16 9. Ifergane G, Buskila D, Simiseshvely N, Zeev K, Cohen H. Prevalence of
17
18
19 fibromyalgia syndrome in migraine patients. *Cephalalgia* 2006;26:451–456.
20
21
22 10. Peres MF, Zukerman E, Young WB, Silberstein SD. Fatigue in chronic migraine
23
24
25 patients. *Cephalalgia* 2002;22:720–724.
26
27
28 11. Whealy M, Nanda S, Vincent A, Mandrekar J, Cutrer FM. Fibromyalgia in
29
30
31 migraine: a retrospective cohort study. *J Headache Pain*. 2018;19(1):61.
32
33
34 12. de Tommaso M, Sciruicchio V, Delussi M, Vecchio E, Goffredo M, Simeone M,
35
36
37 Barbaro MGF. Symptoms of central sensitization and comorbidity for juvenile
38
39
40 fibromyalgia in childhood migraine: an observational study in a tertiary headache
41
42
43 center. *J Headache Pain*. 2017;18(1):59.
44
45
46 13. de Tommaso M. Migraine and fibromyalgia. *J Headache Pain*. 2015;16(Suppl
47
48
49 1):A45.
50
51
52 14. Headache Classification Committee of the International Headache Society (IHS).
53
54
55 The International Classification of Headache Disorders, 3rd edition (beta version).
56
57
58 *Cephalalgia*. 2013; 33:629–808.
59
60

- 1
2
3
4 15. Dodick DW. Clinical practice: chronic daily headache. *N Engl J Med*. 2006;354:
5
6 158-165.
7
8
9
10 16. Nosedá R, Burstein R. Migraine pathophysiology: anatomy of the
11
12 trigeminovascular pathway and associated neurological symptoms, CSD,
13
14 sensitization and modulation of pain. *Pain*. 2013; 154:1.
15
16
17
18 17. Lolognier S, Eijkelkamp N, Wood JN. Mechanical allodynia. *Pflugers Arch*.
19
20 2015;467(1):133-9.
21
22
23
24 18. Staud R. Peripheral pain mechanisms in chronic widespread pain. *Best Pract Res*
25
26 *Clin Rheumatol*. 2011;25:155-164.
27
28
29
30 19. Burstein R. Deconstructing migraine headache into peripheral and central
31
32 sensitization. *Pain*. 2001; 89:107–110.
33
34
35
36 20. Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding
37
38 and future directions. *J Neurol*. 2017; 3:1-9.
39
40
41
42 21. Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic
43
44 widespread pain in patients with fibromyalgia and chronic fatigue syndrome. *Clin*
45
46 *Rheumatol*. 2007; 26: 465–473.
47
48
49
50 22. Clauw DJ. Fibromyalgia A Clinical Review. *JAMA*. 2014;311:1547-1555.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 23. Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive
5
6
7 neurons to cervical input after stimulation of the dura mater.
8
9
10 *Brain*. 2003;126:1801-1813.
11
12
- 13 24. Marcus DA, Bernstein C, Rudy TE. Fibromyalgia and headache: an
14
15
16 epidemiological study supporting migraine as part of the fibromyalgia syndrome.
17
18
19 *Clin Rheumatol* 2005; 24:595–601
20
21
- 22 25. Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states- maybe it is
23
24
25 all in their head. *Best Pract Res Clin Rheumatol*. 2011;25(2):141-54
26
27
- 28 26. Tana C, Santilli F, Martelletti P, di Vincenzo A, Cipollone F, Davi G,
29
30
31 Giamberardino MA. Correlation between migraine severity and cholesterol levels.
32
33
34 *Pain Pract*. 2015;15(7):662-70.
35
36
- 37 27. González-Roldán AM, Bomba IC, Diesch E, Montoya P, Flor H, Kamping S.
38
39
40 Controllability and hippocampal activation during pain expectation in
41
42
43 fibromyalgia syndrome. *Biol Psychol*. 2016;121:39-48.
44
45
- 46 28. Santos DM, Lage LV, Jabur EK, Kaziyama HHS, Iosifescu DV, De Lucia MCS,
47
48
49 et al. The influence of depression on personality traits in patients with
50
51
52 fibromyalgia: a case-control study. *Clin Exp Rheumatol*. 2017;35 Suppl
53
54
55 105:13-19.
56
57
- 58 29. Amouroux R, Rousseau-Salvador C. Anxiety and depression in children and
59
60

- 1
2
3
4 adolescents with migraine: a review of the literature. *Encephale*.
5
6
7 2008;34:504-510.
8
9
- 10 30. Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger
11
12 factors. *Med Clin North Am*. 2001;85:911-941.
13
14
15
- 16 31. Panconesi A. Serotonin and migraine: a reconsideration of the central theory. *J*
17
18 *Headache Pain*. 2008; 9: 267–276.
19
20
21
- 22 32. Becker S, Schweinhardt P. Dysfunctional Neurotransmitter Systems in
23
24 Fibromyalgia, Their Role in Central Stress Circuitry and Pharmacological Actions
25
26 on These Systems. *Pain Res Treat*. 2012;2012:741746.
27
28
29
- 30 33. McBeth J, Lacey RJ, Wilkie R. Predictors of New-Onset Widespread Pain in
31
32 Older Adults. *Arthritis & Rheumatology*. 2014; 66: 757–767.
33
34
35
- 36 34. Choy EH. The role of sleep in pain and fibromyalgia. *Nat Rev*
37
38 *Rheumatol*. 2015;11:513-520.
39
40
41
- 42 35. Moldofsky H. Sleep and pain. *Sleep Medicine Reviews*. 2001; 5: 387–398.
43
44
45
- 46 36. Chen X, Souza RD, Hong ST. The role of gut microbiota in the gut-brain axis:
47
48 current challenges and perspectives. *Protein Cell* 2013; 4: 403–414.
49
50
51
- 52 37. Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to
53
54 behavior. *Neurogastroenterol Motil*. 2011; 23:187-192.
55
56
57
- 58 38. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology
59
60

- 1
2
3
4 for fibromyalgia and overlapping conditions, and related issue of disease versus
5
6
7 illness. *Semin Arthritis Rheum.* 2008; 37:339-352.
8
9
- 10 39. Bernstein C, Burstein R. Sensitization of the Trigeminovascular Pathway:
11
12 Perspective and Implications to Migraine Pathophysiology. *J Clin Neurol*
13
14 2012;8:89-99.
15
16
17
- 18 40. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and
19
20 hypersensitivity in the irritable bowel syndrome. *Pain.* 2009;146:41–46.
21
22
23
- 24 41. Goebel A, Buhner S, Schedel R, Lochs H, Sprutte G. Altered intestinal
25
26 permeability in patients with primary fibromyalgia and in patients with complex
27
28 regional pain syndrome. *Rheumatology* 2008;47:1223-1227.
29
30
31
32
- 33 42. van Hemert S, Breedveld AC, Rovers JM, Vermeiden JP, Witteman BJ, Smits
34
35 MG, et al. Migraine associated with gastrointestinal disorders: review of the
36
37 literature and clinical implications. *Front Neurol.* 2014; 21:241.
38
39
40
41
- 42 43. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions
43
44 between enteric microbiota, central and enteric nervous systems. *Ann*
45
46 *Gastroenterol.* 2015; 28: 203–209.
47
48
49
- 50 44. Berstad A, Valeur J. Gut gateway to generalized pain. *Scand J Pain.* 2016;
51
52 13:164–165.
53
54
55
56
57
58
59
60

- 1
2
3
4 45. Mu C, Yang Y, Zhu W. Gut microbiota: the brain peacekeeper. *Front Microbiol*
5
6
7 2016;7:345.
8
9
- 10 46. Dai YJ, Wang HY, Wang XJ, Kaye AD, Sun YH. Potential Beneficial Effects of
11
12 Probiotics on Human Migraine Headache: A Literature Review. *Pain Physician*.
13
14 2017; 20: 251-255.
15
16
17
- 18 47. Saberi A, Hatamian HR, Kazemnejad E, Ghorbannejad N. Hyperlipidemia in
19
20 migraine: Is it more frequent in migraineurs? *Iran J Neurol*. 2011; 10:46-50.
21
22
23
- 24 48. Salmasi M, Amini L, Javanmard SH, Saadatnia M. Metabolic syndrome in
25
26 migraine headache: A case-control study. *J Res Med Sci*. 2014; 19: 13–17.
27
28
29
- 30 49. Koppen H, van Veldhoven PL. Migraineurs with exercise-triggered attacks have a
31
32 distinct migraine. *J Headache Pain*. 2013;14:99.
33
34
35
- 36 50. Neuss K, Neumann B, Steinhoff BJ, Thegeder H, Bauer A, Reimers D. Physical
37
38 activity and fitness in patients with headache disorders. *Int J Sports Med*.
39
40 1997;18:607-611.
41
42
43
- 44 51. Salmon P. Effects of Physical exercise on anxiety, depression, and sensitivity to
45
46 stress: a unifying theory. *Clin Psychol Rev*. 2001; 21: 33-61.
47
48
49
- 50 52. Valença MM, Medeiros FL, Martins HA, Massaud RM, Peres MF.
51
52 Neuroendocrine dysfunction in fibromyalgia and migraine. *Curr Pain Headache*
53
54 *Rep*. 2009;13:358-364.
55
56
57
58
59
60

- 1
2
3
4 53. Assarzadegan F, Asgarzadeh S, Hatamabadi HR, Shahrami A, Tabatabaey A,
5
6
7 Asgarzadeh M. Serum concentration of magnesium as an independent risk factor
8
9
10 in migraine attacks: a matched case-control study and review of the literature. *Int*
11
12
13 *Clin Psychopharmacol*. 2016;31:287-292.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Figure Legends:**
4

5 Figure 1. Flow chart illustrating the selection of study subjects.
6
7
8
9

10
11 Figure 2. Comparison of cumulative incidence of migraine between patients with and
12
13 without fibromyalgia using the Kaplan–Meier method.
14
15
16

17
18
19
20 Figure 3. Comparison of the cumulative incidence of fibromyalgia between patients
21
22 with and without migraine using the Kaplan–Meier method.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic characteristics and comorbidities in patients with and without fibromyalgia.

Variable	Fibromyalgia		p-value
	No N =132863	Yes N =33216	
Sex	n(%)	n(%)	0.99
Female	71880(54.1)	17970(54.1)	
Male	60983(45.9)	15246(45.9)	
Age, mean(SD)	50.9(16.9)	51.4(16.7)	<0.001 [#]
Stratify age			0.99
≤49	64292(48.4)	10673(48.4)	
50-65	36820(27.7)	9205(27.7)	
65+	31751(23.9)	7938(23.9)	
Comorbidity			
Diabetes	10485(7.89)	3193(9.61)	<0.001
Hypertension	37284(28.1)	11287(34.0)	<0.001
Hyperlipidemia	22446(16.9)	7301(22.0)	<0.001
Depression	4690(3.53)	1804(5.43)	<0.001
Anxiety	10494(7.90)	4214(12.7)	<0.001
Sleep disorder	21095(15.9)	8121(24.5)	<0.001
CAD	17918(13.5)	5821(17.5)	<0.001
Chronic fatigue syndrome	199(0.15)	93(0.28)	<0.001
Irritable bowel syndrome	5125(3.86)	1870(5.63)	<0.001

Chi-square test; #: two-sample t test

Table 2. Comparison of the incidence and hazard ratios of migraine stratified by sex and age between patients with and without fibromyalgia.

Variable	Without fibromyalgia					With fibromyalgia				
	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)
All	1810	876077	2.07	1(Reference)	1(Reference)	954	217386	4.39	2.12(1.96, 2.30)***	1.89(1.75, 2.05)***
Sex										
Female	1373	487506	2.82	1(Reference)	1(Reference)	669	120773	5.54	1.97(1.79, 2.16)***	1.76(1.60, 1.93)***
Male	437	388571	1.12	1(Reference)	1(Reference)	285	96613	2.95	2.62(2.26, 3.05)***	2.29(1.97, 2.67)***
Stratify age										
≤50	922	444710	2.07	1(Reference)	1(Reference)	548	110557	4.96	2.39(2.15, 2.66)***	2.06(1.85, 2.29)***
50-65	564	245579	2.30	1(Reference)	1(Reference)	258	60603	4.26	1.85(1.60, 2.15)***	1.66(1.43, 1.92)***
65+	324	185788	1.74	1(Reference)	1(Reference)	148	46226	3.20	1.83(1.51, 2.23)***	1.69(1.39, 2.05)***
Comorbidity[‡]										
No	774	508879	1.52	1(Reference)	1(Reference)	311	95605	3.25	2.14(1.88, 2.44)***	2.13(1.87, 2.43)***
Yes	1036	367197	2.82	1(Reference)	1(Reference)	643	121780	5.28	1.88(1.71, 2.08)***	1.80(1.63, 1.98)***

Rate[#]: incidence rate per 1000 person-years; crude HR: crude hazard ratio

Adjusted HR[†]: multivariable analysis including sex, age, and the comorbidities of diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, coronary artery disease, chronic fatigue syndrome, and irritable bowel syndrome

***p < 0.001

Comorbidity[‡]: patients with any of the comorbidities of diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, coronary artery disease, chronic fatigue syndrome, or irritable bowel syndrome were classified as the comorbidity group

Table 3. Cox model with hazard ratios and 95% confidence intervals for migraine associated with fibromyalgia and covariates.

Variable	Crude		Adjusted [†]	
	HR	(95% CI)	HR	(95% CI)
Fibromyalgia	2.12	(1.96, 2.30)***	1.89	(1.74, 2.04)***
Sex(Women vs. Men)	2.28	(2.09, 2.48)***	2.08	(1.91, 2.27)***
Age, years	1.00	(0.99, 1.00)**	0.99	(0.99, 1.00)***
Baseline comorbidities (yes vs. no)				
Diabetes	0.82	(0.70, 0.96)*	0.73	(0.61, 0.860)***
Hypertension	1.06	(0.97, 1.15)	-	-
Hyperlipidemia	1.30	(1.19, 1.43)***	1.14	(1.03, 1.27)*
Depression	2.37	(2.06, 2.72)***	1.20	(1.03, 1.39)*
Anxiety	2.68	(2.44, 2.95)***	1.64	(1.47, 1.84)***
Sleep disorder	2.63	(2.43, 2.85)***	1.97	(1.80, 2.15)***
CAD	1.30	(1.18, 1.44)***	1.10	(0.98, 1.23)
Chronic fatigue syndrome	2.24	(1.01, 4.99)*	1.45	(0.65, 3.22)
Irritable bowel syndrome	1.98	(1.71, 2.29)***	1.36	(1.17, 1.58)***

Crude HR: crude hazard ratio; adjusted[†]: multivariable analysis including sex, age, and the comorbidities of diabetes, hyperlipidemia, depression, anxiety, sleep disorder, coronary artery disease, chronic fatigue syndrome, and irritable bowel syndrome

*p < 0.05, **p < 0.01, and ***p < 0.001

Table 4. Demographic characteristics and comorbidities in patients with and without migraine.

Variable	migraine		p-value
	No N =69680	Yes N =17420	
Sex	n(%)	n(%)	0.99
Female	51176(73.4)	12794(73.4)	
Male	18504(26.6)	4626(26.6)	
Age, mean(SD)	44.2(15.6)	44.5(15.3)	0.04 [#]
Stratify age			0.99
≤49	46768(67.1)	11692(67.1)	
50-65	14940(21.4)	3735(21.4)	
65+	7972(11.4)	1993(11.4)	
Comorbidity			
Diabetes	3567(5.12)	975(5.60)	0.01
Hypertension	12563(18.0)	4551(26.1)	<0.001
Hyperlipidemia	8278(11.9)	3187(18.3)	<0.001
Depression	2019(2.90)	1851(10.6)	<0.001
Anxiety	4366(6.27)	3724(21.4)	<0.001
Sleep disorder	9469(13.6)	6976(40.1)	<0.001
CAD	5560(7.98)	2449(14.1)	<0.001
Chronic fatigue syndrome	71(0.10)	41(0.24)	<0.001
Irritable bowel syndrome	2106(3.02)	1224(7.03)	<0.001

Chi-square test; #: two-sample t test

Table 5. Comparison of the incidence and hazard ratios of fibromyalgia stratified by sex and age between patients with and without migraine.

Variable	Without migraine					With migraine				
	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)
All	2034	453130	4.49	1(Reference)	1(Reference)	800	114070	7.01	1.57(1.44, 1.70)***	1.52(1.39, 1.65)***
Sex										
Female	1556	335328	4.64	1(Reference)	1(Reference)	568	84606	6.71	1.45(1.32, 1.60)***	1.43(1.29, 1.59)***
Male	478	117802	4.06	1(Reference)	1(Reference)	232	29464	7.87	1.94(1.66, 2.27)***	1.78(1.50, 2.11)***
Stratify age										
≤50	1060	310621	3.41	1(Reference)	1(Reference)	470	78131	6.02	1.77(1.58, 1.97)***	1.64(1.46, 1.84)***
50-65	608	96607	6.29	1(Reference)	1(Reference)	207	24189	8.56	1.36(1.16, 1.59)***	1.30(1.09, 1.53)**
65+	366	45902	7.97	1(Reference)	1(Reference)	123	11751	10.5	1.32(1.07, 1.61)**	1.28(1.03, 1.58)*
Comorbidity[‡]										
No	1082	309229	3.50	1(Reference)	1(Reference)	255	43664	5.84	1.67(1.46, 1.92)***	1.79(1.56, 2.06)***
Yes	952	143901	6.62	1(Reference)	1(Reference)	545	70406	7.74	1.18(1.06, 1.31)**	1.29(1.16, 1.44)***

Rate[#]: incidence rate per 1000 person-years; crude HR: crude hazard ratio

Adjusted HR[†]: multivariable analysis including sex, age, and the comorbidities of diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, coronary artery disease, and irritable bowel syndrome


*p < 0.05, **p < 0.01, and ***p < 0.001

Comorbidity[‡]: patients with any of the comorbidities of diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, coronary artery disease, chronic fatigue syndrome, or irritable bowel syndrome were classified as the comorbidity group


Table 6. Cox model with hazard ratios and 95% confidence intervals for fibromyalgia associated with migraine and covariates.

Variable	Crude		Adjusted [†]	
	HR	(95% CI)	HR	(95% CI)
Migraine	1.57	(1.44, 1.70)***	1.51	(1.38, 1.65)***
Sex(Women vs. Men)	1.05	(0.97, 1.15)	-	-
Age, years	1.02	(1.02, 1.03)***	1.02	(1.01, 1.02)***
Baseline comorbidities (yes vs. no)				
Diabetes	1.58	(1.36, 1.82)***	0.99	(0.85, 1.16)
Hypertension	1.81	(1.67, 1.96)***	1.10	(0.99, 1.22)
Hyperlipidemia	1.69	(1.54, 1.85)***	1.15	(1.03, 1.28)*
Depression	1.38	(1.17, 1.63)***	1.06	(0.89, 1.26)
Anxiety	1.34	(1.19, 1.51)***	0.92	(0.80, 1.05)
Sleep disorder	1.45	(1.33, 1.58)***	1.09	(0.98, 1.20)
CAD	1.74	(1.57, 1.94)***	1.01	(0.89, 1.14)
Chronic fatigue syndrome	2.11	(0.79, 5.62)	-	-
Irritable bowel syndrome	1.28	(1.06, 1.53)**	0.94	(0.78, 1.13)

Crude HR: crude hazard ratio; adjusted[†]: multivariable analysis including age and the comorbidities of diabetes, hypertension, hyperlipidemia, anxiety, sleep disorders, stroke, and peptic ulcer disease, and use of nonsteroidal anti-inflammatory drugs
 *p < 0.05, **p < 0.01, and ***p < 0.001




126x86mm (300 x 300 DPI)



112x104mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



108x105mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Included on page:
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,5,6
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	5,6
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8-10
Objectives	3	State specific objectives, including any pre-specified hypotheses	10
Methods			
Study design	4	Present key elements of study design early in the paper	11-14
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	11-14
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	11-14
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	11-14
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	11-14
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	11-14
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	11-14
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-14
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11-14
Bias	9	Describe any efforts to address potential sources of bias	11-14
Study size	10	Explain how the study size was arrived at	11-14
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11-14
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	11-14
		(b) Describe any methods used to examine subgroups and interactions	11-14

		(c) Explain how missing data were addressed	11-14
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	11-14
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	11-14
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	11-14
		(e) Describe any sensitivity analyses	11-14
Continued on next page			
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	15,16
		(b) Give reasons for non-participation at each stage	15,16
		(c) Consider use of a flow diagram	15,16
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	15,16
		(b) Indicate number of participants with missing data for each variable of interest	15,16
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	15,16
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	15,16
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	15,16
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	15,16
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	15,16
		(b) Report category boundaries when continuous variables were categorized	15,16
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	15,16
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	15,16
Discussion			
Key results	18	Summarise key results with reference to study objectives	17-23
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	22

1 2 3 4	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-23
5 6 7	Generalisability	21	Discuss the generalisability (external validity) of the study results	17-23
8	Other information			
9 10 11 12	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	2, 3

13
14
15 Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

16
17
18 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Bidirectional Association between Migraine and Fibromyalgia: Retrospective Cohort Analyses of Two Populations

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026581.R3
Article Type:	Research
Date Submitted by the Author:	27-Feb-2019
Complete List of Authors:	Penn, I-Wen ; Fu Jen Catholic University, School of Medicine Chuang, Eric ; University of California Berkeley, Intended B.S. Molecular and Cell Biology Chuang, Tien-Yow ; Taipei Veterans General Hospital, Department of Physical Medicine and Rehabilitation Lin, Cheng-Li; China Medical University Hospital, Management Office for Health Data Kao, Chia-Hung; China Medical University, School of Medicine
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	General practice / Family practice, Neurology, Rehabilitation medicine, Rheumatology
Keywords:	fibromyalgia, Migraine < NEUROLOGY, bidirectional analysis, retrospective cohort

SCHOLARONE™
Manuscripts

1
2
3
4 **Bidirectional Association between Migraine and Fibromyalgia: Retrospective**
5
6
7 **Cohort Analyses of Two Populations**
8
9

10 **Running title:** Bidirectional Association between Fibromyalgia and Migraine
11
12
13
14
15

16 I-Wen Penn^{1,2}, Eric Chuang³, Tien-Yow Chuang⁴, Cheng-Li Lin^{5,6}, Chia-Hung
17
18 Kao^{7,8,9}
19
20
21
22
23
24

25 ¹School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
26
27

28 ²Department of Physical Medicine and Rehabilitation, Fu Jen Catholic University
29
30 Hospital, Fu Jen Catholic University, New Taipei City, Taiwan
31
32
33

34 ³UC Berkeley Mishler Lab Undergraduate Researcher, Intended B.S. Molecular and
35
36 Cell Biology, University of CA, Berkeley, USA
37
38
39

40 ⁴Department of Physical Medicine and Rehabilitation, Taipei Veterans General
41
42 Hospital and National Yang-Ming University, Taipei, Taiwan
43
44
45

46 ⁵Management Office for Health Data, China Medical University Hospital, Taichung,
47
48 Taiwan
49
50
51

52 ⁶College of Medicine, China Medical University, Taichung, Taiwan
53
54

55 ⁷Graduate Institute of Biomedical Sciences and School of Medicine, College of
56
57 Medicine, China Medical University, Taichung, Taiwan
58
59
60

1
2
3
4 ⁸Department of Nuclear Medicine and PET Center, China Medical University
5
6
7 Hospital, Taichung, Taiwan
8
9

10 ⁹Department of Bioinformatics and Medical Engineering, Asia University, Taichung,
11
12
13 Taiwan.
14
15
16
17

18
19 ***Corresponding author:** Chia-Hung Kao, MD, Graduate Institute of Biomedical
20
21
22 Sciences and School of Medicine, College of Medicine, China Medical University,
23
24
25 No. 2, Yuh-Der Road, Taichung 404, Taiwan. E-mail: d10040@mail.cmuh.org.tw;
26
27
28 dr.kaochiahung@gmail.com
29
30
31
32
33
34

35 **List of abbreviations**

36
37
38 FM: Fibromyalgia; HR: hazard ratio; CI: confidence interval; ICD-9-CM:
39
40
41 International Classification of Diseases, Ninth Revision, Clinical Modification; NHI:
42
43
44 National Health Insurance; LHID: Longitudinal Health Insurance Database
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: Fibromyalgia (FM) and migraine are common pain disorders that tend to coexist. This study determined whether these two conditions exhibited any mutual influences.

Setting: Cohort study

Participants: A retrospective, longitudinal cohort study was conducted using data obtained from a nationwide health care database. This study had two arms. Arm 1 comprised 33,216 patients with FM, and Arm 2 consisted of 7420 patients with migraine; all of these patients were diagnosed between 2000 and 2010. Using the aforementioned database, control subjects who had neither FM nor migraine and were matched with the FM and migraine patients by sex, age, and index date of diagnosis were recruited. Each control cohort was four times the size of the corresponding study cohort. Follow-up for the control and study cohorts was conducted until the end of 2011.

Results: The incidence rates of FM and migraine were calculated in Arms 1 and 2, respectively. The overall incidence of migraine was greater in the FM cohort than in the corresponding control cohort [4.39 vs. 2.07 per 1000 person-years; crude hazard ratio (HR) = 2.12, 95% confidence interval (CI) = 1.96–2.30; adjusted HR (aHR) = 1.89, 95% CI = 1.75–2.05]. After adjustment for sex, age, and comorbidities, the

1
2
3
4 overall incidence of FM in the migraine cohort was 1.57 times greater than that in the
5
6
7 corresponding control cohort (7.01 vs. 4.49 per 1000 person-years; aHR = 1.52, 95%
8
9
10 CI = 1.39–1.65).

11
12
13 **Conclusions:** The present study revealed a bidirectional link between FM and
14
15
16 migraine.

17
18
19
20
21
22 *Keywords:* fibromyalgia, migraine, bidirectional analysis, retrospective cohort
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Peer review only

Strengths and limitations of this study

1. Our study contained a large sample size because of its population-based design.
2. We based our study solely on information from diagnoses in patient files and included no information on patients whose cases were unidentified.
3. This study was naturally highly prone to observational bias because patients with migraine and those with FM are generally more likely to seek medical attention for other conditions than are those with neither.
4. Health claims information in the Longitudinal Health Insurance Database mainly comprises documentation on diseases recorded according to the International Classification of Diseases, Ninth Revision, Clinical Modification but lacks descriptions of clinical subsets for disease manifestation or progression such as episodic or chronic migraine and migraine with or without aura.
5. The selection process of two study cohorts and two control cohorts was based solely on inclusion and exclusion criteria and did not involve subjective patient omission.

Introduction

A major symptom of fibromyalgia (FM) is headache. Migraine is a type of headaches, and some migraines are severe enough to be debilitating. Notably, similarities have been observed between migraines and FM, and many instances of overlapping symptoms, causes, and treatments were noted in the present study, where the two conditions were considered in the same context [1]. Several studies have reported that high proportions (20%–36%) of patients with migraine also have FM [2-5]. Similarly, the frequency of migraine occurrence in patients with FM is 45%–80%, suggesting that migraine is common in patients with FM [6, 7]. Despite reports that the prevalence of FM is higher among migraine patients and vice versa [8-13], no explanations have been provided for this high rate of co-occurrence.

Migraine is a complex, recurrent disorder that manifests as a throbbing headache and is frequently associated with nausea, allodynia, and sensitivity to sound or light. Migraines may develop into a chronic condition or disability [14, 15]. Migraine pain is believed to be caused by the nociceptive activation of the trigeminovascular system, including sensory neurons from the trigeminal ganglion and upper cervical nerve roots, which modulate central signals to numerous subcortical sites [16]. The combination of tonic nociceptive input and central disinhibition may also play a role in the development of FM. Many migraineurs experience a condition referred to as

1
2
3
4 “allodynia” during migraine attacks. Typically, allodynia is confined to the head and
5
6
7 neck but may involve other areas of the body [17]. Increasing evidence indicates that
8
9
10 peripheral tissues are relevant contributors to painful impulse input and can initiate or
11
12
13 maintain central sensitization, thereby contributing to the progression of FM [18].
14
15
16 Migraine is believed to trigger FM. Repeated headaches in patients with migraine
17
18
19 may increase the neuronal response to both nociceptive and nonnociceptive
20
21
22 stimulation and induce spontaneous neuronal activity, which may concurrently
23
24
25 increase patient sensitivity to FM [19]. Several studies have highlighted the role of the
26
27
28 hypothalamus in migraines [17]. Evidence indicates the direct and indirect anatomical
29
30
31 connections of the hypothalamus to the thalamus and autonomic brainstem nuclei,
32
33
34 thereby supporting the role of the hypothalamus in nociceptive and autonomic
35
36
37 modulation in patients with migraine [20]. However, brain mechanisms common in
38
39
40 patients with FM result in the central sensitization of pain neurons, leading to the
41
42
43 evolution of a complex syndrome [21].
44
45

46 Early in the course of FM, widespread musculoskeletal pain often appears in the
47
48
49 neck or shoulder region [22]. Neck pain may activate local nociceptors and transmit
50
51
52 pain impulses through upper cervical spinal nerves such as the greater occipital nerve
53
54
55 to the trigeminal nucleus caudalis, thereby inducing a migraine attack [23]. Some
56
57
58 experts believe that FM and migraine headaches both involve defects in the systems
59
60

1
2
3
4 that regulate certain chemical messengers in the brain, including serotonin and
5
6
7 epinephrine (adrenaline) [1]. These defects may be reflected in the similar
8
9
10 psychological comorbidities of the two conditions, including depression, anxiety,
11
12
13 interpersonal sensitivity, and somatization [9]. Psychosocial distress or abnormalities
14
15
16 commonly occur in patients with migraine and those with FM.

17
18
19 Although studies have reported high comorbidity rates for migraine and FM, the
20
21
22 following crucial concerns must be addressed. (1) Most such studies were conducted
23
24
25 at tertiary care centers. Patients are often referred to tertiary clinics when they present
26
27
28 with extreme pain, disability, or medication overuse. Therefore, such sample
29
30
31 populations may differ from patients treated in general practice. (2) Most such studies
32
33
34 used a cross-sectional design to investigate prevalence rather than incidence of
35
36
37 migraine or FM. (3) Whether a significant association exists, suggesting that people
38
39
40 with migraine are more likely to develop FM than the general population or vice versa,
41
42
43 remains unknown. Therefore, our population-based longitudinal cohort was employed
44
45
46 to investigate the link between migraine and FM.

54 55 **Methods**

56 57 58 **Data Source**

1
2
3
4 Data for this research were obtained from the Longitudinal Health Insurance
5
6
7 Database (LHID). The LHID comprises data of insurance claims filed by 1 million
8
9
10 patients under Taiwan's National Health Insurance (NHI) program, which covers 99%
11
12
13 of Taiwan's 23 million citizens with single-payer health insurance. According to a
14
15
16 government report, no differences between the LHID and Taiwan's NHI program
17
18
19 exist with respect to demographic characteristics. The health claims information in the
20
21
22 LHID includes general patient information (e.g., birthdate, sex, occupation),
23
24
25 documentation of diseases [recorded according to the International Classification of
26
27
28 Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)], and other data related
29
30
31 to medical services.
32
33
34
35
36

37 **Ethics statement**

38
39
40 The NHI Research Databank encrypts patients' personal information to protect
41
42
43 privacy and provides researchers with anonymous identification numbers associated
44
45
46 with relevant claims information, including sex, birthdate, medical services received,
47
48
49 and prescriptions. Therefore, patient consent is not required to access the NHI
50
51
52 Research Databank. This study was approved for exemption by the Institutional
53
54
55 Review Board of China Medical University (CMUH104-REC2-115-CR3). In
56
57
58 addition, the Institutional Review Board waived the requirement for patient consent.
59
60

Study Cohorts

A bidirectional cohort study design was used to interpret the longitudinal association between FM and migraine.

Figure 1 displays the procedure for establishing the two arms of this study. For Arm 1, we identified patients with FM (ICD-9-CM code 729.1) aged ≥ 20 years and newly diagnosed ≥ 3 times consecutively within 3 months from 2000–2010. The first diagnosis date was designated as the index date for entry into the FM cohort. Patients with a history of migraine (ICD-9-CM code 346) were excluded from this arm. For each patient with FM, we randomly selected four individuals without FM or migraine from the population of the LHID2000 who were frequency-matched by sex, age (in 5-year increments), and entry date of the patient with FM; these subjects were recruited into the non-FM (control) cohort.

A similar procedure was used for Arm 2 to establish a cohort of patients with migraine who had no history of FM, were aged ≥ 20 years, and were newly diagnosed ≥ 3 times consecutively within 3 months from 2000–2010.

Subjects in both arms were followed until diagnosis of migraine or FM, withdrawal from the NHI program, death, or December 31, 2011. The patients in the two cohorts presented with some baseline comorbidities: diabetes (ICD-9-CM code

1
2
3
4 250), hypertension (ICD-9-CM codes 401–405), hyperlipidemia (ICD-9-CM code
5
6
7 272), depression (ICD-9-CM codes 296.2, 296.3, 296.5, 300.4, 309, and 311), anxiety
8
9
10 (ICD-9-CM codes 300.0, 300.2, 300.3, 308.3, and 309.81), sleep disorder (ICD-9-CM
11
12
13 codes 307.4 and 780.5), coronary artery disease (CAD; ICD-9-CM codes 410–414),
14
15
16 chronic fatigue syndrome (CFS; ICD-9-CM code 780.71), and irritable bowel
17
18
19 syndrome (IBS; ICD-9-CM code 564.1).
20
21
22
23
24

25 **Statistical analyses**

26
27
28 The characteristics of the study cohorts are expressed as means and
29
30 corresponding standard deviations for age and as numbers and percentages for sex and
31
32 comorbidities. Age difference was assessed using a t test, and sex and comorbidity
33
34 distributions were tested using a chi-square test. The incidence density for each cohort
35
36 was calculated as the total event number divided by the sum of follow-ups [per 1000
37
38 person-years (PY)]. The cumulative incidence curve for each cohort was measured
39
40 using the Kaplan–Meier method, and the curve difference was calculated using the
41
42 log-rank test. To determine the risks of migraine and FM in Arms 1 and 2,
43
44 respectively, hazard ratios (HRs) and corresponding 95% confidence intervals (CIs)
45
46 were estimated using single-variable and multivariable Cox proportional hazard
47
48 models. Data management and all statistical analyses were performed using SAS for
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Windows (Version 9.4, SAS Institute, Cary, NC, USA), and incidence curves was
5
6
7 plotted using R software. All significance levels were set as two-sided $p < 0.05$.
8
9

10 11 12 13 **Public and Patient Involvement**

14
15
16 None
17
18
19
20
21
22
23
24

25 **Results**

26
27
28 Table 1 presents the demographic characteristics of the FM and non-FM cohorts.
29
30
31 The age- and sex-matched cohorts exhibited differences in comorbidity distribution.
32
33
34 The prevalence of comorbidities was significantly higher in the FM cohort than in the
35
36
37 non-FM cohort ($p < 0.001$).
38
39

40
41 Table 2 indicates that the migraine incidences were 4.39 and 2.07 per 1000 PY in
42
43 the FM and non-FM cohorts, respectively. Figure 2 reveals a higher incidence curve
44
45
46 for the FM cohort than for the non-FM cohort (log-rank test = 371.4, $p < 0.001$). After
47
48
49 adjustment for age, sex, and comorbidities, the patients with FM exhibited a
50
51
52 1.89-times higher risk of migraine compared with the non-FM subjects (HR = 1.89,
53
54
55 95% CI = 1.75–2.05). Among women, the relative risk of migraine was 1.76-times
56
57
58 higher in patients with FM compared with non-FM subjects (HR = 1.76, 95% CI
59
60

1
2
3
4 1.60–1.93), whereas among men, the risk was 2.29-times higher in patients with FM
5
6
7 than in non-FM subjects (HR = 2.29, 95% CI = 1.97–2.67). Regarding age, the HRs
8
9
10 for migraine in the FM cohort were 2.06 (95% CI = 1.85–2.29), 1.66 (95% CI =
11
12
13 1.43–1.92), and 1.69 (95% CI = 1.39–2.05) for ≤ 50 , 51–65, and ≥ 65 years,
14
15
16 respectively.

17
18
19 Table 3 presents the influence of factors associated with migraine occurrence in
20
21 the FM cohort. Male sex, hyperlipidemia, depression, anxiety, sleep disorder, CAD,
22
23 CFS, and IBS were all associated with higher risk of migraine (all $p < 0.05$).
24
25

26
27
28 Table 4 lists the comorbidities as well as the age- and sex-matched comparisons
29
30 in the migraine cohort, which exhibited a higher prevalence of comorbidities than did
31
32 the nonmigraine cohort.
33
34

35
36
37 Table 5 and Figure 3 reveal that the incidence of FM was significantly higher in
38
39 patients with migraine than in those without (7.01 vs. 4.49 per 1000 PY; log-rank test
40
41 = 116.7, $p < 0.001$). After adjustment for age, sex, and comorbidities, patients with
42
43 migraine exhibited a 1.52-times higher risk of FM compared with those without
44
45 migraine (HR = 1.52, 95% CI = 1.39–1.65). Among female patients, those with
46
47 migraine exhibited a 1.43-times higher risk of FM compared with nonmigraine
48
49 subjects (HR = 1.43, 95% CI = 1.29–1.59), whereas among male patients, those with
50
51 migraine exhibited a 1.78-times higher risk of FM compared with nonmigraine
52
53
54
55
56
57
58
59
60

1
2
3
4 subjects (95% CI = 1.50–2.11). Regarding age, the HRs for FM were 1.64 (95% CI =
5
6
7 1.46–1.84), 1.30 (95% CI = 1.09–1.53), and 1.28 (95% CI = 1.03–1.58) in patients
8
9
10 with migraine aged <50, 50–64, and ≥65 years, respectively.
11
12

13 Table 6 presents the associations of sex, age, and comorbidities with risk of FM.
14
15
16 The variables, including age, migraine, hypertension, hyperlipidemia, depression,
17
18
19 sleep disorder, and CAD, were all associated with lower risk of FM.
20
21
22
23
24
25
26
27

28 Discussion

29
30
31 The results of comparing the two cohort arms suggested a bidirectional risk of
32
33
34 migraine and FM in patients with FM and those with migraine, respectively. The
35
36
37 analysis of Arm 1 revealed incidence rates for migraine of 4.39 and 2.07 per 1000 PY
38
39
40 in patients with and without FM, respectively [adjusted HR (aHR) = 1.89, 95% CI =
41
42
43 1.75–2.05 in patients with FM]. The analysis of Arm 2 revealed incidence rates for
44
45
46 FM of 7.01 and 4.49 per 1000 PY in patients with and without migraine, respectively
47
48
49 (aHR = 1.52, 95% CI = 1.39–1.65 in patients with migraine). These results indicated
50
51
52 that FM had stronger predictive power for the onset of migraine than did migraine for
53
54
55 the onset of FM.
56
57

58 The Kaplan–Meier plots demonstrated that incidence of migraine in the FM
59
60

1
2
3
4 cohort and that of FM in the migraine cohort increased steadily during the 12-year
5
6
7 follow-up period. Moreover, similar patterns were observed in the two corresponding
8
9
10 comparison cohorts. The cumulative incidence measured by the Kaplan–Meier plots
11
12
13 revealed greater risk of migraine among patients with FM than risk of FM among
14
15
16 patients with migraine.

17
18
19 Our predictive analytics have the potential to guide diagnosis and treatment. For
20
21
22 example, a subsequent diagnosis of FM may result from failure of antimigraine
23
24
25 treatment to alleviate fatigue [24]. Because migraine is often more effectively
26
27
28 managed than FM, the authors hypothesized that patients with FM are more likely to
29
30
31 be treated for migraine than are patients with migraine to be treated for FM. Therefore,
32
33
34 clinical trials of patients with migraine in the future have the potential to evaluate the
35
36
37 effects of FM on health outcomes and the efficacy of FM treatment [10].
38
39
40
41
42

43 **Cohort analysis for the association between FM and risk of new-onset migraine**

44
45
46 This study revealed a positive association between FM diagnosis and the risk of
47
48
49 migraine. Adjusting for hypertension, CAD, and CFS had no strong influence on this
50
51
52 association. However, sex, age (particularly in patients aged less than 49 years),
53
54
55 diabetes, hyperlipidemia, depression, anxiety, sleep disorder, and IBS continued to
56
57
58 demonstrate statistically significant effects.
59
60

1
2
3
4 Because “high frequency and chronic migraine increase sensitivity to pain in
5
6
7 fibromyalgia (FM) patients [25], such heightened pain sensitivity may be attenuated
8
9
10 by comorbid diabetes. There is also a documented report showing a significant
11
12
13 positive association between migraine frequency and intensity with total and
14
15
16 [low-density lipoprotein] cholesterol, independent of diet and lifestyle [26].” Several
17
18
19 hypotheses have been proposed to explain the development of chronic widespread
20
21
22 pain and episodic throbbing or pulsating pain across the head and neck regions as
23
24
25 possible effects of comorbidities such as depression and anxiety. Depression and
26
27
28 anxiety disorders have been identified as crucial secondary symptoms of FM [11, 27,
29
30
31 28]. The pain associated with FM may initiate the development of mood disorders as
32
33
34 a result of stress imposed on the body. Furthermore, according to multiple
35
36
37 evidence-based studies, depression and anxiety may induce the onset or present as a
38
39
40 prodrome of migraine [29, 30]. Research has indicated that serotonin levels might be
41
42
43 related to interconnections between anxiety and migraine [31]. A lower level of
44
45
46 serotonin may be central to the dysregulation of descending antinociceptive systems,
47
48
49 leading to FM and migraine [31, 32].

51
52 Poor sleep quality or sleep deprivation in healthy individuals can induce
53
54
55 symptoms of FM [33], suggesting that sleep abnormalities may be a pathological
56
57
58 characteristic of FM rather than merely a result of pain [34]. Relevant literature has
59
60

1
2
3
4 reported the advantages of targeting sleep conditions to relieve the symptoms of
5
6
7 migraine [35]. As the prevalence of sleep disorders increases in both patients with FM
8
9
10 and those with migraine, appreciation of the strong links between FM and migraine
11
12
13 also increases.
14
15

16 IBS frequently coexists with both FM and migraine [36, 37]; however, the
17
18 underlying mechanisms for the association of FM with increased risks of IBS and
19
20 migraine are unclear. FM, migraine, and IBS may be distinct manifestations of a
21
22 common pathophysiological process affecting the gastrointestinal tract. These
23
24 disorders are referred to as “central sensitivity syndrome” and are mutually associated
25
26
27 [38]. A growing amount of evidence indicates that central sensitization phenomena
28
29
30 play a role in the pathogenesis of FM and that of migraine. Central sensitization at the
31
32
33 levels of the spinal dorsal horn and trigeminal nucleus may also be involved in the
34
35
36 progression of migraine attacks, and prolonged nociceptive inputs may result in the
37
38
39 maintenance of supraspinal sensitization and central neuroplastic changes, causing
40
41
42 episodic headaches to become chronic [39]. Notably, increased intestinal permeability
43
44
45 may be observed in IBS [40]. Altered intestinal permeability with overgrowth of
46
47
48 intestinal bacteria may trigger the development of FM [41] and that of migraine [42].
49
50
51 The microbiome–gut–brain axis—a bidirectional communication route of the central
52
53
54 and enteric nervous systems with microbiome through the neural, humoral, endocrine,
55
56
57
58
59
60

1
2
3
4 and immune pathways [36, 37, 43]—has been proposed as a multifaceted
5
6
7 pathophysiological mechanism underlying IBS [43], FM [44, 45], and migraine [42,
8
9
10 46]. In addition, mutual interaction has been established between gut microbiota and
11
12
13 the central, autonomic, and enteric nervous systems through the
14
15
16 hypothalamic–pituitary–adrenal axis [43].
17
18
19
20
21

22 **Cohort analysis for the association between migraine and risk of new-onset FM**

23
24
25 This study revealed higher risk of FM in patients with migraine than in those
26
27
28 without in every factor-based subset of the cohorts. Notably, patients with
29
30
31 hyperlipidemia had higher risk of FM. Moreover, adverse lipid profiles occurred more
32
33
34 frequently in patients with migraine who had a higher body mass index [47, 48].
35
36
37 Although lack of exercise may precipitate the development of an adverse lipid profile,
38
39
40 exercise may trigger acute migraine attacks [49], and some patients may avoid
41
42
43 exercise to prevent migraines. This hypothesis could be supported by the results of
44
45
46 one study that revealed that patients with headache had lower aerobic endurance and
47
48
49 flexibility than did healthy controls [50]. Aerobic exercise could relieve depression
50
51
52 and anxiety and prevent the negative effects of stress [51]. Furthermore, avoiding
53
54
55 exercise may exacerbate mood distress, and thus could be related to the development
56
57
58 of FM.
59
60

1
2
3
4 Increased migraine frequency as a result of migraines becoming chronic
5
6
7 intensifies the sensitivity to pain in somatic areas outside of the cephalic region and
8
9
10 may predispose patients to FM [6]. Hypothalamic neuroendocrine dysfunction has
11
12
13 been proposed as a brain mechanism common to both FM and migraine [52]. Both
14
15
16 conditions also share the mechanism of central sensitization of pain neurons.
17
18
19 Magnesium, which is often used as an agent for relieving migraine headaches, is also
20
21
22 beneficial for treating FM. Low magnesium levels can exacerbate symptoms of FM
23
24
25 and are also implicated in migraines [53]. Researchers have discovered that people
26
27
28 who do not respond to standard migraine treatments often also have FM [17].
29
30
31 Considering the high comorbidity rates of migraine and FM, many professionals
32
33
34 assume that the central nervous system is responsible for pain-processing
35
36
37 abnormalities, including central sensitization and inadequate pain inhibition alongside
38
39
40 repeated headache episodes. Moreover, tonic peripheral nociceptive input is
41
42
43 associated with augmented windup in response to neurotransmitters,
44
45
46 immunomodulation, vascular changes, and hormone influence, which may increase
47
48
49 the risk of FM [1, 6, 36, 37, 43, 52].
50

51
52 Our study contained a large sample because of our population-based design.
53
54
55 Moreover, we were careful to minimize selection bias during analysis, and our ample
56
57
58 documentation of medical profiles allowed for minimal effects from confounding
59
60

1
2
3
4 factors among the subjects. However, this study had limitations. We based our study
5
6
7 solely on information from diagnoses in patient files and included no information
8
9
10 from patients whose cases were unidentified. Poor categorization of a patient's
11
12
13 symptoms may have affected the discernibility between migraine and FM. Because
14
15
16 many crucial variables are not retrievable and various methods are used to diagnose
17
18
19 FM and the numerous subtypes of migraines, our data provides merely a glimpse of
20
21
22 these two conditions. Furthermore, assessing treatment responses in our large
23
24
25 database analysis was impossible, rendering the identification of “diagnosis by
26
27
28 exclusion” difficult in this study. Future studies are recommended to further delineate
29
30
31 “diagnosis by exclusion.” Furthermore, this study did not consider the severity of FM
32
33
34 and migraines in patients; therefore, no definitive statement can be made regarding
35
36
37 the intensity of FM and subsequent risk of developing migraine conditions, or vice
38
39
40 versa. Moreover, this study was naturally highly prone to observational bias because
41
42
43 patients with migraine and those with FM are generally more likely to seek medical
44
45
46 attention for other conditions than are those with neither.
47
48
49
50
51

52 **Conclusion**

53
54
55 This study was the first to reveal a population-based bidirectional association
56
57
58 between onset of FM and that of migraine in patients with migraine and those with
59
60

1
2
3
4 FM, respectively. The risk of migraine was reportedly greater than that of FM. The
5
6
7 incidence rates of FM in the migraine cohort and migraine in the FM cohort increased
8
9
10 with age in both directions. However, the HRs relative to the corresponding
11
12
13 comparison cohorts were attenuated with increases in age.
14
15
16
17
18

19 **Data availability statement**

20
21
22 The dataset used in this study was obtained from Taiwan's Ministry of Health
23
24 and Welfare (MOHW), from which we were required to obtain approval to access the
25
26 data. Any researcher interested in accessing this dataset can submit an application
27
28 form to the MOHW requesting access. Please contact the staff of the MOHW (email:
29
30 stcarolwu@mohw.gov.tw) for further assistance. Taiwan MOHW Address: No. 488,
31
32
33 Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 115, Taiwan (ROC). Phone:
34
35
36
37
38
39
40 +886-2-8590-6848. All relevant data are provided in this manuscript.
41
42
43
44
45
46
47
48

49 **Author contributions:**

50
51
52 **Conceptualization:** I-Wen Penn, Chia-Hung Kao.

53
54
55 **Methodology:** Cheng-Li Lin, Chia-Hung Kao.

56
57
58 **Software:** Cheng-Li Lin, Chia-Hung Kao.
59
60

1
2
3
4 **Validation:** I-Wen Penn, Eric Chuang, Tien-Yow Chuang, Cheng-Li Lin, Chia-Hung
5
6
7 Kao.

8
9
10 **Formal analysis:** I-Wen Penn, Eric Chuang, Tien-Yow Chuang, Cheng-Li Lin,
11
12
13 Chia-Hung Kao.

14
15
16 **Investigation:** Cheng-Li Lin, Chia-Hung Kao.

17
18
19 **Resources:** Cheng-Li Lin, Chia-Hung Kao.

20
21
22 **Data curation:** IWP, EC, TYC, CLL, CHK.

23
24
25 **Writing (original draft preparation):** I-Wen Penn, Eric Chuang, Tien-Yow Chuang,
26
27
28 Cheng-Li Lin, Chia-Hung Kao.

29
30
31 **Writing (review and editing):** I-Wen Penn, Eric Chuang, Tien-Yow Chuang,
32
33
34 Cheng-Li Lin, Chia-Hung Kao.

35
36
37 **Visualization:** I-Wen Penn, Eric Chuang, Tien-Yow Chuang, Cheng-Li Lin,
38
39
40 Chia-Hung Kao.

41
42
43 **Supervision:** Chia-Hung Kao.

44
45
46 **Project administration:** Chia-Hung Kao.

47
48
49 **Funding acquisition:** Chia-Hung Kao.

50
51
52
53
54
55 **Funding**
56
57
58
59
60

1
2
3
4 This work was supported by grants from the MOHW, Taiwan
5
6
7 (MOHW108-TDU-B-212-133004), China Medical University Hospital
8
9
10 (DMR-107-192), Academia Sinica Stroke Biosignature Project (BM10701010021),
11
12
13 the Ministry of Science and Technology (MOST) Clinical Trial Consortium for
14
15
16 Stroke (MOST 107-2321-B-039 -004-), the Tseng-Lien Lin Foundation, Taichung,
17
18
19 Taiwan, and the Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had
20
21
22 no role in the study design, data collection and analysis, the decision to publish, or the
23
24
25 preparation of the manuscript. No additional external funding was received for this
26
27
28 study.
29
30
31
32
33
34

35 **Conflicts of Interest**

36
37
38 All authors report no conflicts of interest.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. de Tommaso M. Prevalence, clinical features and potential therapies for fibromyalgia in primary headaches. *Expert Rev Neurother*. 2012;12:287–95.
2. Evans RW, de Tommaso M. Migraine and Fibromyalgia. *Headache*. 2011;51:295-299.
3. de Tommaso M, Federici A, Serpino C, Vecchio E, Franco G, Sardaro M, et al. Clinical features of headache patients with fibromyalgia comorbidity. *J Headache Pain*. 2011;12:629–638.
4. Küçükşen S, Genç E, Yılmaz H, Sallı A, Gezer İA, Karahan AY, et al. The prevalence of fibromyalgia and its relation with headache characteristics in episodic migraine. *Clin Rheumatol*. 2013;32:983-990.
5. Marcus DA, Bhowmick A. Fibromyalgia comorbidity in a community sample of adults with migraine. *Clin Rheumatol*. 2013;32:1553–1556.
6. Giamberardino MA, Affaitati G, Martelletti P, Tana C, Negro A, Lapenna D, et al. Impact of migraine on fibromyalgia symptoms. *J Headache Pain*. 2015;17:28.
7. Vij B, Whipple MO, Tepper SJ, Mohabbat AB, Stillman M, Vincent A. Frequency of Migraine Headaches in Patients With Fibromyalgia. *Headache*. 2015;55:860–865.

- 1
- 2
- 3
- 4 8. Centonze V, Bassi A, Cassiano A, Munno I, Dalfino L, Causarano V. Migraine,
- 5
- 6
- 7 daily chronic headache and fibromyalgia in the same patient: an evolutive
- 8
- 9
- 10 'continuum' of non organic chronic pain? About 100 clinical cases. *Neurol Sci*
- 11
- 12
- 13 2004; 25:S291–S292.
- 14
- 15
- 16 9. Ifergane G, Buskila D, Simiseshvely N, Zeev K, Cohen H. Prevalence of
- 17
- 18 fibromyalgia syndrome in migraine patients. *Cephalalgia* 2006;26:451–456.
- 19
- 20
- 21
- 22 10. Peres MF, Zukerman E, Young WB, Silberstein SD. Fatigue in chronic migraine
- 23
- 24 patients. *Cephalalgia* 2002;22:720–724.
- 25
- 26
- 27
- 28 11. Whealy M, Nanda S, Vincent A, Mandrekar J, Cutrer FM. Fibromyalgia in
- 29
- 30 migraine: a retrospective cohort study. *J Headache Pain*. 2018;19(1):61.
- 31
- 32
- 33
- 34 12. de Tommaso M, Sciruicchio V, Delussi M, Vecchio E, Goffredo M, Simeone M,
- 35
- 36
- 37 Barbaro MGF. Symptoms of central sensitization and comorbidity for juvenile
- 38
- 39 fibromyalgia in childhood migraine: an observational study in a tertiary headache
- 40
- 41 center. *J Headache Pain*. 2017;18(1):59.
- 42
- 43
- 44
- 45
- 46 13. de Tommaso M. Migraine and fibromyalgia. *J Headache Pain*. 2015;16(Suppl
- 47
- 48 1):A45.
- 49
- 50
- 51
- 52 14. Headache Classification Committee of the International Headache Society (IHS).
- 53
- 54 The International Classification of Headache Disorders, 3rd edition (beta version).
- 55
- 56
- 57 *Cephalalgia*. 2013; 33:629–808.
- 58
- 59
- 60

- 1
2
3
4 15. Dodick DW. Clinical practice: chronic daily headache. *N Engl J Med.* 2006;354:
5
6 158-165.
7
8
9
10 16. Nosedá R, Burstein R. Migraine pathophysiology: anatomy of the
11
12 trigeminovascular pathway and associated neurological symptoms, CSD,
13
14 sensitization and modulation of pain. *Pain.* 2013; 154:1.
15
16
17
18 17. Lolognier S, Eijkelkamp N, Wood JN. Mechanical allodynia. *Pflugers Arch.*
19
20 2015;467(1):133-9.
21
22
23
24 18. Staud R. Peripheral pain mechanisms in chronic widespread pain. *Best Pract Res*
25
26 *Clin Rheumatol.* 2011;25:155-164.
27
28
29
30 19. Burstein R. Deconstructing migraine headache into peripheral and central
31
32 sensitization. *Pain.* 2001; 89:107–110.
33
34
35
36 20. Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding
37
38 and future directions. *J Neurol.* 2017; 3:1-9.
39
40
41
42 21. Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic
43
44 widespread pain in patients with fibromyalgia and chronic fatigue syndrome. *Clin*
45
46 *Rheumatol.* 2007; 26: 465–473.
47
48
49
50 22. Clauw DJ. Fibromyalgia A Clinical Review. *JAMA.* 2014;311:1547-1555.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 23. Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive
5
6
7 neurons to cervical input after stimulation of the dura mater.
8
9
10 *Brain*. 2003;126:1801-1813.
11
12
13 24. Marcus DA, Bernstein C, Rudy TE. Fibromyalgia and headache: an
14
15
16 epidemiological study supporting migraine as part of the fibromyalgia syndrome.
17
18
19 *Clin Rheumatol* 2005; 24:595–601
20
21
22 25. Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states- maybe it is
23
24
25 all in their head. *Best Pract Res Clin Rheumatol*. 2011;25(2):141-54
26
27
28 26. Tana C, Santilli F, Martelletti P, di Vincenzo A, Cipollone F, Davi G,
29
30
31 Giamberardino MA. Correlation between migraine severity and cholesterol levels.
32
33
34 *Pain Pract*. 2015;15(7):662-70.
35
36
37 27. González-Roldán AM, Bomba IC, Diesch E, Montoya P, Flor H, Kamping S.
38
39
40 Controllability and hippocampal activation during pain expectation in
41
42
43 fibromyalgia syndrome. *Biol Psychol*. 2016;121:39-48.
44
45
46 28. Santos DM, Lage LV, Jabur EK, Kaziyama HHS, Iosifescu DV, De Lucia MCS,
47
48
49 et al. The influence of depression on personality traits in patients with
50
51
52 fibromyalgia: a case-control study. *Clin Exp Rheumatol*. 2017;35 Suppl
53
54
55 105:13-19.
56
57
58 29. Amouroux R, Rousseau-Salvador C. Anxiety and depression in children and
59
60

- 1
2
3
4 adolescents with migraine: a review of the literature. *Encephale*.
5
6
7 2008;34:504-510.
8
9
- 10 30. Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger
11
12 factors. *Med Clin North Am*. 2001;85:911-941.
13
14
15
- 16 31. Panconesi A. Serotonin and migraine: a reconsideration of the central theory. *J*
17
18 *Headache Pain*. 2008; 9: 267–276.
19
20
21
- 22 32. Becker S, Schweinhardt P. Dysfunctional Neurotransmitter Systems in
23
24 Fibromyalgia, Their Role in Central Stress Circuitry and Pharmacological Actions
25
26 on These Systems. *Pain Res Treat*. 2012;2012:741746.
27
28
29
- 30 33. McBeth J, Lacey RJ, Wilkie R. Predictors of New-Onset Widespread Pain in
31
32 Older Adults. *Arthritis & Rheumatology*. 2014; 66: 757–767.
33
34
35
- 36 34. Choy EH. The role of sleep in pain and fibromyalgia. *Nat Rev*
37
38 *Rheumatol*. 2015;11:513-520.
39
40
41
- 42 35. Moldofsky H. Sleep and pain. *Sleep Medicine Reviews*. 2001; 5: 387–398.
43
44
45
- 46 36. Chen X, Souza RD, Hong ST. The role of gut microbiota in the gut-brain axis:
47
48 current challenges and perspectives. *Protein Cell* 2013; 4: 403–414.
49
50
51
- 52 37. Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to
53
54 behavior. *Neurogastroenterol Motil*. 2011; 23:187-192.
55
56
57
- 58 38. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology
59
60

- 1
2
3
4 for fibromyalgia and overlapping conditions, and related issue of disease versus
5
6
7 illness. *Semin Arthritis Rheum*. 2008; 37:339-352.
8
9
- 10 39. Bernstein C, Burstein R. Sensitization of the Trigeminovascular Pathway:
11
12 Perspective and Implications to Migraine Pathophysiology. *J Clin Neurol*
13
14 2012;8:89-99.
15
16
- 17 40. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and
18
19 hypersensitivity in the irritable bowel syndrome. *Pain*. 2009;146:41–46.
20
21
22
- 23 41. Goebel A, Buhner S, Schedel R, Lochs H, Sprutte G. Altered intestinal
24
25 permeability in patients with primary fibromyalgia and in patients with complex
26
27 regional pain syndrome. *Rheumatology* 2008;47:1223-1227.
28
29
30
- 31 42. van Hemert S, Breedveld AC, Rovers JM, Vermeiden JP, Witteman BJ, Smits
32
33 MG, et al. Migraine associated with gastrointestinal disorders: review of the
34
35 literature and clinical implications. *Front Neurol*. 2014; 21:241.
36
37
38
- 39 43. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions
40
41 between enteric microbiota, central and enteric nervous systems. *Ann*
42
43 *Gastroenterol*. 2015; 28: 203–209.
44
45
46
- 47 44. Berstad A, Valeur J. Gut gateway to generalized pain. *Scand J Pain*.. 2016;
48
49 13:164–165.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 45. Mu C, Yang Y, Zhu W. Gut microbiota: the brain peacekeeper. *Front Microbiol*
5
6
7 2016;7:345.
8
9
- 10 46. Dai YJ, Wang HY, Wang XJ, Kaye AD, Sun YH. Potential Beneficial Effects of
11
12 Probiotics on Human Migraine Headache: A Literature Review. *Pain Physician*.
13
14 2017; 20: 251-255.
15
16
17
- 18 47. Saberi A, Hatamian HR, Kazemnejad E, Ghorbannejad N. Hyperlipidemia in
19
20 migraine: Is it more frequent in migraineurs? *Iran J Neurol*. 2011; 10:46-50.
21
22
23
- 24 48. Salmasi M, Amini L, Javanmard SH, Saadatnia M. Metabolic syndrome in
25
26 migraine headache: A case-control study. *J Res Med Sci*. 2014; 19: 13–17.
27
28
29
- 30 49. Koppen H, van Veldhoven PL. Migraineurs with exercise-triggered attacks have a
31
32 distinct migraine. *J Headache Pain*. 2013;14:99.
33
34
35
- 36 50. Neususs K, Neumann B, Steinhoff BJ, Thegeder H, Bauer A, Reimers D. Physical
37
38 activity and fitness in patients with headache disorders. *Int J Sports Med*.
39
40 1997;18:607-611.
41
42
43
- 44 51. Salmon P. Effects of Physical exercise on anxiety, depression, and sensitivity to
45
46 stress: a unifying theory. *Clin Psychol Rev*. 2001; 21: 33-61.
47
48
49
- 50 52. Valença MM, Medeiros FL, Martins HA, Massaud RM, Peres MF.
51
52 Neuroendocrine dysfunction in fibromyalgia and migraine. *Curr Pain Headache*
53
54 *Rep*. 2009;13:358-364.
55
56
57
58
59
60

- 1
2
3
4 53. Assarzadegan F, Asgarzadeh S, Hatamabadi HR, Shahrami A, Tabatabaey A,
5
6
7 Asgarzadeh M. Serum concentration of magnesium as an independent risk factor
8
9
10 in migraine attacks: a matched case-control study and review of the literature. *Int*
11
12
13 *Clin Psychopharmacol*. 2016;31:287-292.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Figure Legends:**
4

5 Figure 1. Flow chart illustrating the selection of study subjects.
6
7
8
9

10
11 Figure 2. Comparison of cumulative incidence of migraine between patients with and
12
13 without fibromyalgia using the Kaplan–Meier method.
14
15
16

17
18
19
20 Figure 3. Comparison of the cumulative incidence of fibromyalgia between patients
21
22 with and without migraine using the Kaplan–Meier method.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic characteristics and comorbidities in patients with and without fibromyalgia.

Variable	Fibromyalgia		p-value
	No N =132863	Yes N =33216	
Sex	n(%)	n(%)	0.99
Female	71880(54.1)	17970(54.1)	
Male	60983(45.9)	15246(45.9)	
Age, mean(SD)	50.9(16.9)	51.4(16.7)	<0.001 [#]
Stratify age			0.99
≤49	64292(48.4)	10673(48.4)	
50-65	36820(27.7)	9205(27.7)	
65+	31751(23.9)	7938(23.9)	
Comorbidity			
Diabetes	10485(7.89)	3193(9.61)	<0.001
Hypertension	37284(28.1)	11287(34.0)	<0.001
Hyperlipidemia	22446(16.9)	7301(22.0)	<0.001
Depression	4690(3.53)	1804(5.43)	<0.001
Anxiety	10494(7.90)	4214(12.7)	<0.001
Sleep disorder	21095(15.9)	8121(24.5)	<0.001
CAD	17918(13.5)	5821(17.5)	<0.001
Chronic fatigue syndrome	199(0.15)	93(0.28)	<0.001
Irritable bowel syndrome	5125(3.86)	1870(5.63)	<0.001

Chi-square test; #: two-sample t test

Table 2. Comparison of the incidence and hazard ratios of migraine stratified by sex and age between patients with and without fibromyalgia.

Variable	Without fibromyalgia					With fibromyalgia				
	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)
All	1810	876077	2.07	1(Reference)	1(Reference)	954	217386	4.39	2.12(1.96, 2.30)***	1.89(1.75, 2.05)***
Sex										
Female	1373	487506	2.82	1(Reference)	1(Reference)	669	120773	5.54	1.97(1.79, 2.16)***	1.76(1.60, 1.93)***
Male	437	388571	1.12	1(Reference)	1(Reference)	285	96613	2.95	2.62(2.26, 3.05)***	2.29(1.97, 2.67)***
Stratify age										
≤50	922	444710	2.07	1(Reference)	1(Reference)	548	110557	4.96	2.39(2.15, 2.66)***	2.06(1.85, 2.29)***
50-65	564	245579	2.30	1(Reference)	1(Reference)	258	60603	4.26	1.85(1.60, 2.15)***	1.66(1.43, 1.92)***
65+	324	185788	1.74	1(Reference)	1(Reference)	148	46226	3.20	1.83(1.51, 2.23)***	1.69(1.39, 2.05)***
Comorbidity[‡]										
No	774	508879	1.52	1(Reference)	1(Reference)	311	95605	3.25	2.14(1.88, 2.44)***	2.13(1.87, 2.43)***
Yes	1036	367197	2.82	1(Reference)	1(Reference)	643	121780	5.28	1.88(1.71, 2.08)***	1.80(1.63, 1.98)***

Rate[#]: incidence rate per 1000 person-years; crude HR: crude hazard ratio

Adjusted HR[†]: multivariable analysis including sex, age, and the comorbidities of diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, coronary artery disease, chronic fatigue syndrome, and irritable bowel syndrome

***p < 0.001

Comorbidity[‡]: patients with any of the comorbidities of diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, coronary artery disease, chronic fatigue syndrome, or irritable bowel syndrome were classified as the comorbidity group

Table 3. Cox model with hazard ratios and 95% confidence intervals for migraine associated with fibromyalgia and covariates.

Variable	Crude		Adjusted [†]	
	HR	(95% CI)	HR	(95% CI)
Fibromyalgia	2.12	(1.96, 2.30)***	1.89	(1.74, 2.04)***
Sex(Women vs. Men)	2.28	(2.09, 2.48)***	2.08	(1.91, 2.27)***
Age, years	1.00	(0.99, 1.00)**	0.99	(0.99, 1.00)***
Baseline comorbidities (yes vs. no)				
Diabetes	0.82	(0.70, 0.96)*	0.73	(0.61, 0.860)***
Hypertension	1.06	(0.97, 1.15)	-	-
Hyperlipidemia	1.30	(1.19, 1.43)***	1.14	(1.03, 1.27)*
Depression	2.37	(2.06, 2.72)***	1.20	(1.03, 1.39)*
Anxiety	2.68	(2.44, 2.95)***	1.64	(1.47, 1.84)***
Sleep disorder	2.63	(2.43, 2.85)***	1.97	(1.80, 2.15)***
CAD	1.30	(1.18, 1.44)***	1.10	(0.98, 1.23)
Chronic fatigue syndrome	2.24	(1.01, 4.99)*	1.45	(0.65, 3.22)
Irritable bowel syndrome	1.98	(1.71, 2.29)***	1.36	(1.17, 1.58)***

Crude HR: crude hazard ratio; adjusted[†]: multivariable analysis including sex, age, and the comorbidities of diabetes, hyperlipidemia, depression, anxiety, sleep disorder, coronary artery disease, chronic fatigue syndrome, and irritable bowel syndrome

*p < 0.05, **p < 0.01, and ***p < 0.001

Table 4. Demographic characteristics and comorbidities in patients with and without migraine.

Variable	migraine		p-value
	No N =69680	Yes N =17420	
Sex	n(%)	n(%)	0.99
Female	51176(73.4)	12794(73.4)	
Male	18504(26.6)	4626(26.6)	
Age, mean(SD)	44.2(15.6)	44.5(15.3)	0.04 [#]
Stratify age			0.99
≤49	46768(67.1)	11692(67.1)	
50-65	14940(21.4)	3735(21.4)	
65+	7972(11.4)	1993(11.4)	
Comorbidity			
Diabetes	3567(5.12)	975(5.60)	0.01
Hypertension	12563(18.0)	4551(26.1)	<0.001
Hyperlipidemia	8278(11.9)	3187(18.3)	<0.001
Depression	2019(2.90)	1851(10.6)	<0.001
Anxiety	4366(6.27)	3724(21.4)	<0.001
Sleep disorder	9469(13.6)	6976(40.1)	<0.001
CAD	5560(7.98)	2449(14.1)	<0.001
Chronic fatigue syndrome	71(0.10)	41(0.24)	<0.001
Irritable bowel syndrome	2106(3.02)	1224(7.03)	<0.001

Chi-square test; #: two-sample t test

Table 5. Comparison of the incidence and hazard ratios of fibromyalgia stratified by sex and age between patients with and without migraine.

Variable	Without migraine					With migraine				
	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)	Event	PY	Rate [#]	Crude HR (95% CI)	Adjusted HR [†] (95% CI)
All	2034	453130	4.49	1(Reference)	1(Reference)	800	114070	7.01	1.57(1.44, 1.70)***	1.52(1.39, 1.65)***
Sex										
Female	1556	335328	4.64	1(Reference)	1(Reference)	568	84606	6.71	1.45(1.32, 1.60)***	1.43(1.29, 1.59)***
Male	478	117802	4.06	1(Reference)	1(Reference)	232	29464	7.87	1.94(1.66, 2.27)***	1.78(1.50, 2.11)***
Stratify age										
≤50	1060	310621	3.41	1(Reference)	1(Reference)	470	78131	6.02	1.77(1.58, 1.97)***	1.64(1.46, 1.84)***
50-65	608	96607	6.29	1(Reference)	1(Reference)	207	24189	8.56	1.36(1.16, 1.59)***	1.30(1.09, 1.53)**
65+	366	45902	7.97	1(Reference)	1(Reference)	123	11751	10.5	1.32(1.07, 1.61)**	1.28(1.03, 1.58)*
Comorbidity[‡]										
No	1082	309229	3.50	1(Reference)	1(Reference)	255	43664	5.84	1.67(1.46, 1.92)***	1.79(1.56, 2.06)***
Yes	952	143901	6.62	1(Reference)	1(Reference)	545	70406	7.74	1.18(1.06, 1.31)**	1.29(1.16, 1.44)***

Rate[#]: incidence rate per 1000 person-years; crude HR: crude hazard ratio

Adjusted HR[†]: multivariable analysis including sex, age, and the comorbidities of diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, coronary artery disease, and irritable bowel syndrome


*p < 0.05, **p < 0.01, and ***p < 0.001

Comorbidity[‡]: patients with any of the comorbidities of diabetes, hypertension, hyperlipidemia, depression, anxiety, sleep disorder, coronary artery disease, chronic fatigue syndrome, or irritable bowel syndrome were classified as the comorbidity group


Table 6. Cox model with hazard ratios and 95% confidence intervals for fibromyalgia associated with migraine and covariates.

Variable	Crude		Adjusted [†]	
	HR	(95% CI)	HR	(95% CI)
Migraine	1.57	(1.44, 1.70)***	1.51	(1.38, 1.65)***
Sex(Women vs. Men)	1.05	(0.97, 1.15)	-	-
Age, years	1.02	(1.02, 1.03)***	1.02	(1.01, 1.02)***
Baseline comorbidities (yes vs. no)				
Diabetes	1.58	(1.36, 1.82)***	0.99	(0.85, 1.16)
Hypertension	1.81	(1.67, 1.96)***	1.10	(0.99, 1.22)
Hyperlipidemia	1.69	(1.54, 1.85)***	1.15	(1.03, 1.28)*
Depression	1.38	(1.17, 1.63)***	1.06	(0.89, 1.26)
Anxiety	1.34	(1.19, 1.51)***	0.92	(0.80, 1.05)
Sleep disorder	1.45	(1.33, 1.58)***	1.09	(0.98, 1.20)
CAD	1.74	(1.57, 1.94)***	1.01	(0.89, 1.14)
Chronic fatigue syndrome	2.11	(0.79, 5.62)	-	-
Irritable bowel syndrome	1.28	(1.06, 1.53)**	0.94	(0.78, 1.13)

Crude HR: crude hazard ratio; adjusted[†]: multivariable analysis including age and the comorbidities of diabetes, hypertension, hyperlipidemia, anxiety, sleep disorders, stroke, and peptic ulcer disease, and use of nonsteroidal anti-inflammatory drugs
 *p < 0.05, **p < 0.01, and ***p < 0.001




126x86mm (300 x 300 DPI)



112x104mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



108x105mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Included on page:
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,5,6
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	5,6
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8-10
Objectives	3	State specific objectives, including any pre-specified hypotheses	10
Methods			
Study design	4	Present key elements of study design early in the paper	11-14
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	11-14
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	11-14
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	11-14
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	11-14
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	11-14
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	11-14
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-14
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11-14
Bias	9	Describe any efforts to address potential sources of bias	11-14
Study size	10	Explain how the study size was arrived at	11-14
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11-14
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	11-14
		(b) Describe any methods used to examine subgroups and interactions	11-14

		(c) Explain how missing data were addressed	11-14
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	11-14
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	11-14
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	11-14
		(e) Describe any sensitivity analyses	11-14
Continued on next page			
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	15,16
		(b) Give reasons for non-participation at each stage	15,16
		(c) Consider use of a flow diagram	15,16
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	15,16
		(b) Indicate number of participants with missing data for each variable of interest	15,16
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	15,16
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	15,16
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	15,16
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	15,16
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	15,16
		(b) Report category boundaries when continuous variables were categorized	15,16
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	15,16
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	15,16
Discussion			
Key results	18	Summarise key results with reference to study objectives	17-23
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	22

1 2 3 4	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-23
5 6 7	Generalisability	21	Discuss the generalisability (external validity) of the study results	17-23
8	Other information			
9 10 11 12	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	2, 3

13
14
15 Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

16
17
18 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60